Trial Outcomes & Findings for First Time in Human (FTIH) Study to Evaluate Safety, Tolerability, Immunogenicity, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3511294 Administered Subcutaneously (SC) in Subjects With Mild to Moderate Asthma (NCT NCT03287310)

Last Updated: 2021-03-01

Results Overview

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; other important medical events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed before; is associated with liver injury and impaired liver function.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

50 participants

Primary outcome timeframe

Up to Week 40

Results posted on

2021-03-01

Participant Flow

This was double-blind, placebo-controlled, single ascending dose study in participants with mild to moderate asthma to assess safety, tolerability, immunogenicity, pharmacokinetics and pharmcodynamics of GSK3511294 administered subcutaneously. The study was conducted in Germany and United Kingdom.

A total of 50 participants were enrolled in this study, of which two did not receive any study treatment and 48 were included in the Safety Population.

Participant milestones

Participant milestones
Measure	Placebo Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2 mg Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10 mg Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30 mg Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100 mg Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300 mg Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Overall Study STARTED	12	6	6	9	9	6
Overall Study COMPLETED	12	6	6	9	9	6
Overall Study NOT COMPLETED	0	0	0	0	0	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

First Time in Human (FTIH) Study to Evaluate Safety, Tolerability, Immunogenicity, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3511294 Administered Subcutaneously (SC) in Subjects With Mild to Moderate Asthma

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Placebo n=12 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1	Total n=48 Participants Total of all reporting groups
Race/Ethnicity, Customized Black/Afr. Amer./White/Caucasian/European Heritage	1 Participants n=99 Participants	0 Participants n=107 Participants	0 Participants n=206 Participants	0 Participants n=157 Participants	0 Participants n=390 Participants	0 Participants n=16 Participants	1 Participants n=3 Participants
Age, Continuous	44.0 years STANDARD_DEVIATION 13.37 • n=99 Participants	43.5 years STANDARD_DEVIATION 10.71 • n=107 Participants	44.7 years STANDARD_DEVIATION 13.20 • n=206 Participants	44.9 years STANDARD_DEVIATION 10.23 • n=157 Participants	42.0 years STANDARD_DEVIATION 10.84 • n=390 Participants	45.2 years STANDARD_DEVIATION 11.18 • n=16 Participants	44.0 years STANDARD_DEVIATION 11.17 • n=3 Participants
Sex: Female, Male Female	0 Participants n=99 Participants	0 Participants n=107 Participants	0 Participants n=206 Participants	0 Participants n=157 Participants	1 Participants n=390 Participants	1 Participants n=16 Participants	2 Participants n=3 Participants
Sex: Female, Male Male	12 Participants n=99 Participants	6 Participants n=107 Participants	6 Participants n=206 Participants	9 Participants n=157 Participants	8 Participants n=390 Participants	5 Participants n=16 Participants	46 Participants n=3 Participants
Race/Ethnicity, Customized Central/South Asian Heritage	1 Participants n=99 Participants	0 Participants n=107 Participants	0 Participants n=206 Participants	1 Participants n=157 Participants	0 Participants n=390 Participants	0 Participants n=16 Participants	2 Participants n=3 Participants
Race/Ethnicity, Customized Black or African American (Afr. Amer.)	0 Participants n=99 Participants	1 Participants n=107 Participants	0 Participants n=206 Participants	1 Participants n=157 Participants	0 Participants n=390 Participants	0 Participants n=16 Participants	2 Participants n=3 Participants
Race/Ethnicity, Customized Arabic/North African Heritage	1 Participants n=99 Participants	0 Participants n=107 Participants	0 Participants n=206 Participants	0 Participants n=157 Participants	0 Participants n=390 Participants	0 Participants n=16 Participants	1 Participants n=3 Participants
Race/Ethnicity, Customized White/Caucasian/European Heritage	9 Participants n=99 Participants	5 Participants n=107 Participants	6 Participants n=206 Participants	7 Participants n=157 Participants	9 Participants n=390 Participants	6 Participants n=16 Participants	42 Participants n=3 Participants

PRIMARY outcome

Timeframe: Up to Week 40

Population: Safety Population comprised of all randomized participants who received at least one dose of the study treatment.

Outcome measures

Outcome measures
Measure	Placebo n=12 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Number of Participants With Adverse Events (AEs) and Serious AEs (SAE) Any SAE	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Adverse Events (AEs) and Serious AEs (SAE) Any AE	11 Participants	2 Participants	6 Participants	8 Participants	9 Participants	4 Participants

PRIMARY outcome

Timeframe: Up to Week 40

Population: Safety Population.

AESIs were defined as Hypersensitivity (narrow) and Injection site reactions like hematoma and swelling.

Outcome measures

Outcome measures
Measure	Placebo n=12 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Number of Participants With Adverse Events of Special Interest (AESI) Hypersensitivity	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants
Number of Participants With Adverse Events of Special Interest (AESI) Injection Site Reaction: swelling	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Number of Participants With Adverse Events of Special Interest (AESI) Injection Site Reaction: hematoma	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants

PRIMARY outcome

Timeframe: Baseline and at Days 2, 3, 4 and 5, Weeks 1, 2, 4, 8, 12, 18, 24, 26, 32, 36 and 40

Population: Safety Population. Only those participants with planned assessments at that particular time point has been presented (represented by n= X in the category titles).

Blood samples were collected at indicated time-points for analysis of hematology parameters like platelet count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Placebo n=12 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Basophils, Day 2,n=12,6,6,8,9,6	-0.006 Giga cells per liter Standard Deviation 0.0247	-0.020 Giga cells per liter Standard Deviation 0.0297	0.003 Giga cells per liter Standard Deviation 0.0103	-0.003 Giga cells per liter Standard Deviation 0.0238	0.001 Giga cells per liter Standard Deviation 0.0302	-0.018 Giga cells per liter Standard Deviation 0.0160
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Basophils, Week 12,n=12,5,6,9,9,5	0.002 Giga cells per liter Standard Deviation 0.0229	-0.014 Giga cells per liter Standard Deviation 0.0297	-0.008 Giga cells per liter Standard Deviation 0.0147	-0.003 Giga cells per liter Standard Deviation 0.0245	-0.004 Giga cells per liter Standard Deviation 0.0142	-0.006 Giga cells per liter Standard Deviation 0.0055
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Basophils, Week 18,n=12,6,6,9,9,6	-0.002 Giga cells per liter Standard Deviation 0.0229	0.010 Giga cells per liter Standard Deviation 0.0310	-0.012 Giga cells per liter Standard Deviation 0.0160	-0.001 Giga cells per liter Standard Deviation 0.0267	0.010 Giga cells per liter Standard Deviation 0.0278	-0.005 Giga cells per liter Standard Deviation 0.0105
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Eosinophils, Week 18,n=12,6,6,9,9,6	0.029 Giga cells per liter Standard Deviation 0.1263	-0.148 Giga cells per liter Standard Deviation 0.0685	-0.208 Giga cells per liter Standard Deviation 0.1153	-0.359 Giga cells per liter Standard Deviation 0.1445	-0.338 Giga cells per liter Standard Deviation 0.1786	-0.253 Giga cells per liter Standard Deviation 0.1067
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Eosinophils, Week 40,n=2,0,0,0,0,6	0.245 Giga cells per liter Standard Deviation 0.1344	—	—	—	—	-0.222 Giga cells per liter Standard Deviation 0.1196
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Lymphocytes, Day 2,n=12,6,6,8,9,6	-0.010 Giga cells per liter Standard Deviation 0.3897	0.135 Giga cells per liter Standard Deviation 0.2886	0.108 Giga cells per liter Standard Deviation 0.2185	-0.061 Giga cells per liter Standard Deviation 0.3165	-0.157 Giga cells per liter Standard Deviation 0.3336	0.100 Giga cells per liter Standard Deviation 0.2804
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Lymphocytes, Day 3,n=12,6,6,9,9,6	0.064 Giga cells per liter Standard Deviation 0.4447	0.330 Giga cells per liter Standard Deviation 0.3571	0.143 Giga cells per liter Standard Deviation 0.1810	-0.140 Giga cells per liter Standard Deviation 0.2382	-0.081 Giga cells per liter Standard Deviation 0.4131	0.143 Giga cells per liter Standard Deviation 0.3296
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Lymphocytes, Day 5,n=11,6,6,9,9,6	-0.077 Giga cells per liter Standard Deviation 0.4746	0.108 Giga cells per liter Standard Deviation 0.2319	0.085 Giga cells per liter Standard Deviation 0.1302	-0.253 Giga cells per liter Standard Deviation 0.2983	0.104 Giga cells per liter Standard Deviation 0.4463	0.047 Giga cells per liter Standard Deviation 0.1226
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Lymphocytes, Week 1,n=12,6,6,9,9,5	0.048 Giga cells per liter Standard Deviation 0.4628	0.295 Giga cells per liter Standard Deviation 0.2404	0.058 Giga cells per liter Standard Deviation 0.4116	-0.060 Giga cells per liter Standard Deviation 0.3248	-0.018 Giga cells per liter Standard Deviation 0.4217	-0.154 Giga cells per liter Standard Deviation 0.2587
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Neutrophil, Day 5,n=11,6,6,9,9,6	0.155 Giga cells per liter Standard Deviation 0.7789	0.085 Giga cells per liter Standard Deviation 0.6109	-0.003 Giga cells per liter Standard Deviation 0.3494	0.041 Giga cells per liter Standard Deviation 0.7075	0.184 Giga cells per liter Standard Deviation 1.0809	0.103 Giga cells per liter Standard Deviation 0.2639
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Monocytes, Week 26,n=12,6,6,9,9,6	0.040 Giga cells per liter Standard Deviation 0.0888	-0.037 Giga cells per liter Standard Deviation 0.1129	0.010 Giga cells per liter Standard Deviation 0.0551	0.036 Giga cells per liter Standard Deviation 0.1267	0.121 Giga cells per liter Standard Deviation 0.1500	0.013 Giga cells per liter Standard Deviation 0.0720
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Monocytes, Week 32,n=6,6,6,0,0,6	-0.035 Giga cells per liter Standard Deviation 0.0817	-0.013 Giga cells per liter Standard Deviation 0.1600	0.098 Giga cells per liter Standard Deviation 0.0783	—	—	-0.012 Giga cells per liter Standard Deviation 0.0662
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Monocytes, Week 36,n=6,0,0,9,9,0	0.067 Giga cells per liter Standard Deviation 0.0717	—	—	0.053 Giga cells per liter Standard Deviation 0.1624	0.158 Giga cells per liter Standard Deviation 0.2126	—
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Monocytes, Week 40,n=2,0,0,0,0,6	0.040 Giga cells per liter Standard Deviation 0.0566	—	—	—	—	-0.032 Giga cells per liter Standard Deviation 0.0873
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Platelet, Day 2,n=12,5,5,9,9,6	-9.7 Giga cells per liter Standard Deviation 19.00	-6.8 Giga cells per liter Standard Deviation 10.40	-6.4 Giga cells per liter Standard Deviation 15.27	-6.8 Giga cells per liter Standard Deviation 17.99	6.1 Giga cells per liter Standard Deviation 22.05	-1.5 Giga cells per liter Standard Deviation 19.32
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Platelet, Day 3,n=12,5,6,9,9,6	-2.8 Giga cells per liter Standard Deviation 16.72	-9.4 Giga cells per liter Standard Deviation 8.29	5.7 Giga cells per liter Standard Deviation 13.00	-7.1 Giga cells per liter Standard Deviation 19.98	1.7 Giga cells per liter Standard Deviation 19.24	-0.8 Giga cells per liter Standard Deviation 19.60
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Basophils, Day 3,n=12,6,6,9,9,6	0.002 Giga cells per liter Standard Deviation 0.0356	0.003 Giga cells per liter Standard Deviation 0.0450	0.010 Giga cells per liter Standard Deviation 0.0126	-0.003 Giga cells per liter Standard Deviation 0.0260	-0.003 Giga cells per liter Standard Deviation 0.0224	-0.007 Giga cells per liter Standard Deviation 0.0121
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Basophils, Day 4,n=12,6,6,8,8,6	-0.003 Giga cells per liter Standard Deviation 0.0296	0.002 Giga cells per liter Standard Deviation 0.0214	-0.008 Giga cells per liter Standard Deviation 0.0325	-0.004 Giga cells per liter Standard Deviation 0.0207	-0.001 Giga cells per liter Standard Deviation 0.0136	0.002 Giga cells per liter Standard Deviation 0.0214
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Basophils, Day 5,n=11,6,6,9,9,6	-0.020 Giga cells per liter Standard Deviation 0.0224	-0.008 Giga cells per liter Standard Deviation 0.0204	-0.020 Giga cells per liter Standard Deviation 0.0141	-0.009 Giga cells per liter Standard Deviation 0.0196	-0.003 Giga cells per liter Standard Deviation 0.0255	-0.025 Giga cells per liter Standard Deviation 0.0164
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Basophils, Week 1,n=12,6,6,9,9,5	-0.001 Giga cells per liter Standard Deviation 0.0257	-0.017 Giga cells per liter Standard Deviation 0.0207	-0.018 Giga cells per liter Standard Deviation 0.0306	0.002 Giga cells per liter Standard Deviation 0.0291	0.001 Giga cells per liter Standard Deviation 0.0162	-0.006 Giga cells per liter Standard Deviation 0.0055
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Basophils, Week 2,n=12,6,5,9,9,6	-0.006 Giga cells per liter Standard Deviation 0.0215	-0.018 Giga cells per liter Standard Deviation 0.0204	0.000 Giga cells per liter Standard Deviation 0.0274	-0.004 Giga cells per liter Standard Deviation 0.0224	-0.007 Giga cells per liter Standard Deviation 0.0158	-0.007 Giga cells per liter Standard Deviation 0.0137
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Basophils, Week 4,n=12,6,5,9,9,6	-0.010 Giga cells per liter Standard Deviation 0.0316	-0.002 Giga cells per liter Standard Deviation 0.0232	-0.004 Giga cells per liter Standard Deviation 0.0167	0.002 Giga cells per liter Standard Deviation 0.0172	-0.006 Giga cells per liter Standard Deviation 0.0265	-0.010 Giga cells per liter Standard Deviation 0.0126
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Basophils, Week 8,n=12,6,6,9,9,6	0.005 Giga cells per liter Standard Deviation 0.0183	0.007 Giga cells per liter Standard Deviation 0.0266	-0.022 Giga cells per liter Standard Deviation 0.0271	-0.010 Giga cells per liter Standard Deviation 0.0122	-0.002 Giga cells per liter Standard Deviation 0.0186	-0.015 Giga cells per liter Standard Deviation 0.0138
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Basophils, Week 24,n=11,6,6,9,9,6	-0.005 Giga cells per liter Standard Deviation 0.0157	0.002 Giga cells per liter Standard Deviation 0.0264	-0.005 Giga cells per liter Standard Deviation 0.0288	-0.004 Giga cells per liter Standard Deviation 0.0313	-0.001 Giga cells per liter Standard Deviation 0.0154	-0.018 Giga cells per liter Standard Deviation 0.0117
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Basophils, Week 26,n=12,6,6,9,9,6	-0.004 Giga cells per liter Standard Deviation 0.0284	0.002 Giga cells per liter Standard Deviation 0.0306	0.000 Giga cells per liter Standard Deviation 0.0219	0.008 Giga cells per liter Standard Deviation 0.0383	-0.002 Giga cells per liter Standard Deviation 0.0199	-0.008 Giga cells per liter Standard Deviation 0.0133
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Basophils, Week 32,n=6,6,6,0,0,6	-0.002 Giga cells per liter Standard Deviation 0.0376	0.010 Giga cells per liter Standard Deviation 0.0210	0.005 Giga cells per liter Standard Deviation 0.0339	—	—	-0.008 Giga cells per liter Standard Deviation 0.0117
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Basophils, Week 36,n=6,0,0,9,9,0	-0.002 Giga cells per liter Standard Deviation 0.0214	—	—	0.021 Giga cells per liter Standard Deviation 0.0247	-0.002 Giga cells per liter Standard Deviation 0.0199	—
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Basophils, Week 40,n=2,0,0,0,0,6	0.000 Giga cells per liter Standard Deviation 0.0000	—	—	—	—	-0.012 Giga cells per liter Standard Deviation 0.0313
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Eosinophils, Day 2,n=12,6,6,8,9,6	0.024 Giga cells per liter Standard Deviation 0.1412	-0.120 Giga cells per liter Standard Deviation 0.0587	-0.145 Giga cells per liter Standard Deviation 0.0797	-0.251 Giga cells per liter Standard Deviation 0.1504	-0.208 Giga cells per liter Standard Deviation 0.1685	-0.152 Giga cells per liter Standard Deviation 0.0794
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Eosinophils, Day 3,n=12,6,6,9,9,6	-0.001 Giga cells per liter Standard Deviation 0.1986	-0.167 Giga cells per liter Standard Deviation 0.0755	-0.203 Giga cells per liter Standard Deviation 0.0876	-0.289 Giga cells per liter Standard Deviation 0.0987	-0.287 Giga cells per liter Standard Deviation 0.1744	-0.182 Giga cells per liter Standard Deviation 0.0920
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Eosinophils, Day 4,n=12,6,6,8,8,6	0.014 Giga cells per liter Standard Deviation 0.1950	-0.172 Giga cells per liter Standard Deviation 0.0749	-0.212 Giga cells per liter Standard Deviation 0.1144	-0.348 Giga cells per liter Standard Deviation 0.1149	-0.300 Giga cells per liter Standard Deviation 0.1829	-0.192 Giga cells per liter Standard Deviation 0.0643
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Eosinophils, Day 5,n=11,6,6,9,9,6	-0.034 Giga cells per liter Standard Deviation 0.1529	-0.202 Giga cells per liter Standard Deviation 0.0799	-0.235 Giga cells per liter Standard Deviation 0.1117	-0.326 Giga cells per liter Standard Deviation 0.1385	-0.276 Giga cells per liter Standard Deviation 0.1351	-0.210 Giga cells per liter Standard Deviation 0.0767
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Eosinophils, Week 1,n=12,6,6,9,9,5	0.033 Giga cells per liter Standard Deviation 0.1461	-0.195 Giga cells per liter Standard Deviation 0.0609	-0.242 Giga cells per liter Standard Deviation 0.1189	-0.324 Giga cells per liter Standard Deviation 0.1350	-0.298 Giga cells per liter Standard Deviation 0.1824	-0.206 Giga cells per liter Standard Deviation 0.0568
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Eosinophils, Week 2,n=12,6,5,9,9,6	0.072 Giga cells per liter Standard Deviation 0.1809	-0.212 Giga cells per liter Standard Deviation 0.0895	-0.210 Giga cells per liter Standard Deviation 0.0886	-0.344 Giga cells per liter Standard Deviation 0.1334	-0.307 Giga cells per liter Standard Deviation 0.1602	-0.223 Giga cells per liter Standard Deviation 0.0952
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Eosinophils, Week 4,n=12,6,5,9,9,6	0.025 Giga cells per liter Standard Deviation 0.1635	-0.227 Giga cells per liter Standard Deviation 0.0712	-0.238 Giga cells per liter Standard Deviation 0.1150	-0.366 Giga cells per liter Standard Deviation 0.1466	-0.321 Giga cells per liter Standard Deviation 0.1969	-0.253 Giga cells per liter Standard Deviation 0.0855
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Eosinophils, Week 8,n=12,6,6,9,9,6	0.036 Giga cells per liter Standard Deviation 0.1486	-0.230 Giga cells per liter Standard Deviation 0.0769	-0.280 Giga cells per liter Standard Deviation 0.1202	-0.379 Giga cells per liter Standard Deviation 0.1519	-0.343 Giga cells per liter Standard Deviation 0.1841	-0.252 Giga cells per liter Standard Deviation 0.1007
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Eosinophils, Week 12,n=12,5,6,9,9,5	0.025 Giga cells per liter Standard Deviation 0.1566	-0.174 Giga cells per liter Standard Deviation 0.0777	-0.262 Giga cells per liter Standard Deviation 0.1087	-0.371 Giga cells per liter Standard Deviation 0.1484	-0.336 Giga cells per liter Standard Deviation 0.1895	-0.250 Giga cells per liter Standard Deviation 0.1245
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Eosinophils, Week 24,n=11,6,6,9,9,6	-0.021 Giga cells per liter Standard Deviation 0.1436	-0.072 Giga cells per liter Standard Deviation 0.0662	-0.103 Giga cells per liter Standard Deviation 0.1916	-0.300 Giga cells per liter Standard Deviation 0.1546	-0.334 Giga cells per liter Standard Deviation 0.1769	-0.245 Giga cells per liter Standard Deviation 0.1017
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Eosinophils, Week 26,n=12,6,6,9,9,6	0.035 Giga cells per liter Standard Deviation 0.1812	-0.042 Giga cells per liter Standard Deviation 0.0571	-0.037 Giga cells per liter Standard Deviation 0.2813	-0.273 Giga cells per liter Standard Deviation 0.1773	-0.319 Giga cells per liter Standard Deviation 0.1724	-0.252 Giga cells per liter Standard Deviation 0.0920
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Eosinophils, Week 32,n=6,6,6,0,0,6	0.008 Giga cells per liter Standard Deviation 0.0935	0.042 Giga cells per liter Standard Deviation 0.1153	0.003 Giga cells per liter Standard Deviation 0.2467	—	—	-0.235 Giga cells per liter Standard Deviation 0.1205
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Eosinophils, Week 36,n=6,0,0,9,9,0	-0.045 Giga cells per liter Standard Deviation 0.1758	—	—	-0.041 Giga cells per liter Standard Deviation 0.2734	-0.258 Giga cells per liter Standard Deviation 0.1594	—
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Lymphocytes, Day 4,n=12,6,6,8,8,6	0.006 Giga cells per liter Standard Deviation 0.4963	0.193 Giga cells per liter Standard Deviation 0.3242	0.172 Giga cells per liter Standard Deviation 0.3474	0.005 Giga cells per liter Standard Deviation 0.1753	0.005 Giga cells per liter Standard Deviation 0.3798	0.210 Giga cells per liter Standard Deviation 0.2772
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Lymphocytes, Week 2,n=12,6,5,9,9,6	-0.133 Giga cells per liter Standard Deviation 0.4107	0.222 Giga cells per liter Standard Deviation 0.3543	0.096 Giga cells per liter Standard Deviation 0.4117	-0.120 Giga cells per liter Standard Deviation 0.3304	-0.068 Giga cells per liter Standard Deviation 0.4104	0.047 Giga cells per liter Standard Deviation 0.1189
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Lymphocytes, Week 4,n=12,6,5,9,9,6	-0.189 Giga cells per liter Standard Deviation 0.4616	0.088 Giga cells per liter Standard Deviation 0.2938	0.056 Giga cells per liter Standard Deviation 0.2899	-0.062 Giga cells per liter Standard Deviation 0.2346	-0.052 Giga cells per liter Standard Deviation 0.5189	-0.137 Giga cells per liter Standard Deviation 0.2103
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Lymphocytes, Week 8,n=12,6,6,9,9,6	-0.057 Giga cells per liter Standard Deviation 0.4665	0.105 Giga cells per liter Standard Deviation 0.2670	-0.107 Giga cells per liter Standard Deviation 0.3584	-0.188 Giga cells per liter Standard Deviation 0.2277	0.052 Giga cells per liter Standard Deviation 0.3287	-0.075 Giga cells per liter Standard Deviation 0.0672
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Lymphocytes, Week 12,n=12,5,6,9,9,5	-0.142 Giga cells per liter Standard Deviation 0.4107	0.228 Giga cells per liter Standard Deviation 0.1968	0.072 Giga cells per liter Standard Deviation 0.4113	0.014 Giga cells per liter Standard Deviation 0.2490	0.048 Giga cells per liter Standard Deviation 0.3231	-0.388 Giga cells per liter Standard Deviation 0.2237
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Lymphocytes, Week 18,n=12,6,6,9,9,6	-0.212 Giga cells per liter Standard Deviation 0.4094	-0.032 Giga cells per liter Standard Deviation 0.2213	-0.042 Giga cells per liter Standard Deviation 0.3612	-0.097 Giga cells per liter Standard Deviation 0.4088	0.050 Giga cells per liter Standard Deviation 0.4539	-0.063 Giga cells per liter Standard Deviation 0.1788
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Monocytes, Week 2,n=12,6,5,9,9,6	0.013 Giga cells per liter Standard Deviation 0.0945	0.050 Giga cells per liter Standard Deviation 0.1621	0.056 Giga cells per liter Standard Deviation 0.0451	0.004 Giga cells per liter Standard Deviation 0.0975	0.118 Giga cells per liter Standard Deviation 0.1738	0.090 Giga cells per liter Standard Deviation 0.2697
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Monocytes, Week 4,n=12,6,5,9,9,6	0.001 Giga cells per liter Standard Deviation 0.0757	0.103 Giga cells per liter Standard Deviation 0.1382	-0.018 Giga cells per liter Standard Deviation 0.0817	0.042 Giga cells per liter Standard Deviation 0.0559	0.041 Giga cells per liter Standard Deviation 0.1014	-0.003 Giga cells per liter Standard Deviation 0.1201
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Monocytes, Week 8,n=12,6,6,9,9,6	0.048 Giga cells per liter Standard Deviation 0.1377	0.123 Giga cells per liter Standard Deviation 0.1681	-0.053 Giga cells per liter Standard Deviation 0.0484	-0.006 Giga cells per liter Standard Deviation 0.0648	0.080 Giga cells per liter Standard Deviation 0.1211	0.058 Giga cells per liter Standard Deviation 0.1509
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Monocytes, Week 12,n=12,5,6,9,9,5	0.007 Giga cells per liter Standard Deviation 0.1042	0.050 Giga cells per liter Standard Deviation 0.0561	-0.013 Giga cells per liter Standard Deviation 0.0841	0.059 Giga cells per liter Standard Deviation 0.0864	0.140 Giga cells per liter Standard Deviation 0.1734	0.084 Giga cells per liter Standard Deviation 0.1680
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Monocytes, Week 18,n=12,6,6,9,9,6	0.042 Giga cells per liter Standard Deviation 0.0897	-0.040 Giga cells per liter Standard Deviation 0.1362	-0.045 Giga cells per liter Standard Deviation 0.0944	0.018 Giga cells per liter Standard Deviation 0.1475	0.092 Giga cells per liter Standard Deviation 0.0874	0.043 Giga cells per liter Standard Deviation 0.1516
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Monocytes, Week 24,n=11,6,6,9,9,6	0.028 Giga cells per liter Standard Deviation 0.1181	-0.013 Giga cells per liter Standard Deviation 0.0989	0.070 Giga cells per liter Standard Deviation 0.0921	0.047 Giga cells per liter Standard Deviation 0.1301	0.159 Giga cells per liter Standard Deviation 0.2567	0.037 Giga cells per liter Standard Deviation 0.0975
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Platelet, Day 4,n=12,5,5,8,8,6	-5.6 Giga cells per liter Standard Deviation 18.64	-5.8 Giga cells per liter Standard Deviation 3.63	6.6 Giga cells per liter Standard Deviation 15.66	-0.4 Giga cells per liter Standard Deviation 18.86	-1.1 Giga cells per liter Standard Deviation 21.56	-0.2 Giga cells per liter Standard Deviation 6.62
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Platelet, Day 5,n=12,5,6,9,9,6	-7.6 Giga cells per liter Standard Deviation 17.59	-3.6 Giga cells per liter Standard Deviation 13.89	-3.0 Giga cells per liter Standard Deviation 18.11	-4.6 Giga cells per liter Standard Deviation 19.09	6.2 Giga cells per liter Standard Deviation 22.90	-2.8 Giga cells per liter Standard Deviation 18.62
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Platelet, Week 1,n=12,5,6,9,8,6	-0.9 Giga cells per liter Standard Deviation 20.21	-10.2 Giga cells per liter Standard Deviation 11.30	5.0 Giga cells per liter Standard Deviation 21.08	-3.9 Giga cells per liter Standard Deviation 12.41	16.8 Giga cells per liter Standard Deviation 25.37	-13.8 Giga cells per liter Standard Deviation 28.69
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Platelet, Week 2,n=12,5,6,9,9,6	3.5 Giga cells per liter Standard Deviation 16.51	2.8 Giga cells per liter Standard Deviation 13.59	-6.3 Giga cells per liter Standard Deviation 29.38	-0.9 Giga cells per liter Standard Deviation 25.09	25.0 Giga cells per liter Standard Deviation 38.64	-15.5 Giga cells per liter Standard Deviation 39.81
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Platelet, Week 4,n=12,5,4,9,9,6	-11.5 Giga cells per liter Standard Deviation 26.10	-6.8 Giga cells per liter Standard Deviation 20.93	1.3 Giga cells per liter Standard Deviation 37.07	-1.6 Giga cells per liter Standard Deviation 17.61	12.3 Giga cells per liter Standard Deviation 35.87	-5.0 Giga cells per liter Standard Deviation 22.80
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Platelet, Week 8,n=12,5,5,9,9,6	4.3 Giga cells per liter Standard Deviation 22.85	11.6 Giga cells per liter Standard Deviation 23.71	2.6 Giga cells per liter Standard Deviation 29.01	-11.3 Giga cells per liter Standard Deviation 21.03	22.0 Giga cells per liter Standard Deviation 30.81	-3.5 Giga cells per liter Standard Deviation 23.89
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Platelet, Week 12,n=12,5,6,9,9,5	-14.8 Giga cells per liter Standard Deviation 26.42	-6.0 Giga cells per liter Standard Deviation 16.63	-9.0 Giga cells per liter Standard Deviation 26.83	-10.8 Giga cells per liter Standard Deviation 10.15	27.4 Giga cells per liter Standard Deviation 43.23	-25.6 Giga cells per liter Standard Deviation 24.39
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Platelet, Week 18,n=12,5,6,9,9,6	-8.6 Giga cells per liter Standard Deviation 21.65	-13.4 Giga cells per liter Standard Deviation 20.42	-14.0 Giga cells per liter Standard Deviation 9.53	1.6 Giga cells per liter Standard Deviation 19.51	15.9 Giga cells per liter Standard Deviation 22.45	2.2 Giga cells per liter Standard Deviation 28.92
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Platelet, Week 24,n=10,5,6,9,9,6	-1.9 Giga cells per liter Standard Deviation 14.81	-7.8 Giga cells per liter Standard Deviation 18.35	-10.0 Giga cells per liter Standard Deviation 14.97	-1.6 Giga cells per liter Standard Deviation 19.94	19.7 Giga cells per liter Standard Deviation 30.07	-5.7 Giga cells per liter Standard Deviation 39.38
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Platelet, Week 26,n=12,5,6,9,9,6	2.4 Giga cells per liter Standard Deviation 30.14	-13.8 Giga cells per liter Standard Deviation 17.70	-19.3 Giga cells per liter Standard Deviation 13.81	-2.4 Giga cells per liter Standard Deviation 12.21	11.8 Giga cells per liter Standard Deviation 36.37	-6.8 Giga cells per liter Standard Deviation 17.38
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Platelet, Week 32,n=6,5,6,0,0,6	5.5 Giga cells per liter Standard Deviation 18.71	-0.6 Giga cells per liter Standard Deviation 15.37	-6.3 Giga cells per liter Standard Deviation 10.39	—	—	-15.7 Giga cells per liter Standard Deviation 51.15
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Platelet, Week 36,n=6,0,0,9,9,0	-1.8 Giga cells per liter Standard Deviation 25.65	—	—	-0.3 Giga cells per liter Standard Deviation 12.37	13.9 Giga cells per liter Standard Deviation 24.15	—
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Platelet, Week 40,n=2,0,0,0,0,6	-20.0 Giga cells per liter Standard Deviation 2.83	—	—	—	—	-11.7 Giga cells per liter Standard Deviation 30.80
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Neutrophil, Day 2,n=12,6,6,8,9,6	-0.078 Giga cells per liter Standard Deviation 0.8813	0.413 Giga cells per liter Standard Deviation 0.6493	-0.005 Giga cells per liter Standard Deviation 0.9228	0.301 Giga cells per liter Standard Deviation 0.5042	0.241 Giga cells per liter Standard Deviation 0.8219	0.102 Giga cells per liter Standard Deviation 0.4630
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Neutrophil, Day 3,n=12,6,6,9,9,6	0.161 Giga cells per liter Standard Deviation 0.4542	0.015 Giga cells per liter Standard Deviation 0.6691	0.225 Giga cells per liter Standard Deviation 0.6850	0.077 Giga cells per liter Standard Deviation 0.9525	0.217 Giga cells per liter Standard Deviation 1.1014	0.038 Giga cells per liter Standard Deviation 0.5158
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Neutrophil, Day 4,n=12,6,6,8,8,6	0.390 Giga cells per liter Standard Deviation 0.4832	0.560 Giga cells per liter Standard Deviation 0.4666	0.438 Giga cells per liter Standard Deviation 0.9293	0.151 Giga cells per liter Standard Deviation 0.9472	0.130 Giga cells per liter Standard Deviation 1.0414	0.215 Giga cells per liter Standard Deviation 0.4194
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Neutrophil, Week 1,n=12,6,6,9,9,5	-0.179 Giga cells per liter Standard Deviation 0.6365	-0.483 Giga cells per liter Standard Deviation 1.2069	-0.160 Giga cells per liter Standard Deviation 0.3280	-0.151 Giga cells per liter Standard Deviation 0.5955	0.174 Giga cells per liter Standard Deviation 0.8992	0.070 Giga cells per liter Standard Deviation 0.4346
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Neutrophil, Week 2,n=12,6,5,9,9,6	-0.209 Giga cells per liter Standard Deviation 0.4662	-0.738 Giga cells per liter Standard Deviation 0.7110	-0.142 Giga cells per liter Standard Deviation 1.0604	-0.192 Giga cells per liter Standard Deviation 0.9481	0.229 Giga cells per liter Standard Deviation 0.8853	-0.310 Giga cells per liter Standard Deviation 0.6362
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Neutrophil, Week 4,n=12,6,5,9,9,6	-0.540 Giga cells per liter Standard Deviation 0.4797	-0.768 Giga cells per liter Standard Deviation 0.7810	-0.156 Giga cells per liter Standard Deviation 0.9674	-0.279 Giga cells per liter Standard Deviation 0.5859	-0.340 Giga cells per liter Standard Deviation 0.7049	0.023 Giga cells per liter Standard Deviation 0.7539
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Neutrophil, Week 8,n=12,6,6,9,9,6	-0.218 Giga cells per liter Standard Deviation 0.7893	0.497 Giga cells per liter Standard Deviation 1.6165	-0.277 Giga cells per liter Standard Deviation 0.9128	-0.069 Giga cells per liter Standard Deviation 1.0047	-0.127 Giga cells per liter Standard Deviation 0.5829	0.258 Giga cells per liter Standard Deviation 0.5218
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Neutrophil, Week 12,n=12,5,6,9,9,5	0.043 Giga cells per liter Standard Deviation 0.9639	-0.712 Giga cells per liter Standard Deviation 0.5890	0.053 Giga cells per liter Standard Deviation 1.0187	-0.180 Giga cells per liter Standard Deviation 0.4760	-0.344 Giga cells per liter Standard Deviation 0.4840	-0.362 Giga cells per liter Standard Deviation 0.5607
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Neutrophil, Week 18,n=12,6,6,9,9,6	-0.093 Giga cells per liter Standard Deviation 0.9727	-0.158 Giga cells per liter Standard Deviation 0.7786	0.015 Giga cells per liter Standard Deviation 0.7474	-0.012 Giga cells per liter Standard Deviation 0.8076	-0.151 Giga cells per liter Standard Deviation 0.5728	-0.027 Giga cells per liter Standard Deviation 0.6629
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Neutrophil, Week 24,n=11,6,6,9,9,6	-0.326 Giga cells per liter Standard Deviation 0.4501	-0.752 Giga cells per liter Standard Deviation 0.9422	-0.370 Giga cells per liter Standard Deviation 0.3746	-0.144 Giga cells per liter Standard Deviation 0.5243	0.140 Giga cells per liter Standard Deviation 0.5795	-0.128 Giga cells per liter Standard Deviation 0.4311
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Neutrophil, Week 26,n=12,6,6,9,9,6	-0.105 Giga cells per liter Standard Deviation 0.7933	-0.527 Giga cells per liter Standard Deviation 0.6332	-0.622 Giga cells per liter Standard Deviation 0.6065	-0.259 Giga cells per liter Standard Deviation 0.9389	0.104 Giga cells per liter Standard Deviation 0.7127	-0.295 Giga cells per liter Standard Deviation 0.2855
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Neutrophil, Week 32,n=6,6,6,0,0,6	-0.393 Giga cells per liter Standard Deviation 0.8219	-0.708 Giga cells per liter Standard Deviation 0.7757	0.880 Giga cells per liter Standard Deviation 1.9211	—	—	-0.360 Giga cells per liter Standard Deviation 0.3275
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Neutrophil, Week 36,n=6,0,0,9,9,0	-0.163 Giga cells per liter Standard Deviation 0.8441	—	—	-0.384 Giga cells per liter Standard Deviation 0.4763	-0.004 Giga cells per liter Standard Deviation 0.9080	—
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Neutrophil, Week 40,n=2,0,0,0,0,6	-0.005 Giga cells per liter Standard Deviation 0.1061	—	—	—	—	0.332 Giga cells per liter Standard Deviation 0.3452
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Lymphocytes, Week 24,n=11,6,6,9,9,6	-0.179 Giga cells per liter Standard Deviation 0.3876	-0.028 Giga cells per liter Standard Deviation 0.3616	-0.040 Giga cells per liter Standard Deviation 0.2744	-0.070 Giga cells per liter Standard Deviation 0.3102	0.052 Giga cells per liter Standard Deviation 0.9838	-0.132 Giga cells per liter Standard Deviation 0.1619
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Lymphocytes, Week 26,n=12,6,6,9,9,6	-0.088 Giga cells per liter Standard Deviation 0.4361	-0.223 Giga cells per liter Standard Deviation 0.3808	-0.138 Giga cells per liter Standard Deviation 0.3577	-0.116 Giga cells per liter Standard Deviation 0.4946	0.018 Giga cells per liter Standard Deviation 0.5392	-0.188 Giga cells per liter Standard Deviation 0.2566
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Lymphocytes, Week 32,n=6,6,6,0,0,6	-0.165 Giga cells per liter Standard Deviation 0.6851	-0.057 Giga cells per liter Standard Deviation 0.2842	-0.197 Giga cells per liter Standard Deviation 0.5467	—	—	-0.148 Giga cells per liter Standard Deviation 0.2017
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Lymphocytes, Week 36,n=6,0,0,9,9,0	0.007 Giga cells per liter Standard Deviation 0.1838	—	—	-0.043 Giga cells per liter Standard Deviation 0.4393	0.006 Giga cells per liter Standard Deviation 0.4176	—
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Lymphocytes, Week 40,n=2,0,0,0,0,6	0.285 Giga cells per liter Standard Deviation 0.3465	—	—	—	—	-0.125 Giga cells per liter Standard Deviation 0.2966
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Monocytes, Day 2,n=12,6,6,8,9,6	-0.002 Giga cells per liter Standard Deviation 0.0914	0.017 Giga cells per liter Standard Deviation 0.1357	0.123 Giga cells per liter Standard Deviation 0.1240	0.015 Giga cells per liter Standard Deviation 0.1176	0.019 Giga cells per liter Standard Deviation 0.0715	0.052 Giga cells per liter Standard Deviation 0.1947
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Monocytes, Day 3,n=12,6,6,9,9,6	0.029 Giga cells per liter Standard Deviation 0.1001	0.028 Giga cells per liter Standard Deviation 0.1533	0.100 Giga cells per liter Standard Deviation 0.1235	-0.028 Giga cells per liter Standard Deviation 0.0753	0.032 Giga cells per liter Standard Deviation 0.0952	0.018 Giga cells per liter Standard Deviation 0.1514
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Monocytes, Day 4,n=12,6,6,8,8,6	0.032 Giga cells per liter Standard Deviation 0.0936	-0.002 Giga cells per liter Standard Deviation 0.1258	0.118 Giga cells per liter Standard Deviation 0.1057	-0.038 Giga cells per liter Standard Deviation 0.0927	0.068 Giga cells per liter Standard Deviation 0.1074	0.050 Giga cells per liter Standard Deviation 0.0434
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Monocytes, Day 5,n=11,6,6,9,9,6	-0.034 Giga cells per liter Standard Deviation 0.0841	-0.025 Giga cells per liter Standard Deviation 0.0701	0.053 Giga cells per liter Standard Deviation 0.1299	-0.100 Giga cells per liter Standard Deviation 0.1470	0.074 Giga cells per liter Standard Deviation 0.1874	-0.035 Giga cells per liter Standard Deviation 0.0766
Change From Baseline in Neutrophil, Lymphocyte, Monocyte, Eosinophil, Basophil and Platelet Count Monocytes, Week 1,n=12,6,6,9,9,5	0.006 Giga cells per liter Standard Deviation 0.0998	0.072 Giga cells per liter Standard Deviation 0.1127	0.057 Giga cells per liter Standard Deviation 0.1786	0.032 Giga cells per liter Standard Deviation 0.0578	0.101 Giga cells per liter Standard Deviation 0.1039	-0.012 Giga cells per liter Standard Deviation 0.0926

PRIMARY outcome

Timeframe: Baseline and at Days 2, 3, 4 and 5, Weeks 1, 2, 4, 8, 12, 18, 24, 26, 32, 36 and 40

Population: Safety Population. Only those participants with planned assessments at that particular time point has been presented (represented by n= X in the category titles).

Blood samples were collected at indicated time-points for analysis of hematology parameters like RBC count. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Placebo n=12 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Change From Baseline in Red Blood Cell Count (RBC) Day 2,n=12,6,6,9,9,6	-0.08 Trillion cells per liter Standard Deviation 0.212	-0.07 Trillion cells per liter Standard Deviation 0.197	0.08 Trillion cells per liter Standard Deviation 0.223	0.00 Trillion cells per liter Standard Deviation 0.194	0.16 Trillion cells per liter Standard Deviation 0.246	0.05 Trillion cells per liter Standard Deviation 0.243
Change From Baseline in Red Blood Cell Count (RBC) Day 3,n=12,6,6,9,9,6	0.03 Trillion cells per liter Standard Deviation 0.214	-0.08 Trillion cells per liter Standard Deviation 0.133	0.13 Trillion cells per liter Standard Deviation 0.242	0.01 Trillion cells per liter Standard Deviation 0.190	0.06 Trillion cells per liter Standard Deviation 0.133	0.03 Trillion cells per liter Standard Deviation 0.186
Change From Baseline in Red Blood Cell Count (RBC) Day 4,n=12,6,6,8,8,6	-0.04 Trillion cells per liter Standard Deviation 0.211	-0.08 Trillion cells per liter Standard Deviation 0.133	0.10 Trillion cells per liter Standard Deviation 0.179	-0.03 Trillion cells per liter Standard Deviation 0.149	0.04 Trillion cells per liter Standard Deviation 0.185	0.10 Trillion cells per liter Standard Deviation 0.141
Change From Baseline in Red Blood Cell Count (RBC) Day 5,n=12,6,6,9,9,6	-0.18 Trillion cells per liter Standard Deviation 0.175	-0.22 Trillion cells per liter Standard Deviation 0.133	-0.10 Trillion cells per liter Standard Deviation 0.261	-0.08 Trillion cells per liter Standard Deviation 0.120	0.03 Trillion cells per liter Standard Deviation 0.316	0.05 Trillion cells per liter Standard Deviation 0.187
Change From Baseline in Red Blood Cell Count (RBC) Week 1,n=12,6,6,9,9,5	-0.15 Trillion cells per liter Standard Deviation 0.215	-0.37 Trillion cells per liter Standard Deviation 0.175	0.00 Trillion cells per liter Standard Deviation 0.190	-0.03 Trillion cells per liter Standard Deviation 0.218	0.07 Trillion cells per liter Standard Deviation 0.180	-0.02 Trillion cells per liter Standard Deviation 0.147
Change From Baseline in Red Blood Cell Count (RBC) Week 2,n=12,6,6,9,9,6	-0.11 Trillion cells per liter Standard Deviation 0.156	-0.28 Trillion cells per liter Standard Deviation 0.133	-0.18 Trillion cells per liter Standard Deviation 0.183	-0.07 Trillion cells per liter Standard Deviation 0.206	0.11 Trillion cells per liter Standard Deviation 0.232	-0.08 Trillion cells per liter Standard Deviation 0.194
Change From Baseline in Red Blood Cell Count (RBC) Week 4,n=12,6,5,9,9,6	-0.18 Trillion cells per liter Standard Deviation 0.248	-0.35 Trillion cells per liter Standard Deviation 0.055	-0.16 Trillion cells per liter Standard Deviation 0.230	-0.08 Trillion cells per liter Standard Deviation 0.192	0.09 Trillion cells per liter Standard Deviation 0.293	-0.03 Trillion cells per liter Standard Deviation 0.137
Change From Baseline in Red Blood Cell Count (RBC) Week 8,n=12,6,6,9,9,6	-0.03 Trillion cells per liter Standard Deviation 0.253	-0.23 Trillion cells per liter Standard Deviation 0.186	-0.02 Trillion cells per liter Standard Deviation 0.248	-0.13 Trillion cells per liter Standard Deviation 0.200	0.18 Trillion cells per liter Standard Deviation 0.277	0.07 Trillion cells per liter Standard Deviation 0.103
Change From Baseline in Red Blood Cell Count (RBC) Week 12,n=12,6,6,9,9,5	-0.13 Trillion cells per liter Standard Deviation 0.176	-0.25 Trillion cells per liter Standard Deviation 0.138	-0.05 Trillion cells per liter Standard Deviation 0.251	-0.01 Trillion cells per liter Standard Deviation 0.237	0.19 Trillion cells per liter Standard Deviation 0.237	0.00 Trillion cells per liter Standard Deviation 0.141
Change From Baseline in Red Blood Cell Count (RBC) Week 18,n=12,6,6,9,9,6	-0.02 Trillion cells per liter Standard Deviation 0.292	-0.20 Trillion cells per liter Standard Deviation 0.219	-0.08 Trillion cells per liter Standard Deviation 0.271	-0.02 Trillion cells per liter Standard Deviation 0.228	0.27 Trillion cells per liter Standard Deviation 0.283	0.17 Trillion cells per liter Standard Deviation 0.163
Change From Baseline in Red Blood Cell Count (RBC) Week 24,n=11,6,6,9,9,6	-0.11 Trillion cells per liter Standard Deviation 0.221	-0.27 Trillion cells per liter Standard Deviation 0.175	-0.05 Trillion cells per liter Standard Deviation 0.164	0.01 Trillion cells per liter Standard Deviation 0.169	0.13 Trillion cells per liter Standard Deviation 0.229	0.17 Trillion cells per liter Standard Deviation 0.151
Change From Baseline in Red Blood Cell Count (RBC) Week 26,n=12,6,6,9,9,6	-0.12 Trillion cells per liter Standard Deviation 0.301	-0.33 Trillion cells per liter Standard Deviation 0.216	-0.08 Trillion cells per liter Standard Deviation 0.204	-0.02 Trillion cells per liter Standard Deviation 0.120	0.20 Trillion cells per liter Standard Deviation 0.194	0.12 Trillion cells per liter Standard Deviation 0.117
Change From Baseline in Red Blood Cell Count (RBC) Week 32,n=6,6,6,0,0,6	-0.10 Trillion cells per liter Standard Deviation 0.237	-0.18 Trillion cells per liter Standard Deviation 0.183	0.08 Trillion cells per liter Standard Deviation 0.248	—	—	0.05 Trillion cells per liter Standard Deviation 0.176
Change From Baseline in Red Blood Cell Count (RBC) Week 36,n=6,0,0,9,9,0	0.12 Trillion cells per liter Standard Deviation 0.232	—	—	0.10 Trillion cells per liter Standard Deviation 0.122	0.33 Trillion cells per liter Standard Deviation 0.357	—
Change From Baseline in Red Blood Cell Count (RBC) Week 40,n=2,0,0,0,0,6	-0.05 Trillion cells per liter Standard Deviation 0.071	—	—	—	—	0.12 Trillion cells per liter Standard Deviation 0.098

PRIMARY outcome

Timeframe: Baseline and at Days 2, 3, 4 and 5, Weeks 1, 2, 4, 8, 12, 18, 24, 26, 32, 36 and 40

Population: Safety Population. Only those participants with planned assessments at that particular time point has been presented (represented by n= X in the category titles).

Blood samples were collected at indicated time-points for analysis of hematology parameters like MCV. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Placebo n=12 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Change From Baseline in Mean Corpuscle Volume (MCV) Day 2,n=12,6,6,9,9,6	0.2 Femtoliters Standard Deviation 0.94	0.2 Femtoliters Standard Deviation 0.75	0.2 Femtoliters Standard Deviation 0.75	0.1 Femtoliters Standard Deviation 2.85	-0.3 Femtoliters Standard Deviation 1.00	1.3 Femtoliters Standard Deviation 2.16
Change From Baseline in Mean Corpuscle Volume (MCV) Day 3,n=12,6,6,9,9,6	0.7 Femtoliters Standard Deviation 1.07	-0.3 Femtoliters Standard Deviation 0.82	0.2 Femtoliters Standard Deviation 0.75	0.0 Femtoliters Standard Deviation 1.32	-1.0 Femtoliters Standard Deviation 1.41	0.3 Femtoliters Standard Deviation 1.37
Change From Baseline in Mean Corpuscle Volume (MCV) Day 4,n=12,6,6,8,8,6	0.3 Femtoliters Standard Deviation 0.78	-0.5 Femtoliters Standard Deviation 1.05	0.0 Femtoliters Standard Deviation 1.26	-0.1 Femtoliters Standard Deviation 0.83	-1.8 Femtoliters Standard Deviation 0.89	0.2 Femtoliters Standard Deviation 0.98
Change From Baseline in Mean Corpuscle Volume (MCV) Day 5,n=12,6,6,9,9,6	1.3 Femtoliters Standard Deviation 1.92	0.5 Femtoliters Standard Deviation 0.55	0.3 Femtoliters Standard Deviation 0.82	2.0 Femtoliters Standard Deviation 2.92	-1.0 Femtoliters Standard Deviation 3.50	0.7 Femtoliters Standard Deviation 1.75
Change From Baseline in Mean Corpuscle Volume (MCV) Week 1,n=12,6,6,9,9,6	-0.2 Femtoliters Standard Deviation 0.94	-0.8 Femtoliters Standard Deviation 1.33	0.2 Femtoliters Standard Deviation 0.75	-1.2 Femtoliters Standard Deviation 1.20	-1.7 Femtoliters Standard Deviation 2.06	-0.7 Femtoliters Standard Deviation 1.21
Change From Baseline in Mean Corpuscle Volume (MCV) Week 2,n=12,6,6,9,9,6	0.0 Femtoliters Standard Deviation 1.28	-0.3 Femtoliters Standard Deviation 1.51	0.2 Femtoliters Standard Deviation 0.75	-0.9 Femtoliters Standard Deviation 1.17	-1.4 Femtoliters Standard Deviation 2.51	-0.3 Femtoliters Standard Deviation 1.63
Change From Baseline in Mean Corpuscle Volume (MCV) Week 4,n=12,6,5,9,9,6	0.7 Femtoliters Standard Deviation 2.39	-0.8 Femtoliters Standard Deviation 2.14	0.2 Femtoliters Standard Deviation 0.45	-0.7 Femtoliters Standard Deviation 0.87	-1.6 Femtoliters Standard Deviation 2.13	-0.2 Femtoliters Standard Deviation 0.98
Change From Baseline in Mean Corpuscle Volume (MCV) Week 8,n=12,6,6,9,9,6	0.3 Femtoliters Standard Deviation 1.23	-0.3 Femtoliters Standard Deviation 1.51	0.2 Femtoliters Standard Deviation 0.75	0.0 Femtoliters Standard Deviation 1.12	-2.2 Femtoliters Standard Deviation 2.91	-0.2 Femtoliters Standard Deviation 1.17
Change From Baseline in Mean Corpuscle Volume (MCV) Week 12,n=12,6,6,9,9,5	0.5 Femtoliters Standard Deviation 1.09	-1.2 Femtoliters Standard Deviation 1.94	0.2 Femtoliters Standard Deviation 0.75	-0.7 Femtoliters Standard Deviation 1.87	-2.4 Femtoliters Standard Deviation 2.55	-1.2 Femtoliters Standard Deviation 0.84
Change From Baseline in Mean Corpuscle Volume (MCV) Week 18,n=12,6,6,9,9,6	-0.4 Femtoliters Standard Deviation 1.73	-0.8 Femtoliters Standard Deviation 1.33	0.5 Femtoliters Standard Deviation 1.64	-1.9 Femtoliters Standard Deviation 1.05	-2.8 Femtoliters Standard Deviation 3.07	-1.0 Femtoliters Standard Deviation 1.10
Change From Baseline in Mean Corpuscle Volume (MCV) Week 24,n=11,6,6,9,9,6	-0.8 Femtoliters Standard Deviation 1.78	-0.3 Femtoliters Standard Deviation 1.86	0.8 Femtoliters Standard Deviation 1.72	-1.6 Femtoliters Standard Deviation 1.51	-2.4 Femtoliters Standard Deviation 3.54	-0.7 Femtoliters Standard Deviation 1.03
Change From Baseline in Mean Corpuscle Volume (MCV) Week 26,n=12,6,6,9,9,6	-0.5 Femtoliters Standard Deviation 2.24	0.0 Femtoliters Standard Deviation 2.10	0.5 Femtoliters Standard Deviation 0.84	-1.7 Femtoliters Standard Deviation 1.58	-2.3 Femtoliters Standard Deviation 3.04	-0.3 Femtoliters Standard Deviation 1.03
Change From Baseline in Mean Corpuscle Volume (MCV) Week 32,n=6,6,6,0,0,6	0.5 Femtoliters Standard Deviation 1.38	0.0 Femtoliters Standard Deviation 2.45	0.8 Femtoliters Standard Deviation 1.47	—	—	-0.2 Femtoliters Standard Deviation 0.98
Change From Baseline in Mean Corpuscle Volume (MCV) Week 36,n=6,0,0,9,9,0	-1.5 Femtoliters Standard Deviation 1.05	—	—	-1.9 Femtoliters Standard Deviation 1.05	-1.8 Femtoliters Standard Deviation 2.44	—
Change From Baseline in Mean Corpuscle Volume (MCV) Week 40,n=2,0,0,0,0,6	-0.5 Femtoliters Standard Deviation 0.71	—	—	—	—	1.2 Femtoliters Standard Deviation 0.75

PRIMARY outcome

Timeframe: Baseline and at Days 2, 3, 4 and 5, Weeks 1, 2, 4, 8, 12, 18, 24, 26, 32, 36 and 40

Population: Safety Population. Only those participants with planned assessments at that particular time point has been presented (represented by n= X in the category titles).

Blood samples were collected at indicated time-points for analysis of hematology parameters like MCH. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Placebo n=12 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Change From Baseline in Mean Corpuscle Hemoglobin (MCH) Week 4,n=12,6,5,9,9,6	0.15 Picograms Standard Deviation 1.153	0.30 Picograms Standard Deviation 0.374	0.12 Picograms Standard Deviation 0.268	-0.29 Picograms Standard Deviation 0.404	-0.06 Picograms Standard Deviation 0.394	-0.22 Picograms Standard Deviation 0.343
Change From Baseline in Mean Corpuscle Hemoglobin (MCH) Day 2,n=12,6,6,9,9,6	0.03 Picograms Standard Deviation 0.588	0.23 Picograms Standard Deviation 0.388	0.02 Picograms Standard Deviation 0.299	-0.04 Picograms Standard Deviation 0.255	-0.02 Picograms Standard Deviation 0.277	-0.07 Picograms Standard Deviation 0.450
Change From Baseline in Mean Corpuscle Hemoglobin (MCH) Day 3,n=12,6,6,9,9,6	0.13 Picograms Standard Deviation 0.485	0.25 Picograms Standard Deviation 0.389	0.10 Picograms Standard Deviation 0.283	-0.02 Picograms Standard Deviation 0.228	0.20 Picograms Standard Deviation 0.444	-0.08 Picograms Standard Deviation 0.172
Change From Baseline in Mean Corpuscle Hemoglobin (MCH) Day 4,n=12,6,6,8,8,6	0.14 Picograms Standard Deviation 0.542	0.17 Picograms Standard Deviation 0.480	0.18 Picograms Standard Deviation 0.299	0.05 Picograms Standard Deviation 0.351	0.01 Picograms Standard Deviation 0.432	0.12 Picograms Standard Deviation 0.325
Change From Baseline in Mean Corpuscle Hemoglobin (MCH) Day 5,n=12,6,6,9,9,6	0.08 Picograms Standard Deviation 0.626	0.17 Picograms Standard Deviation 0.314	0.22 Picograms Standard Deviation 0.449	-0.03 Picograms Standard Deviation 0.346	0.02 Picograms Standard Deviation 0.331	-0.22 Picograms Standard Deviation 0.240
Change From Baseline in Mean Corpuscle Hemoglobin (MCH) Week 1,n=12,6,6,9,9,5	-0.07 Picograms Standard Deviation 0.433	0.38 Picograms Standard Deviation 0.542	-0.07 Picograms Standard Deviation 0.273	0.00 Picograms Standard Deviation 0.381	0.00 Picograms Standard Deviation 0.427	-0.08 Picograms Standard Deviation 0.553
Change From Baseline in Mean Corpuscle Hemoglobin (MCH) Week 2,n=12,6,6,9,9,6	-0.02 Picograms Standard Deviation 0.495	0.33 Picograms Standard Deviation 0.516	0.25 Picograms Standard Deviation 0.418	-0.08 Picograms Standard Deviation 0.331	-0.04 Picograms Standard Deviation 0.088	-0.02 Picograms Standard Deviation 0.240
Change From Baseline in Mean Corpuscle Hemoglobin (MCH) Week 8,n=12,6,6,9,9,6	-0.06 Picograms Standard Deviation 0.429	0.25 Picograms Standard Deviation 0.860	0.30 Picograms Standard Deviation 0.410	-0.30 Picograms Standard Deviation 0.287	-0.11 Picograms Standard Deviation 0.655	-0.22 Picograms Standard Deviation 0.286
Change From Baseline in Mean Corpuscle Hemoglobin (MCH) Week 12,n=12,6,6,9,9,5	-0.08 Picograms Standard Deviation 0.583	0.32 Picograms Standard Deviation 0.882	0.02 Picograms Standard Deviation 0.624	-0.42 Picograms Standard Deviation 0.415	-0.04 Picograms Standard Deviation 0.541	-0.60 Picograms Standard Deviation 0.561
Change From Baseline in Mean Corpuscle Hemoglobin (MCH) Week 18,n=12,6,6,9,9,6	-0.13 Picograms Standard Deviation 0.805	0.78 Picograms Standard Deviation 0.382	-0.10 Picograms Standard Deviation 0.616	-0.37 Picograms Standard Deviation 0.384	0.01 Picograms Standard Deviation 0.627	-0.78 Picograms Standard Deviation 0.382
Change From Baseline in Mean Corpuscle Hemoglobin (MCH) Week 24,n=11,6,6,9,9,6	-0.44 Picograms Standard Deviation 0.883	0.87 Picograms Standard Deviation 0.799	0.23 Picograms Standard Deviation 0.356	-0.37 Picograms Standard Deviation 0.510	-0.37 Picograms Standard Deviation 0.632	-0.90 Picograms Standard Deviation 0.237
Change From Baseline in Mean Corpuscle Hemoglobin (MCH) Week 26,n=12,6,6,9,9,6	-0.27 Picograms Standard Deviation 0.946	1.05 Picograms Standard Deviation 0.505	0.10 Picograms Standard Deviation 0.473	-0.38 Picograms Standard Deviation 0.432	-0.71 Picograms Standard Deviation 0.818	-1.07 Picograms Standard Deviation 0.393
Change From Baseline in Mean Corpuscle Hemoglobin (MCH) Week 32,n=6,6,6,0,0,6	0.22 Picograms Standard Deviation 0.975	0.67 Picograms Standard Deviation 0.625	0.53 Picograms Standard Deviation 0.909	—	—	-0.58 Picograms Standard Deviation 0.331
Change From Baseline in Mean Corpuscle Hemoglobin (MCH) Week 36,n=6,0,0,9,9,0	-1.00 Picograms Standard Deviation 0.525	—	—	-1.00 Picograms Standard Deviation 0.403	-0.68 Picograms Standard Deviation 0.438	—
Change From Baseline in Mean Corpuscle Hemoglobin (MCH) Week 40,n=2,0,0,0,0,6	-0.55 Picograms Standard Deviation 0.071	—	—	—	—	-0.68 Picograms Standard Deviation 0.232

PRIMARY outcome

Timeframe: Baseline and at Days 2, 3, 4 and 5, Weeks 1, 2, 4, 8, 12, 18, 24, 26, 32, 36 and 40

Population: Safety Population. Only those participants with planned assessments at that particular time point has been presented (represented by n= X in the category titles).

Blood samples were collected at indicated time-points for analysis of hematology parameters like hemoglobin. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Placebo n=12 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Change From Baseline in Hemoglobin Day 2,n=12,6,6,9,9,6	-2.4 Grams per liter Standard Deviation 6.83	0.3 Grams per liter Standard Deviation 6.80	3.7 Grams per liter Standard Deviation 7.09	-0.4 Grams per liter Standard Deviation 6.00	4.3 Grams per liter Standard Deviation 7.12	0.2 Grams per liter Standard Deviation 8.52
Change From Baseline in Hemoglobin Day 3,n=12,6,6,9,9,6	1.6 Grams per liter Standard Deviation 6.78	-0.5 Grams per liter Standard Deviation 4.04	5.8 Grams per liter Standard Deviation 8.80	0.1 Grams per liter Standard Deviation 6.62	2.2 Grams per liter Standard Deviation 4.35	-0.5 Grams per liter Standard Deviation 5.82
Change From Baseline in Hemoglobin Day 4,n=12,6,6,8,8,6	-0.8 Grams per liter Standard Deviation 6.69	-1.3 Grams per liter Standard Deviation 4.59	3.7 Grams per liter Standard Deviation 6.02	-1.0 Grams per liter Standard Deviation 4.14	1.4 Grams per liter Standard Deviation 5.32	3.2 Grams per liter Standard Deviation 5.12
Change From Baseline in Hemoglobin Day 5,n=12,6,6,9,9,6	-5.0 Grams per liter Standard Deviation 4.65	-4.8 Grams per liter Standard Deviation 3.82	-0.3 Grams per liter Standard Deviation 7.84	-2.9 Grams per liter Standard Deviation 4.54	0.8 Grams per liter Standard Deviation 8.86	-0.3 Grams per liter Standard Deviation 5.13
Change From Baseline in Hemoglobin Week 1,n=12,6,6,9,9,6	-4.9 Grams per liter Standard Deviation 6.50	-8.3 Grams per liter Standard Deviation 5.28	0.2 Grams per liter Standard Deviation 6.79	-1.4 Grams per liter Standard Deviation 7.00	2.0 Grams per liter Standard Deviation 6.42	-1.5 Grams per liter Standard Deviation 3.27
Change From Baseline in Hemoglobin Week 2,n=12,6,6,9,9,6	-3.3 Grams per liter Standard Deviation 5.79	-6.2 Grams per liter Standard Deviation 4.67	-3.7 Grams per liter Standard Deviation 5.72	-2.4 Grams per liter Standard Deviation 6.29	3.3 Grams per liter Standard Deviation 7.73	-3.5 Grams per liter Standard Deviation 6.50
Change From Baseline in Hemoglobin Week 4,n=12,6,5,9,9,6	-4.2 Grams per liter Standard Deviation 5.08	-8.0 Grams per liter Standard Deviation 4.10	-3.0 Grams per liter Standard Deviation 7.94	-4.2 Grams per liter Standard Deviation 6.61	2.6 Grams per liter Standard Deviation 10.36	-2.5 Grams per liter Standard Deviation 4.09
Change From Baseline in Hemoglobin Week 8,n=12,6,6,9,9,6	-1.1 Grams per liter Standard Deviation 8.83	-4.8 Grams per liter Standard Deviation 4.96	1.5 Grams per liter Standard Deviation 8.71	-5.6 Grams per liter Standard Deviation 6.27	4.9 Grams per liter Standard Deviation 7.80	-0.2 Grams per liter Standard Deviation 2.48
Change From Baseline in Hemoglobin Week 12,n=12,6,6,9,9,5	-4.3 Grams per liter Standard Deviation 6.50	-4.8 Grams per liter Standard Deviation 4.49	-0.2 Grams per liter Standard Deviation 9.28	-2.8 Grams per liter Standard Deviation 7.98	5.9 Grams per liter Standard Deviation 6.39	-3.6 Grams per liter Standard Deviation 2.07
Change From Baseline in Hemoglobin Week 18,n=12,6,6,9,9,6	-1.6 Grams per liter Standard Deviation 8.47	-1.8 Grams per liter Standard Deviation 6.77	-2.3 Grams per liter Standard Deviation 6.62	-2.4 Grams per liter Standard Deviation 6.09	8.3 Grams per liter Standard Deviation 9.25	0.5 Grams per liter Standard Deviation 4.72
Change From Baseline in Hemoglobin Week 24,n=11,6,6,9,9,6	-5.3 Grams per liter Standard Deviation 8.31	-3.2 Grams per liter Standard Deviation 7.99	0.5 Grams per liter Standard Deviation 6.09	-1.7 Grams per liter Standard Deviation 6.36	2.4 Grams per liter Standard Deviation 7.67	-0.2 Grams per liter Standard Deviation 3.37
Change From Baseline in Hemoglobin Week 26,n=12,6,6,9,9,6	-4.6 Grams per liter Standard Deviation 9.70	-4.5 Grams per liter Standard Deviation 8.07	-1.0 Grams per liter Standard Deviation 5.76	-2.2 Grams per liter Standard Deviation 3.42	2.9 Grams per liter Standard Deviation 6.23	-2.7 Grams per liter Standard Deviation 4.32
Change From Baseline in Hemoglobin Week 32,n=6,6,6,0,0,6	-1.7 Grams per liter Standard Deviation 3.78	-1.8 Grams per liter Standard Deviation 4.79	5.2 Grams per liter Standard Deviation 8.38	—	—	-1.8 Grams per liter Standard Deviation 5.71
Change From Baseline in Hemoglobin Week 36,n=6,0,0,9,9,0	-1.8 Grams per liter Standard Deviation 8.47	—	—	-2.4 Grams per liter Standard Deviation 3.13	6.9 Grams per liter Standard Deviation 10.67	—
Change From Baseline in Hemoglobin Week 40,n=2,0,0,0,0,6	-3.5 Grams per liter Standard Deviation 3.54	—	—	—	—	-0.2 Grams per liter Standard Deviation 4.17

PRIMARY outcome

Timeframe: Baseline and at Days 2, 3, 4 and 5, Weeks 1, 2, 4, 8, 12, 18, 24, 26, 32, 36 and 40

Population: Safety Population. Only those participants with planned assessments at that particular time point has been presented (represented by n= X in the category titles).

Blood samples were collected at indicated time-points for analysis of hematology parameters like hematocrit. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Placebo n=12 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Change From Baseline in Hematocrit Week 26,n=12,6,6,9,9,6	-0.013 Proportion of red blood cells in blood Standard Deviation 0.02378	-0.029 Proportion of red blood cells in blood Standard Deviation 0.02593	-0.004 Proportion of red blood cells in blood Standard Deviation 0.01813	-0.007 Proportion of red blood cells in blood Standard Deviation 0.01424	0.008 Proportion of red blood cells in blood Standard Deviation 0.01829	0.006 Proportion of red blood cells in blood Standard Deviation 0.01091
Change From Baseline in Hematocrit Week 32,n=6,6,6,0,0,6	-0.005 Proportion of red blood cells in blood Standard Deviation 0.01904	-0.015 Proportion of red blood cells in blood Standard Deviation 0.02220	0.009 Proportion of red blood cells in blood Standard Deviation 0.02413	—	—	0.002 Proportion of red blood cells in blood Standard Deviation 0.01851
Change From Baseline in Hematocrit Week 36,n=6,0,0,9,9,0	0.001 Proportion of red blood cells in blood Standard Deviation 0.01862	—	—	-0.001 Proportion of red blood cells in blood Standard Deviation 0.01237	0.022 Proportion of red blood cells in blood Standard Deviation 0.03464	—
Change From Baseline in Hematocrit Day 2,n=12,6,6,9,9,6	-0.007 Proportion of red blood cells in blood Standard Deviation 0.01961	-0.001 Proportion of red blood cells in blood Standard Deviation 0.01884	0.009 Proportion of red blood cells in blood Standard Deviation 0.02262	0.000 Proportion of red blood cells in blood Standard Deviation 0.01500	0.011 Proportion of red blood cells in blood Standard Deviation 0.02356	0.007 Proportion of red blood cells in blood Standard Deviation 0.02689
Change From Baseline in Hematocrit Day 3,n=12,6,6,9,9,6	0.005 Proportion of red blood cells in blood Standard Deviation 0.01925	-0.007 Proportion of red blood cells in blood Standard Deviation 0.01374	0.014 Proportion of red blood cells in blood Standard Deviation 0.02667	0.001 Proportion of red blood cells in blood Standard Deviation 0.01634	-0.000 Proportion of red blood cells in blood Standard Deviation 0.01198	0.001 Proportion of red blood cells in blood Standard Deviation 0.01584
Change From Baseline in Hematocrit Day 4,n=12,6,6,8,8,6	-0.003 Proportion of red blood cells in blood Standard Deviation 0.01777	-0.009 Proportion of red blood cells in blood Standard Deviation 0.01803	0.005 Proportion of red blood cells in blood Standard Deviation 0.02170	-0.003 Proportion of red blood cells in blood Standard Deviation 0.01663	-0.004 Proportion of red blood cells in blood Standard Deviation 0.01858	0.008 Proportion of red blood cells in blood Standard Deviation 0.01251
Change From Baseline in Hematocrit Day 5,n=12,6,6,9,9,6	-0.010 Proportion of red blood cells in blood Standard Deviation 0.01509	-0.015 Proportion of red blood cells in blood Standard Deviation 0.01340	-0.004 Proportion of red blood cells in blood Standard Deviation 0.02743	0.001 Proportion of red blood cells in blood Standard Deviation 0.01970	-0.001 Proportion of red blood cells in blood Standard Deviation 0.03295	0.006 Proportion of red blood cells in blood Standard Deviation 0.01061
Change From Baseline in Hematocrit Week 1,n=12,6,6,9,9,6	-0.014 Proportion of red blood cells in blood Standard Deviation 0.01894	-0.034 Proportion of red blood cells in blood Standard Deviation 0.01549	0.000 Proportion of red blood cells in blood Standard Deviation 0.02138	-0.008 Proportion of red blood cells in blood Standard Deviation 0.02644	-0.001 Proportion of red blood cells in blood Standard Deviation 0.02068	-0.005 Proportion of red blood cells in blood Standard Deviation 0.01076
Change From Baseline in Hematocrit Week 2,n=12,6,6,9,9,6	-0.010 Proportion of red blood cells in blood Standard Deviation 0.01670	-0.025 Proportion of red blood cells in blood Standard Deviation 0.01626	-0.016 Proportion of red blood cells in blood Standard Deviation 0.01928	-0.009 Proportion of red blood cells in blood Standard Deviation 0.01960	0.002 Proportion of red blood cells in blood Standard Deviation 0.02469	-0.011 Proportion of red blood cells in blood Standard Deviation 0.01759
Change From Baseline in Hematocrit Week 4,n=12,6,5,9,9,6	-0.011 Proportion of red blood cells in blood Standard Deviation 0.01840	-0.032 Proportion of red blood cells in blood Standard Deviation 0.01393	-0.010 Proportion of red blood cells in blood Standard Deviation 0.02192	-0.010 Proportion of red blood cells in blood Standard Deviation 0.02063	0.001 Proportion of red blood cells in blood Standard Deviation 0.02962	-0.004 Proportion of red blood cells in blood Standard Deviation 0.01315
Change From Baseline in Hematocrit Week 8,n=12,6,6,9,9,6	-0.001 Proportion of red blood cells in blood Standard Deviation 0.02285	-0.020 Proportion of red blood cells in blood Standard Deviation 0.02119	-0.000 Proportion of red blood cells in blood Standard Deviation 0.02367	-0.011 Proportion of red blood cells in blood Standard Deviation 0.01889	0.005 Proportion of red blood cells in blood Standard Deviation 0.03084	0.002 Proportion of red blood cells in blood Standard Deviation 0.00750
Change From Baseline in Hematocrit Week 12,n=12,6,6,9,9,5	-0.010 Proportion of red blood cells in blood Standard Deviation 0.01745	-0.025 Proportion of red blood cells in blood Standard Deviation 0.01262	-0.001 Proportion of red blood cells in blood Standard Deviation 0.02587	-0.005 Proportion of red blood cells in blood Standard Deviation 0.02379	0.006 Proportion of red blood cells in blood Standard Deviation 0.02343	-0.006 Proportion of red blood cells in blood Standard Deviation 0.01279
Change From Baseline in Hematocrit Week 18,n=12,6,6,9,9,6	-0.004 Proportion of red blood cells in blood Standard Deviation 0.02680	-0.020 Proportion of red blood cells in blood Standard Deviation 0.02140	-0.005 Proportion of red blood cells in blood Standard Deviation 0.03041	-0.010 Proportion of red blood cells in blood Standard Deviation 0.02016	0.012 Proportion of red blood cells in blood Standard Deviation 0.02972	0.008 Proportion of red blood cells in blood Standard Deviation 0.01515
Change From Baseline in Hematocrit Week 24,n=11,6,6,9,9,6	-0.013 Proportion of red blood cells in blood Standard Deviation 0.02108	-0.023 Proportion of red blood cells in blood Standard Deviation 0.02325	0.001 Proportion of red blood cells in blood Standard Deviation 0.01955	-0.006 Proportion of red blood cells in blood Standard Deviation 0.01726	0.001 Proportion of red blood cells in blood Standard Deviation 0.02607	0.009 Proportion of red blood cells in blood Standard Deviation 0.01184
Change From Baseline in Hematocrit Week 40,n=2,0,0,0,0,6	-0.004 Proportion of red blood cells in blood Standard Deviation 0.00495	—	—	—	—	0.016 Proportion of red blood cells in blood Standard Deviation 0.00816

PRIMARY outcome

Timeframe: Baseline and at Days 2, 3, 4 and 5, Weeks 1, 2, 4, 8, 12, 18, 24, 26, 32, 36 and 40

Population: Safety Population. Only those participants with planned assessments at that particular time point has been presented (represented by n= X in the category titles).

Blood samples were collected at indicated time-points for analysis of clinical parameters like hsCRP. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Placebo n=12 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Change From Baseline in Clinical Chemistry Parameter: High Sensitivity C-reactive Protein (hsCRP) Day 2,n=12,6,6,9,9,6	-0.3443 Milligrams per liter Standard Deviation 0.44689	-0.1217 Milligrams per liter Standard Deviation 0.28604	-0.7367 Milligrams per liter Standard Deviation 0.90943	-0.3178 Milligrams per liter Standard Deviation 0.45880	-1.0956 Milligrams per liter Standard Deviation 1.50219	-0.4867 Milligrams per liter Standard Deviation 0.50816
Change From Baseline in Clinical Chemistry Parameter: High Sensitivity C-reactive Protein (hsCRP) Day 3,n=11,6,6,9,9,6	-0.4376 Milligrams per liter Standard Deviation 0.43692	-0.1417 Milligrams per liter Standard Deviation 0.25818	-0.8200 Milligrams per liter Standard Deviation 1.10247	-0.4367 Milligrams per liter Standard Deviation 0.71042	-1.4100 Milligrams per liter Standard Deviation 2.19445	-0.4817 Milligrams per liter Standard Deviation 0.53663
Change From Baseline in Clinical Chemistry Parameter: High Sensitivity C-reactive Protein (hsCRP) Day 4,n=12,6,6,9,9,6	-0.4570 Milligrams per liter Standard Deviation 0.42874	-0.1917 Milligrams per liter Standard Deviation 0.23095	-0.8683 Milligrams per liter Standard Deviation 1.21224	-0.5356 Milligrams per liter Standard Deviation 0.91155	-1.5311 Milligrams per liter Standard Deviation 2.32545	-0.5867 Milligrams per liter Standard Deviation 0.66476
Change From Baseline in Clinical Chemistry Parameter: High Sensitivity C-reactive Protein (hsCRP) Day 5,n=12,6,6,9,9,6	-0.3953 Milligrams per liter Standard Deviation 0.37761	-0.0117 Milligrams per liter Standard Deviation 0.31244	-0.7150 Milligrams per liter Standard Deviation 1.23395	-0.5322 Milligrams per liter Standard Deviation 0.95860	-1.4289 Milligrams per liter Standard Deviation 2.35532	-0.5867 Milligrams per liter Standard Deviation 0.77590
Change From Baseline in Clinical Chemistry Parameter: High Sensitivity C-reactive Protein (hsCRP) Week 1,n=11,6,6,9,9,6	-0.2176 Milligrams per liter Standard Deviation 0.37960	0.2183 Milligrams per liter Standard Deviation 0.23086	-0.3033 Milligrams per liter Standard Deviation 1.32284	-0.5772 Milligrams per liter Standard Deviation 0.86704	-1.3156 Milligrams per liter Standard Deviation 2.57735	-0.5717 Milligrams per liter Standard Deviation 0.69534
Change From Baseline in Clinical Chemistry Parameter: High Sensitivity C-reactive Protein (hsCRP) Week 2,n=12,6,6,9,9,6	0.0638 Milligrams per liter Standard Deviation 0.44620	0.0167 Milligrams per liter Standard Deviation 0.21435	-0.6967 Milligrams per liter Standard Deviation 1.30606	0.1733 Milligrams per liter Standard Deviation 0.86781	0.2478 Milligrams per liter Standard Deviation 2.91047	-0.0967 Milligrams per liter Standard Deviation 0.50091
Change From Baseline in Clinical Chemistry Parameter: High Sensitivity C-reactive Protein (hsCRP) Week 4,n=12,6,6,9,9,6	-0.1253 Milligrams per liter Standard Deviation 0.55902	0.1433 Milligrams per liter Standard Deviation 0.66069	-0.6433 Milligrams per liter Standard Deviation 1.28969	-0.2689 Milligrams per liter Standard Deviation 0.86847	2.6422 Milligrams per liter Standard Deviation 11.57024	-0.4317 Milligrams per liter Standard Deviation 0.54653
Change From Baseline in Clinical Chemistry Parameter: High Sensitivity C-reactive Protein (hsCRP) Week 8,n=12,6,6,9,9,6	0.5955 Milligrams per liter Standard Deviation 1.62268	1.2817 Milligrams per liter Standard Deviation 1.79930	-0.3633 Milligrams per liter Standard Deviation 1.66310	-0.0878 Milligrams per liter Standard Deviation 0.61243	-1.1656 Milligrams per liter Standard Deviation 2.91829	-0.2517 Milligrams per liter Standard Deviation 0.74440
Change From Baseline in Clinical Chemistry Parameter: High Sensitivity C-reactive Protein (hsCRP) Week 12,n=12,6,6,9,9,6	0.1455 Milligrams per liter Standard Deviation 1.29507	-0.1033 Milligrams per liter Standard Deviation 0.36784	0.1250 Milligrams per liter Standard Deviation 0.61656	0.9089 Milligrams per liter Standard Deviation 1.31831	-0.4067 Milligrams per liter Standard Deviation 3.85725	0.1000 Milligrams per liter Standard Deviation 0.55274
Change From Baseline in Clinical Chemistry Parameter: High Sensitivity C-reactive Protein (hsCRP) Week 18,n=12,6,6,9,9,6	0.1538 Milligrams per liter Standard Deviation 0.54412	0.1883 Milligrams per liter Standard Deviation 0.22851	0.1317 Milligrams per liter Standard Deviation 1.77035	0.0700 Milligrams per liter Standard Deviation 1.19067	-1.1267 Milligrams per liter Standard Deviation 2.89881	-0.3300 Milligrams per liter Standard Deviation 0.53457
Change From Baseline in Clinical Chemistry Parameter: High Sensitivity C-reactive Protein (hsCRP) Week 24,n=12,6,6,9,9,6	0.1163 Milligrams per liter Standard Deviation 1.06052	0.4383 Milligrams per liter Standard Deviation 1.46248	-0.6383 Milligrams per liter Standard Deviation 1.36902	0.1356 Milligrams per liter Standard Deviation 0.80296	-0.7989 Milligrams per liter Standard Deviation 3.36420	-0.2142 Milligrams per liter Standard Deviation 1.09332
Change From Baseline in Clinical Chemistry Parameter: High Sensitivity C-reactive Protein (hsCRP) Week 26,n=12,6,6,9,9,6	0.2438 Milligrams per liter Standard Deviation 0.75525	1.6333 Milligrams per liter Standard Deviation 3.95614	-0.6383 Milligrams per liter Standard Deviation 1.13732	0.3344 Milligrams per liter Standard Deviation 0.53761	-0.6933 Milligrams per liter Standard Deviation 3.25344	0.2400 Milligrams per liter Standard Deviation 0.76467
Change From Baseline in Clinical Chemistry Parameter: High Sensitivity C-reactive Protein (hsCRP) Week 32,n=6,5,6,0,0,6	0.6393 Milligrams per liter Standard Deviation 1.03514	0.2860 Milligrams per liter Standard Deviation 0.82509	-0.2400 Milligrams per liter Standard Deviation 1.63862	—	—	-0.1367 Milligrams per liter Standard Deviation 0.73277
Change From Baseline in Clinical Chemistry Parameter: High Sensitivity C-reactive Protein (hsCRP) Week 36,n=6,0,0,9,9,0	0.4917 Milligrams per liter Standard Deviation 1.31750	—	—	-0.5456 Milligrams per liter Standard Deviation 1.15831	-0.1911 Milligrams per liter Standard Deviation 3.93159	—
Change From Baseline in Clinical Chemistry Parameter: High Sensitivity C-reactive Protein (hsCRP) Week 40,n=2,0,0,0,0,6	-0.1450 Milligrams per liter Standard Deviation 0.00707	—	—	—	—	0.4333 Milligrams per liter Standard Deviation 1.74105

PRIMARY outcome

Timeframe: Baseline and at Days 2, 3, 4 and 5, Weeks 1, 2, 4, 8, 12, 18, 24, 26, 32, 36 and 40

Population: Safety Population. Only those participants with planned assessments at that particular time point has been presented (represented by n= X in the category titles).

Blood samples were collected at indicated time-points for analysis of clinical parameters like total protein and albumin. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Placebo n=12 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Change From Baseline in Clinical Chemistry Parameter of Total Protein and Albumin Albumin, Week 4,n=12,6,6,9,9,6	-1.8 Grams per liter Standard Deviation 2.42	-1.0 Grams per liter Standard Deviation 2.28	-0.3 Grams per liter Standard Deviation 2.88	-1.3 Grams per liter Standard Deviation 1.87	-0.6 Grams per liter Standard Deviation 2.19	-1.3 Grams per liter Standard Deviation 2.73
Change From Baseline in Clinical Chemistry Parameter of Total Protein and Albumin Albumin, Week 18,n=12,6,6,9,9,6	-0.5 Grams per liter Standard Deviation 2.35	-0.3 Grams per liter Standard Deviation 2.94	-1.5 Grams per liter Standard Deviation 1.64	-0.7 Grams per liter Standard Deviation 2.06	0.2 Grams per liter Standard Deviation 2.44	0.2 Grams per liter Standard Deviation 1.94
Change From Baseline in Clinical Chemistry Parameter of Total Protein and Albumin Total protein, Day 2,n=12,6,5,9,9,6	-2.8 Grams per liter Standard Deviation 3.74	-2.3 Grams per liter Standard Deviation 1.97	-0.6 Grams per liter Standard Deviation 3.36	-3.8 Grams per liter Standard Deviation 3.56	0.7 Grams per liter Standard Deviation 4.90	-0.2 Grams per liter Standard Deviation 4.40
Change From Baseline in Clinical Chemistry Parameter of Total Protein and Albumin Total protein, Day 3,n=12,6,6,9,9,6	-1.4 Grams per liter Standard Deviation 3.68	-2.5 Grams per liter Standard Deviation 2.17	0.2 Grams per liter Standard Deviation 3.43	-1.7 Grams per liter Standard Deviation 4.18	-0.7 Grams per liter Standard Deviation 3.16	0.0 Grams per liter Standard Deviation 3.22
Change From Baseline in Clinical Chemistry Parameter of Total Protein and Albumin Total protein, Day 4,n=12,6,6,9,9,6	-1.8 Grams per liter Standard Deviation 4.34	-1.2 Grams per liter Standard Deviation 2.14	0.3 Grams per liter Standard Deviation 2.58	-2.8 Grams per liter Standard Deviation 3.46	-0.4 Grams per liter Standard Deviation 2.65	1.7 Grams per liter Standard Deviation 2.88
Change From Baseline in Clinical Chemistry Parameter of Total Protein and Albumin Total protein, Day 5,n=12,6,6,9,9,6	-3.3 Grams per liter Standard Deviation 2.77	-2.7 Grams per liter Standard Deviation 2.58	-0.7 Grams per liter Standard Deviation 4.72	-3.2 Grams per liter Standard Deviation 4.02	0.1 Grams per liter Standard Deviation 5.78	0.0 Grams per liter Standard Deviation 3.41
Change From Baseline in Clinical Chemistry Parameter of Total Protein and Albumin Total protein, Week 1,n=11,6,6,9,9,5	-1.6 Grams per liter Standard Deviation 2.87	-2.3 Grams per liter Standard Deviation 4.23	-2.8 Grams per liter Standard Deviation 2.99	-1.2 Grams per liter Standard Deviation 4.29	-1.1 Grams per liter Standard Deviation 3.62	-1.4 Grams per liter Standard Deviation 1.95
Change From Baseline in Clinical Chemistry Parameter of Total Protein and Albumin Total protein, Week 2,n=12,6,6,9,9,6	-1.8 Grams per liter Standard Deviation 3.28	-2.8 Grams per liter Standard Deviation 4.26	-2.8 Grams per liter Standard Deviation 2.99	-1.2 Grams per liter Standard Deviation 4.29	1.1 Grams per liter Standard Deviation 4.08	-1.0 Grams per liter Standard Deviation 3.58
Change From Baseline in Clinical Chemistry Parameter of Total Protein and Albumin Total protein, Week 4,n=12,6,6,9,9,6	-2.5 Grams per liter Standard Deviation 3.48	-3.3 Grams per liter Standard Deviation 3.01	-0.8 Grams per liter Standard Deviation 5.19	-1.4 Grams per liter Standard Deviation 3.09	-0.1 Grams per liter Standard Deviation 4.78	-1.0 Grams per liter Standard Deviation 3.41
Change From Baseline in Clinical Chemistry Parameter of Total Protein and Albumin Total protein, Week 8,n=12,6,6,9,9,6	-1.0 Grams per liter Standard Deviation 4.33	-0.8 Grams per liter Standard Deviation 5.15	0.2 Grams per liter Standard Deviation 4.54	-3.0 Grams per liter Standard Deviation 3.94	1.4 Grams per liter Standard Deviation 3.75	1.2 Grams per liter Standard Deviation 3.37
Change From Baseline in Clinical Chemistry Parameter of Total Protein and Albumin Total protein, Week 12,n=12,6,6,9,9,6	-2.8 Grams per liter Standard Deviation 2.67	-3.5 Grams per liter Standard Deviation 4.59	-0.5 Grams per liter Standard Deviation 3.62	-2.6 Grams per liter Standard Deviation 3.71	2.7 Grams per liter Standard Deviation 2.78	0.0 Grams per liter Standard Deviation 2.10
Change From Baseline in Clinical Chemistry Parameter of Total Protein and Albumin Total protein, Week 18,n=12,6,6,9,9,6	-1.3 Grams per liter Standard Deviation 2.56	-1.8 Grams per liter Standard Deviation 5.23	-1.7 Grams per liter Standard Deviation 3.20	-2.0 Grams per liter Standard Deviation 3.64	1.7 Grams per liter Standard Deviation 3.50	1.5 Grams per liter Standard Deviation 3.08
Change From Baseline in Clinical Chemistry Parameter of Total Protein and Albumin Total protein, Week 24,n=12,6,6,9,9,6	-3.3 Grams per liter Standard Deviation 3.79	-2.8 Grams per liter Standard Deviation 4.54	-1.0 Grams per liter Standard Deviation 3.35	-2.7 Grams per liter Standard Deviation 3.04	0.6 Grams per liter Standard Deviation 3.71	0.3 Grams per liter Standard Deviation 2.73
Change From Baseline in Clinical Chemistry Parameter of Total Protein and Albumin Total protein, Week 26,n=12,6,6,9,9,6	-2.5 Grams per liter Standard Deviation 3.55	-3.5 Grams per liter Standard Deviation 2.88	-2.3 Grams per liter Standard Deviation 3.39	-3.7 Grams per liter Standard Deviation 1.87	1.0 Grams per liter Standard Deviation 2.40	0.3 Grams per liter Standard Deviation 2.34
Change From Baseline in Clinical Chemistry Parameter of Total Protein and Albumin Total protein, Week 32,n=6,6,6,0,0,6	-1.7 Grams per liter Standard Deviation 3.93	0.0 Grams per liter Standard Deviation 3.63	0.3 Grams per liter Standard Deviation 5.09	—	—	-0.7 Grams per liter Standard Deviation 2.66
Change From Baseline in Clinical Chemistry Parameter of Total Protein and Albumin Total protein, Week 36,n=6,0,0,9,9,0	-1.5 Grams per liter Standard Deviation 4.51	—	—	-2.6 Grams per liter Standard Deviation 3.21	1.8 Grams per liter Standard Deviation 3.77	—
Change From Baseline in Clinical Chemistry Parameter of Total Protein and Albumin Total protein, Week 40,n=2,0,0,0,0,6	-2.5 Grams per liter Standard Deviation 3.54	—	—	—	—	0.7 Grams per liter Standard Deviation 1.63
Change From Baseline in Clinical Chemistry Parameter of Total Protein and Albumin Albumin, Day 2,n=12,6,5,9,9,6	-2.1 Grams per liter Standard Deviation 2.68	-1.3 Grams per liter Standard Deviation 2.42	-1.6 Grams per liter Standard Deviation 2.07	-2.4 Grams per liter Standard Deviation 2.01	-0.6 Grams per liter Standard Deviation 3.36	-0.5 Grams per liter Standard Deviation 3.39
Change From Baseline in Clinical Chemistry Parameter of Total Protein and Albumin Albumin, Day 3,n=12,6,6,9,9,6	-0.8 Grams per liter Standard Deviation 2.70	-1.3 Grams per liter Standard Deviation 1.97	-0.2 Grams per liter Standard Deviation 2.48	-1.4 Grams per liter Standard Deviation 2.83	-1.3 Grams per liter Standard Deviation 2.06	-0.3 Grams per liter Standard Deviation 2.07
Change From Baseline in Clinical Chemistry Parameter of Total Protein and Albumin Albumin, Day 4,n=12,6,6,9,9,6	-1.3 Grams per liter Standard Deviation 2.63	-0.5 Grams per liter Standard Deviation 1.22	-0.7 Grams per liter Standard Deviation 1.86	-2.2 Grams per liter Standard Deviation 2.33	-1.4 Grams per liter Standard Deviation 1.81	0.3 Grams per liter Standard Deviation 2.16
Change From Baseline in Clinical Chemistry Parameter of Total Protein and Albumin Albumin, Day 5,n=12,6,6,9,9,6	-1.6 Grams per liter Standard Deviation 1.68	-1.5 Grams per liter Standard Deviation 1.87	-0.8 Grams per liter Standard Deviation 3.54	-2.3 Grams per liter Standard Deviation 2.50	-0.2 Grams per liter Standard Deviation 3.49	-0.2 Grams per liter Standard Deviation 2.56
Change From Baseline in Clinical Chemistry Parameter of Total Protein and Albumin Albumin, Week 1,n=11,6,6,9,9,5	-0.5 Grams per liter Standard Deviation 2.34	-0.2 Grams per liter Standard Deviation 2.86	0.0 Grams per liter Standard Deviation 2.68	-2.2 Grams per liter Standard Deviation 2.28	-1.4 Grams per liter Standard Deviation 2.07	-1.4 Grams per liter Standard Deviation 2.97
Change From Baseline in Clinical Chemistry Parameter of Total Protein and Albumin Albumin, Week 2,n=12,6,6,9,9,6	-0.8 Grams per liter Standard Deviation 2.25	-0.2 Grams per liter Standard Deviation 1.83	-1.7 Grams per liter Standard Deviation 2.16	-0.8 Grams per liter Standard Deviation 2.86	0.4 Grams per liter Standard Deviation 1.88	-0.5 Grams per liter Standard Deviation 1.52
Change From Baseline in Clinical Chemistry Parameter of Total Protein and Albumin Albumin, Week 8,n=12,6,6,9,9,6	-0.8 Grams per liter Standard Deviation 2.73	-0.3 Grams per liter Standard Deviation 2.88	0.7 Grams per liter Standard Deviation 2.94	-2.0 Grams per liter Standard Deviation 2.69	0.7 Grams per liter Standard Deviation 2.83	0.7 Grams per liter Standard Deviation 2.34
Change From Baseline in Clinical Chemistry Parameter of Total Protein and Albumin Albumin, Week 12,n=12,6,6,9,9,6	-1.5 Grams per liter Standard Deviation 1.73	-1.3 Grams per liter Standard Deviation 2.80	0.0 Grams per liter Standard Deviation 2.45	-1.7 Grams per liter Standard Deviation 2.40	0.4 Grams per liter Standard Deviation 1.33	-0.2 Grams per liter Standard Deviation 2.32
Change From Baseline in Clinical Chemistry Parameter of Total Protein and Albumin Albumin, Week 24,n=12,6,6,9,9,6	-1.7 Grams per liter Standard Deviation 2.19	0.3 Grams per liter Standard Deviation 2.73	-0.8 Grams per liter Standard Deviation 2.32	-2.0 Grams per liter Standard Deviation 1.87	0.4 Grams per liter Standard Deviation 2.79	-0.2 Grams per liter Standard Deviation 2.04
Change From Baseline in Clinical Chemistry Parameter of Total Protein and Albumin Albumin, Week 26,n=12,6,6,9,9,6	-1.6 Grams per liter Standard Deviation 2.27	-0.8 Grams per liter Standard Deviation 1.72	-1.8 Grams per liter Standard Deviation 2.93	-2.1 Grams per liter Standard Deviation 0.60	0.1 Grams per liter Standard Deviation 1.69	-0.3 Grams per liter Standard Deviation 2.07
Change From Baseline in Clinical Chemistry Parameter of Total Protein and Albumin Albumin, Week 32,n=6,6,6,0,0,6	-0.5 Grams per liter Standard Deviation 3.02	1.2 Grams per liter Standard Deviation 3.06	-0.2 Grams per liter Standard Deviation 2.93	—	—	-0.8 Grams per liter Standard Deviation 2.14
Change From Baseline in Clinical Chemistry Parameter of Total Protein and Albumin Albumin, Week 36,n=6,0,0,9,9,0	-0.7 Grams per liter Standard Deviation 2.94	—	—	-1.4 Grams per liter Standard Deviation 1.67	0.6 Grams per liter Standard Deviation 2.40	—
Change From Baseline in Clinical Chemistry Parameter of Total Protein and Albumin Albumin, Week 40,n=2,0,0,0,0,6	-1.0 Grams per liter Standard Deviation 2.83	—	—	—	—	-0.3 Grams per liter Standard Deviation 1.63

PRIMARY outcome

Timeframe: Baseline and at Days 2, 3, 4 and 5, Weeks 1, 2, 4, 8, 12, 18, 24, 26, 32, 36 and 40

Population: Safety Population. Only those participants with planned assessments at that particular time point has been presented (represented by n= X in the category titles).

Blood samples were collected at indicated time-points for analysis of clinical parameters like total bilirubin, direct bilirubin and creatinine. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Placebo n=12 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Total bilirubin, Day 2,n=12,6,5,9,9,6	-0.8 Micromoles per liter Standard Deviation 3.86	-1.3 Micromoles per liter Standard Deviation 3.27	-1.6 Micromoles per liter Standard Deviation 4.34	-0.2 Micromoles per liter Standard Deviation 3.23	0.0 Micromoles per liter Standard Deviation 5.20	1.0 Micromoles per liter Standard Deviation 3.03
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Total bilirubin, Day 4,n=12,6,6,9,9,6	-1.0 Micromoles per liter Standard Deviation 3.13	-2.7 Micromoles per liter Standard Deviation 5.01	-2.0 Micromoles per liter Standard Deviation 7.48	0.0 Micromoles per liter Standard Deviation 4.47	0.0 Micromoles per liter Standard Deviation 4.47	1.0 Micromoles per liter Standard Deviation 3.29
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Total bilirubin, Day 5,n=12,6,6,9,9,6	-2.3 Micromoles per liter Standard Deviation 4.58	-5.0 Micromoles per liter Standard Deviation 5.76	-2.0 Micromoles per liter Standard Deviation 3.58	-0.9 Micromoles per liter Standard Deviation 5.49	-1.3 Micromoles per liter Standard Deviation 2.45	-0.7 Micromoles per liter Standard Deviation 3.27
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Total bilirubin, Week 1,n=11,6,6,9,9,5	-1.5 Micromoles per liter Standard Deviation 4.82	-0.7 Micromoles per liter Standard Deviation 4.50	1.7 Micromoles per liter Standard Deviation 1.97	-1.1 Micromoles per liter Standard Deviation 4.91	0.4 Micromoles per liter Standard Deviation 3.84	-2.0 Micromoles per liter Standard Deviation 2.83
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Total bilirubin, Week 2,n=12,6,6,9,9,6	-1.2 Micromoles per liter Standard Deviation 3.46	-2.3 Micromoles per liter Standard Deviation 6.12	0.7 Micromoles per liter Standard Deviation 2.73	2.2 Micromoles per liter Standard Deviation 2.91	0.4 Micromoles per liter Standard Deviation 5.55	0.7 Micromoles per liter Standard Deviation 2.42
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Total bilirubin, Week 4,n=12,6,6,9,9,6	-0.7 Micromoles per liter Standard Deviation 2.15	0.3 Micromoles per liter Standard Deviation 2.34	0.3 Micromoles per liter Standard Deviation 1.97	0.0 Micromoles per liter Standard Deviation 2.45	-0.4 Micromoles per liter Standard Deviation 5.81	1.0 Micromoles per liter Standard Deviation 2.76
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Total bilirubin, Week 8,n=12,6,6,9,9,6	-1.2 Micromoles per liter Standard Deviation 4.04	-1.0 Micromoles per liter Standard Deviation 6.29	2.0 Micromoles per liter Standard Deviation 2.83	2.2 Micromoles per liter Standard Deviation 4.06	0.4 Micromoles per liter Standard Deviation 5.46	-1.0 Micromoles per liter Standard Deviation 4.69
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Total bilirubin, Week 12,n=12,6,6,9,9,6	-1.3 Micromoles per liter Standard Deviation 4.03	0.0 Micromoles per liter Standard Deviation 2.19	4.3 Micromoles per liter Standard Deviation 5.85	-0.9 Micromoles per liter Standard Deviation 2.03	0.0 Micromoles per liter Standard Deviation 4.69	-0.7 Micromoles per liter Standard Deviation 4.50
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Total bilirubin, Week 18,n=12,6,6,9,9,6	-0.3 Micromoles per liter Standard Deviation 3.70	-1.3 Micromoles per liter Standard Deviation 6.53	2.0 Micromoles per liter Standard Deviation 2.83	0.7 Micromoles per liter Standard Deviation 1.73	0.4 Micromoles per liter Standard Deviation 6.23	-1.0 Micromoles per liter Standard Deviation 3.52
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Total bilirubin, Week 24,n=12,6,6,9,9,6	-0.8 Micromoles per liter Standard Deviation 4.47	-1.3 Micromoles per liter Standard Deviation 3.27	1.7 Micromoles per liter Standard Deviation 3.88	0.2 Micromoles per liter Standard Deviation 2.54	1.6 Micromoles per liter Standard Deviation 6.98	2.0 Micromoles per liter Standard Deviation 4.56
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Total bilirubin, Week 32,n=6,6,6,0,0,6	0.7 Micromoles per liter Standard Deviation 2.07	-1.0 Micromoles per liter Standard Deviation 5.62	0.0 Micromoles per liter Standard Deviation 5.22	—	—	0.0 Micromoles per liter Standard Deviation 4.90
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Total bilirubin, Week 36,n=6,0,0,9,9,0	-0.7 Micromoles per liter Standard Deviation 7.12	—	—	0.4 Micromoles per liter Standard Deviation 3.13	-1.1 Micromoles per liter Standard Deviation 5.67	—
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Direct bilirubin, Day 2,n=12,6,5,9,9,6	-0.3 Micromoles per liter Standard Deviation 1.15	-0.7 Micromoles per liter Standard Deviation 1.03	-0.4 Micromoles per liter Standard Deviation 0.89	-0.2 Micromoles per liter Standard Deviation 1.20	0.2 Micromoles per liter Standard Deviation 1.20	0.3 Micromoles per liter Standard Deviation 0.82
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Direct bilirubin, Day 3,n=12,6,6,9,9,6	-0.5 Micromoles per liter Standard Deviation 0.90	-0.3 Micromoles per liter Standard Deviation 0.82	-0.3 Micromoles per liter Standard Deviation 0.82	0.4 Micromoles per liter Standard Deviation 1.67	0.0 Micromoles per liter Standard Deviation 1.00	0.0 Micromoles per liter Standard Deviation 1.26
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Direct bilirubin, Day 4,n=12,6,6,9,9,6	-0.5 Micromoles per liter Standard Deviation 0.90	-0.3 Micromoles per liter Standard Deviation 0.82	-0.7 Micromoles per liter Standard Deviation 1.03	0.2 Micromoles per liter Standard Deviation 1.56	0.2 Micromoles per liter Standard Deviation 1.20	-0.3 Micromoles per liter Standard Deviation 0.82
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Direct bilirubin, Day 5,n=12,6,6,9,9,6	-0.7 Micromoles per liter Standard Deviation 0.98	-0.7 Micromoles per liter Standard Deviation 1.03	-0.7 Micromoles per liter Standard Deviation 1.03	0.2 Micromoles per liter Standard Deviation 1.56	0.0 Micromoles per liter Standard Deviation 1.00	-0.7 Micromoles per liter Standard Deviation 1.03
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Direct bilirubin, Week 4,n=12,6,6,9,9,6	0.0 Micromoles per liter Standard Deviation 0.85	0.0 Micromoles per liter Standard Deviation 1.26	0.3 Micromoles per liter Standard Deviation 0.82	0.2 Micromoles per liter Standard Deviation 1.20	0.2 Micromoles per liter Standard Deviation 1.20	0.0 Micromoles per liter Standard Deviation 1.26
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Direct bilirubin, Week 8,n=12,6,6,9,9,6	-0.2 Micromoles per liter Standard Deviation 1.03	0.0 Micromoles per liter Standard Deviation 0.00	0.3 Micromoles per liter Standard Deviation 0.82	0.9 Micromoles per liter Standard Deviation 1.45	0.4 Micromoles per liter Standard Deviation 1.33	-0.7 Micromoles per liter Standard Deviation 1.03
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Direct bilirubin, Week 12,n=12,6,6,9,9,6	-0.5 Micromoles per liter Standard Deviation 0.90	0.0 Micromoles per liter Standard Deviation 1.26	0.3 Micromoles per liter Standard Deviation 0.82	0.2 Micromoles per liter Standard Deviation 1.20	0.2 Micromoles per liter Standard Deviation 1.20	-0.3 Micromoles per liter Standard Deviation 1.51
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Direct bilirubin, Week 18,n=12,6,6,9,9,6	-0.2 Micromoles per liter Standard Deviation 1.03	0.0 Micromoles per liter Standard Deviation 1.26	0.0 Micromoles per liter Standard Deviation 0.00	0.7 Micromoles per liter Standard Deviation 1.00	0.4 Micromoles per liter Standard Deviation 1.33	0.0 Micromoles per liter Standard Deviation 1.26
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Direct bilirubin, Week 24,n=12,6,6,9,9,6	-0.3 Micromoles per liter Standard Deviation 0.78	0.3 Micromoles per liter Standard Deviation 1.51	-0.3 Micromoles per liter Standard Deviation 0.82	0.2 Micromoles per liter Standard Deviation 1.20	0.9 Micromoles per liter Standard Deviation 1.76	0.0 Micromoles per liter Standard Deviation 1.26
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Direct bilirubin, Week 26,n=12,6,6,9,9,6	0.0 Micromoles per liter Standard Deviation 1.21	0.7 Micromoles per liter Standard Deviation 1.03	0.3 Micromoles per liter Standard Deviation 0.82	0.0 Micromoles per liter Standard Deviation 1.41	0.0 Micromoles per liter Standard Deviation 1.00	0.0 Micromoles per liter Standard Deviation 1.26
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Direct bilirubin, Week 32,n=6,6,6,0,0,6	-0.3 Micromoles per liter Standard Deviation 0.82	-0.3 Micromoles per liter Standard Deviation 0.82	-0.3 Micromoles per liter Standard Deviation 1.51	—	—	0.0 Micromoles per liter Standard Deviation 1.26
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Creatinine, Day 2,n=12,6,5,9,9,6	-2.80 Micromoles per liter Standard Deviation 5.501	-1.03 Micromoles per liter Standard Deviation 3.930	-1.42 Micromoles per liter Standard Deviation 3.512	-4.91 Micromoles per liter Standard Deviation 4.835	-0.77 Micromoles per liter Standard Deviation 4.863	-1.63 Micromoles per liter Standard Deviation 6.417
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Creatinine, Day 3,n=12,6,6,9,9,6	-3.48 Micromoles per liter Standard Deviation 6.036	-1.78 Micromoles per liter Standard Deviation 3.571	-2.95 Micromoles per liter Standard Deviation 6.208	-1.58 Micromoles per liter Standard Deviation 4.913	-1.87 Micromoles per liter Standard Deviation 5.026	-1.20 Micromoles per liter Standard Deviation 3.795
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Creatinine, Day 4,n=12,6,6,9,9,6	0.29 Micromoles per liter Standard Deviation 6.544	-0.73 Micromoles per liter Standard Deviation 4.126	-0.75 Micromoles per liter Standard Deviation 7.123	-4.64 Micromoles per liter Standard Deviation 6.296	-0.88 Micromoles per liter Standard Deviation 3.180	3.68 Micromoles per liter Standard Deviation 7.962
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Creatinine, Day 5,n=12,6,6,9,9,6	-2.73 Micromoles per liter Standard Deviation 5.166	0.72 Micromoles per liter Standard Deviation 1.883	-2.53 Micromoles per liter Standard Deviation 4.541	-4.63 Micromoles per liter Standard Deviation 6.355	0.39 Micromoles per liter Standard Deviation 3.085	-1.62 Micromoles per liter Standard Deviation 5.216
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Creatinine, Week 1,n=11,6,6,9,9,5	-2.49 Micromoles per liter Standard Deviation 7.084	3.68 Micromoles per liter Standard Deviation 4.892	-2.08 Micromoles per liter Standard Deviation 6.098	-3.06 Micromoles per liter Standard Deviation 6.393	0.59 Micromoles per liter Standard Deviation 4.303	-0.70 Micromoles per liter Standard Deviation 7.736
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Creatinine, Week 8,n=12,6,6,9,9,6	-1.40 Micromoles per liter Standard Deviation 6.462	0.28 Micromoles per liter Standard Deviation 5.062	-1.20 Micromoles per liter Standard Deviation 7.277	0.19 Micromoles per liter Standard Deviation 3.718	6.00 Micromoles per liter Standard Deviation 4.511	1.63 Micromoles per liter Standard Deviation 4.317
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Creatinine, Week 12,n=12,6,6,9,9,6	-0.30 Micromoles per liter Standard Deviation 7.643	0.88 Micromoles per liter Standard Deviation 5.043	1.03 Micromoles per liter Standard Deviation 5.846	-0.41 Micromoles per liter Standard Deviation 4.748	5.01 Micromoles per liter Standard Deviation 3.820	0.72 Micromoles per liter Standard Deviation 4.532
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Creatinine, Week 32,n=6,6,6,0,0,6	0.00 Micromoles per liter Standard Deviation 5.871	0.87 Micromoles per liter Standard Deviation 5.904	6.60 Micromoles per liter Standard Deviation 6.880	—	—	2.05 Micromoles per liter Standard Deviation 2.474
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Creatinine, Week 4,n=12,6,6,9,9,6	-1.28 Micromoles per liter Standard Deviation 4.730	-2.80 Micromoles per liter Standard Deviation 3.839	0.27 Micromoles per liter Standard Deviation 3.837	0.09 Micromoles per liter Standard Deviation 6.843	0.59 Micromoles per liter Standard Deviation 5.989	6.05 Micromoles per liter Standard Deviation 6.066
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Total bilirubin, Day 3,n=12,6,6,9,9,6	-1.3 Micromoles per liter Standard Deviation 3.45	-1.7 Micromoles per liter Standard Deviation 3.44	-1.7 Micromoles per liter Standard Deviation 4.97	0.2 Micromoles per liter Standard Deviation 3.80	-0.4 Micromoles per liter Standard Deviation 4.77	0.3 Micromoles per liter Standard Deviation 2.34
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Total bilirubin, Week 26,n=12,6,6,9,9,6	-1.3 Micromoles per liter Standard Deviation 4.70	2.7 Micromoles per liter Standard Deviation 3.93	0.3 Micromoles per liter Standard Deviation 3.88	-0.2 Micromoles per liter Standard Deviation 3.80	-0.7 Micromoles per liter Standard Deviation 4.12	1.7 Micromoles per liter Standard Deviation 2.34
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Total bilirubin, Week 40,n=2,0,0,0,0,6	2.0 Micromoles per liter Standard Deviation 0.00	—	—	—	—	0.7 Micromoles per liter Standard Deviation 2.07
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Direct bilirubin, Week 1,n=11,6,6,9,9,5	-0.5 Micromoles per liter Standard Deviation 0.93	-0.3 Micromoles per liter Standard Deviation 0.82	-0.3 Micromoles per liter Standard Deviation 0.82	0.0 Micromoles per liter Standard Deviation 1.41	0.0 Micromoles per liter Standard Deviation 1.00	-0.8 Micromoles per liter Standard Deviation 1.10
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Direct bilirubin, Week 2,n=12,6,6,9,9,6	-0.3 Micromoles per liter Standard Deviation 1.15	0.0 Micromoles per liter Standard Deviation 0.00	0.0 Micromoles per liter Standard Deviation 0.00	0.7 Micromoles per liter Standard Deviation 1.41	0.2 Micromoles per liter Standard Deviation 1.20	0.3 Micromoles per liter Standard Deviation 1.51
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Direct bilirubin, Week 36,n=6,0,0,9,9,0	0.0 Micromoles per liter Standard Deviation 1.79	—	—	0.0 Micromoles per liter Standard Deviation 1.00	0.4 Micromoles per liter Standard Deviation 1.67	—
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Direct bilirubin, Week 40,n=2,0,0,0,0,6	-1.0 Micromoles per liter Standard Deviation 1.41	—	—	—	—	-0.3 Micromoles per liter Standard Deviation 0.82
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Creatinine, Week 2,n=12,6,6,9,9,6	-1.12 Micromoles per liter Standard Deviation 5.854	1.47 Micromoles per liter Standard Deviation 5.019	-0.90 Micromoles per liter Standard Deviation 6.377	-2.67 Micromoles per liter Standard Deviation 5.702	2.27 Micromoles per liter Standard Deviation 5.322	0.73 Micromoles per liter Standard Deviation 7.868
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Creatinine, Week 18,n=12,6,6,9,9,6	-1.27 Micromoles per liter Standard Deviation 7.753	1.75 Micromoles per liter Standard Deviation 4.831	2.05 Micromoles per liter Standard Deviation 7.131	2.83 Micromoles per liter Standard Deviation 5.033	4.42 Micromoles per liter Standard Deviation 5.191	1.15 Micromoles per liter Standard Deviation 6.297
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Creatinine, Week 24,n=12,6,6,9,9,6	0.89 Micromoles per liter Standard Deviation 4.393	1.77 Micromoles per liter Standard Deviation 5.597	1.60 Micromoles per liter Standard Deviation 5.877	7.07 Micromoles per liter Standard Deviation 6.581	2.66 Micromoles per liter Standard Deviation 6.005	2.20 Micromoles per liter Standard Deviation 4.431
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Creatinine, Week 26,n=12,6,6,9,9,6	-2.29 Micromoles per liter Standard Deviation 5.633	-2.22 Micromoles per liter Standard Deviation 5.017	0.27 Micromoles per liter Standard Deviation 15.342	3.16 Micromoles per liter Standard Deviation 6.620	0.69 Micromoles per liter Standard Deviation 3.857	3.22 Micromoles per liter Standard Deviation 5.653
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Creatinine, Week 36,n=6,0,0,9,9,0	-0.60 Micromoles per liter Standard Deviation 4.767	—	—	2.57 Micromoles per liter Standard Deviation 4.347	10.42 Micromoles per liter Standard Deviation 6.864	—
Change From Baseline in Clinical Chemistry Parameters Like Total Bilirubin, Direct Bilirubin and Creatinine Creatinine, Week 40,n=2,0,0,0,0,6	1.75 Micromoles per liter Standard Deviation 2.475	—	—	—	—	1.60 Micromoles per liter Standard Deviation 6.174

PRIMARY outcome

Timeframe: Baseline and at Days 2, 3, 4 and 5, Weeks 1, 2, 4, 8, 12, 18, 24, 26, 32, 36 and 40

Population: Safety Population. Only those participants with planned assessments at that particular time point has been presented (represented by n= X in the category titles).

Urinary specific gravity measurement is a routine part of urinalysis. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The concentration of the excreted molecules determines the urine's specific gravity.

Outcome measures

Outcome measures
Measure	Placebo n=3 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=2 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg n=1 Participants Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg n=5 Participants Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg n=1 Participants Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg n=1 Participants Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Urine Specific Gravity Analysis by Dipstick Method Day 3,n=2,0,0,1,0,0	1.0265 Ratio Standard Deviation 0.00212	—	—	1.0280 Ratio Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	—	—
Urine Specific Gravity Analysis by Dipstick Method Week 24,n=1,1,0,4,0,0	1.0200 Ratio Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	1.0230 Ratio Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	—	1.0200 Ratio Standard Deviation 0.00374	—	—
Urine Specific Gravity Analysis by Dipstick Method Week 26,n=0,0,0,2,0,0	—	—	—	1.0240 Ratio Standard Deviation 0.00566	—	—
Urine Specific Gravity Analysis by Dipstick Method Week 32,n=1,0,0,0,0,0	1.0150 Ratio Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	—	—	—	—	—
Urine Specific Gravity Analysis by Dipstick Method Day 2,n=1,2,0,2,0,0	1.0200 Ratio Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	1.0125 Ratio Standard Deviation 0.00354	—	1.0120 Ratio Standard Deviation 0.00283	—	—
Urine Specific Gravity Analysis by Dipstick Method Day 4,n=0,0,1,1,0,0	—	—	1.0150 Ratio Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	1.0290 Ratio Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	—	—
Urine Specific Gravity Analysis by Dipstick Method Day 5,n=2,0,0,2,1,0	1.0275 Ratio Standard Deviation 0.00354	—	—	1.0205 Ratio Standard Deviation 0.00919	1.0140 Ratio Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	—
Urine Specific Gravity Analysis by Dipstick Method Week 1,n=2,1,1,3,0,0	1.0235 Ratio Standard Deviation 0.00212	1.0260 Ratio Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	1.0250 Ratio Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	1.0197 Ratio Standard Deviation 0.00751	—	—
Urine Specific Gravity Analysis by Dipstick Method Week 2,n=1,0,0,4,1,0	1.0250 Ratio Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	—	—	1.0218 Ratio Standard Deviation 0.00822	1.0130 Ratio Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	—
Urine Specific Gravity Analysis by Dipstick Method Week 4,n=3,1,1,5,0,1	1.0193 Ratio Standard Deviation 0.00839	1.0150 Ratio Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	1.0250 Ratio Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	1.0158 Ratio Standard Deviation 0.01052	—	1.0270 Ratio Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.
Urine Specific Gravity Analysis by Dipstick Method Week 8,n=1,0,0,2,0,0	1.0300 Ratio Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	—	—	1.0220 Ratio Standard Deviation 0.00566	—	—
Urine Specific Gravity Analysis by Dipstick Method Week 12,n=0,1,0,1,0,0	—	1.0180 Ratio Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	—	1.0230 Ratio Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	—	—
Urine Specific Gravity Analysis by Dipstick Method Week 18,n=3,1,0,1,0,0	1.0260 Ratio Standard Deviation 0.00265	1.0180 Ratio Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	—	1.0230 Ratio Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	—	—

PRIMARY outcome

Timeframe: Baseline and at 2 and 8 hours at Day 1; Days 2, 3, 4 and 5; Weeks 1, 2, 4, 8, 12, 18, 24, 26, 32, 36 and 40

Population: Safety Population. Only those participants with planned assessments at that particular time point has been presented (represented by n= X in the category titles).

SBP and DBP were assessed in a supine position after 5 minutes of rest. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Placebo n=12 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, 2 hours Day1,n=12,6,6,9,9,6	-0.3 Millimeters of mercury Standard Deviation 6.08	-2.2 Millimeters of mercury Standard Deviation 7.47	3.3 Millimeters of mercury Standard Deviation 7.37	-0.9 Millimeters of mercury Standard Deviation 7.18	-1.8 Millimeters of mercury Standard Deviation 7.19	-2.0 Millimeters of mercury Standard Deviation 8.58
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, Week 1,n=12,6,6,9,9,6	0.6 Millimeters of mercury Standard Deviation 5.37	3.7 Millimeters of mercury Standard Deviation 6.98	4.3 Millimeters of mercury Standard Deviation 9.27	-0.4 Millimeters of mercury Standard Deviation 5.68	0.8 Millimeters of mercury Standard Deviation 3.38	0.0 Millimeters of mercury Standard Deviation 5.44
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, Week 2,n=12,6,6,9,9,6	1.1 Millimeters of mercury Standard Deviation 6.23	4.7 Millimeters of mercury Standard Deviation 5.65	6.0 Millimeters of mercury Standard Deviation 8.99	1.6 Millimeters of mercury Standard Deviation 4.36	1.9 Millimeters of mercury Standard Deviation 6.92	0.2 Millimeters of mercury Standard Deviation 4.62
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, Week 24,n=12,6,6,9,9,6	-1.6 Millimeters of mercury Standard Deviation 7.77	6.3 Millimeters of mercury Standard Deviation 5.35	4.0 Millimeters of mercury Standard Deviation 9.78	5.3 Millimeters of mercury Standard Deviation 6.56	1.1 Millimeters of mercury Standard Deviation 9.12	2.0 Millimeters of mercury Standard Deviation 5.66
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, Week 26,n=12,6,6,9,9,6	-0.5 Millimeters of mercury Standard Deviation 7.23	3.2 Millimeters of mercury Standard Deviation 4.36	3.8 Millimeters of mercury Standard Deviation 9.45	6.6 Millimeters of mercury Standard Deviation 8.38	1.8 Millimeters of mercury Standard Deviation 8.61	0.2 Millimeters of mercury Standard Deviation 3.97
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, Week 32,n=6,6,6,0,0,6	1.3 Millimeters of mercury Standard Deviation 2.34	-0.2 Millimeters of mercury Standard Deviation 6.49	7.0 Millimeters of mercury Standard Deviation 4.34	—	—	2.0 Millimeters of mercury Standard Deviation 7.64
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, Week 36,n=6,0,0,9,9,0	2.3 Millimeters of mercury Standard Deviation 13.13	—	—	3.6 Millimeters of mercury Standard Deviation 5.64	2.3 Millimeters of mercury Standard Deviation 8.82	—
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, 8 hours Day1,n=12,6,6,9,9,6	0.0 Millimeters of mercury Standard Deviation 6.00	4.2 Millimeters of mercury Standard Deviation 10.01	3.0 Millimeters of mercury Standard Deviation 8.46	1.7 Millimeters of mercury Standard Deviation 10.69	4.9 Millimeters of mercury Standard Deviation 7.52	-2.2 Millimeters of mercury Standard Deviation 5.64
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, Week 2,n=12,6,6,9,9,6	-2.6 Millimeters of mercury Standard Deviation 5.90	1.0 Millimeters of mercury Standard Deviation 10.22	5.8 Millimeters of mercury Standard Deviation 5.85	4.2 Millimeters of mercury Standard Deviation 10.45	0.8 Millimeters of mercury Standard Deviation 11.04	-2.8 Millimeters of mercury Standard Deviation 9.83
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, Day 2,n=12,6,6,9,9,6	-2.5 Millimeters of mercury Standard Deviation 7.00	-0.8 Millimeters of mercury Standard Deviation 8.08	6.0 Millimeters of mercury Standard Deviation 4.86	1.8 Millimeters of mercury Standard Deviation 9.11	6.3 Millimeters of mercury Standard Deviation 7.42	-5.3 Millimeters of mercury Standard Deviation 4.37
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, Day 3,n=12,6,6,9,9,6	2.6 Millimeters of mercury Standard Deviation 9.21	-2.2 Millimeters of mercury Standard Deviation 7.36	3.7 Millimeters of mercury Standard Deviation 9.16	1.0 Millimeters of mercury Standard Deviation 10.68	-0.1 Millimeters of mercury Standard Deviation 4.43	-5.0 Millimeters of mercury Standard Deviation 6.00
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, Day 4,n=12,6,6,9,9,6	0.8 Millimeters of mercury Standard Deviation 5.75	-2.2 Millimeters of mercury Standard Deviation 6.24	2.3 Millimeters of mercury Standard Deviation 8.09	0.3 Millimeters of mercury Standard Deviation 6.91	2.9 Millimeters of mercury Standard Deviation 6.86	-3.3 Millimeters of mercury Standard Deviation 7.39
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, Day 5,n=12,6,6,9,9,6	-3.0 Millimeters of mercury Standard Deviation 6.05	0.8 Millimeters of mercury Standard Deviation 6.82	1.0 Millimeters of mercury Standard Deviation 7.72	-2.8 Millimeters of mercury Standard Deviation 9.81	0.4 Millimeters of mercury Standard Deviation 3.91	-4.7 Millimeters of mercury Standard Deviation 4.46
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, Week 1,n=12,6,6,9,9,6	-0.3 Millimeters of mercury Standard Deviation 8.86	0.3 Millimeters of mercury Standard Deviation 7.50	1.5 Millimeters of mercury Standard Deviation 6.60	-2.7 Millimeters of mercury Standard Deviation 9.06	1.7 Millimeters of mercury Standard Deviation 5.02	0.2 Millimeters of mercury Standard Deviation 8.13
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, Week 4,n=12,6,6,9,9,6	-1.6 Millimeters of mercury Standard Deviation 8.80	0.3 Millimeters of mercury Standard Deviation 8.82	7.0 Millimeters of mercury Standard Deviation 11.26	3.2 Millimeters of mercury Standard Deviation 14.09	0.9 Millimeters of mercury Standard Deviation 6.11	-2.3 Millimeters of mercury Standard Deviation 7.15
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, Week 8,n=12,6,6,9,9,6	0.7 Millimeters of mercury Standard Deviation 9.71	0.0 Millimeters of mercury Standard Deviation 9.27	2.0 Millimeters of mercury Standard Deviation 12.66	3.1 Millimeters of mercury Standard Deviation 8.52	-1.4 Millimeters of mercury Standard Deviation 6.60	-1.8 Millimeters of mercury Standard Deviation 5.91
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, Week 12,n=12,6,6,9,9,6	-0.8 Millimeters of mercury Standard Deviation 5.13	1.2 Millimeters of mercury Standard Deviation 5.19	2.3 Millimeters of mercury Standard Deviation 9.97	5.4 Millimeters of mercury Standard Deviation 9.41	0.0 Millimeters of mercury Standard Deviation 7.37	-4.2 Millimeters of mercury Standard Deviation 11.18
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, Week 18,n=12,6,6,9,9,6	-0.6 Millimeters of mercury Standard Deviation 6.86	4.2 Millimeters of mercury Standard Deviation 9.15	3.8 Millimeters of mercury Standard Deviation 13.33	2.0 Millimeters of mercury Standard Deviation 8.76	2.1 Millimeters of mercury Standard Deviation 9.52	-7.3 Millimeters of mercury Standard Deviation 15.49
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, Week 24,n=12,6,6,9,9,6	-0.8 Millimeters of mercury Standard Deviation 8.22	9.3 Millimeters of mercury Standard Deviation 10.42	3.7 Millimeters of mercury Standard Deviation 6.59	2.9 Millimeters of mercury Standard Deviation 9.91	1.9 Millimeters of mercury Standard Deviation 12.06	-2.2 Millimeters of mercury Standard Deviation 6.46
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, Week 26,n=12,6,6,9,9,6	3.0 Millimeters of mercury Standard Deviation 11.95	3.2 Millimeters of mercury Standard Deviation 6.11	3.2 Millimeters of mercury Standard Deviation 5.91	7.9 Millimeters of mercury Standard Deviation 10.13	2.9 Millimeters of mercury Standard Deviation 7.56	-5.8 Millimeters of mercury Standard Deviation 6.11
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, Week 32,n=6,6,6,0,0,6	3.0 Millimeters of mercury Standard Deviation 6.90	-3.8 Millimeters of mercury Standard Deviation 12.45	8.7 Millimeters of mercury Standard Deviation 10.61	—	—	-3.3 Millimeters of mercury Standard Deviation 6.89
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, Week 36,n=6,0,0,9,9,0	-3.5 Millimeters of mercury Standard Deviation 13.72	—	—	2.8 Millimeters of mercury Standard Deviation 9.59	2.8 Millimeters of mercury Standard Deviation 7.77	—
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) SBP, Week 40,n=2,0,0,0,0,6	-15.0 Millimeters of mercury Standard Deviation 14.14	—	—	—	—	-5.8 Millimeters of mercury Standard Deviation 17.52
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, 2 hours Day1,n=12,6,6,9,9,6	-2.9 Millimeters of mercury Standard Deviation 5.00	3.3 Millimeters of mercury Standard Deviation 4.89	4.3 Millimeters of mercury Standard Deviation 9.14	-2.2 Millimeters of mercury Standard Deviation 4.18	-2.2 Millimeters of mercury Standard Deviation 6.14	-3.8 Millimeters of mercury Standard Deviation 1.94
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, 8 hours Day1,n=12,6,6,9,9,6	-0.6 Millimeters of mercury Standard Deviation 4.34	2.0 Millimeters of mercury Standard Deviation 7.46	0.5 Millimeters of mercury Standard Deviation 9.52	-1.3 Millimeters of mercury Standard Deviation 4.58	-2.0 Millimeters of mercury Standard Deviation 5.74	-1.8 Millimeters of mercury Standard Deviation 5.56
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, Day 2,n=12,6,6,9,9,6	-0.2 Millimeters of mercury Standard Deviation 4.47	0.8 Millimeters of mercury Standard Deviation 4.49	3.0 Millimeters of mercury Standard Deviation 5.83	-1.1 Millimeters of mercury Standard Deviation 5.67	4.7 Millimeters of mercury Standard Deviation 4.18	0.0 Millimeters of mercury Standard Deviation 4.94
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, Day 3,n=12,6,6,9,9,6	0.6 Millimeters of mercury Standard Deviation 3.99	-1.3 Millimeters of mercury Standard Deviation 7.26	3.0 Millimeters of mercury Standard Deviation 7.04	-2.6 Millimeters of mercury Standard Deviation 5.41	-0.3 Millimeters of mercury Standard Deviation 4.30	-0.3 Millimeters of mercury Standard Deviation 6.44
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, Day 4,n=12,6,6,9,9,6	-0.1 Millimeters of mercury Standard Deviation 5.04	2.3 Millimeters of mercury Standard Deviation 4.80	-1.0 Millimeters of mercury Standard Deviation 5.69	-0.2 Millimeters of mercury Standard Deviation 5.14	0.1 Millimeters of mercury Standard Deviation 3.76	-2.8 Millimeters of mercury Standard Deviation 3.82
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, Day 5,n=12,6,6,9,9,6	-1.4 Millimeters of mercury Standard Deviation 4.40	4.8 Millimeters of mercury Standard Deviation 6.49	0.7 Millimeters of mercury Standard Deviation 8.09	-4.1 Millimeters of mercury Standard Deviation 7.29	0.9 Millimeters of mercury Standard Deviation 4.23	-1.5 Millimeters of mercury Standard Deviation 2.81
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, Week 4,n=12,6,6,9,9,6	0.3 Millimeters of mercury Standard Deviation 6.17	1.3 Millimeters of mercury Standard Deviation 7.74	4.2 Millimeters of mercury Standard Deviation 11.36	3.1 Millimeters of mercury Standard Deviation 6.09	1.6 Millimeters of mercury Standard Deviation 5.41	3.8 Millimeters of mercury Standard Deviation 4.40
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, Week 8,n=12,6,6,9,9,6	1.3 Millimeters of mercury Standard Deviation 3.73	5.2 Millimeters of mercury Standard Deviation 5.49	5.5 Millimeters of mercury Standard Deviation 13.28	3.3 Millimeters of mercury Standard Deviation 4.95	0.7 Millimeters of mercury Standard Deviation 4.21	0.5 Millimeters of mercury Standard Deviation 3.94
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, Week 12,n=12,6,6,9,9,6	0.9 Millimeters of mercury Standard Deviation 6.29	3.2 Millimeters of mercury Standard Deviation 5.91	1.7 Millimeters of mercury Standard Deviation 14.15	3.4 Millimeters of mercury Standard Deviation 5.39	3.6 Millimeters of mercury Standard Deviation 4.72	1.3 Millimeters of mercury Standard Deviation 5.09
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, Week 18,n=12,6,6,9,9,6	-2.1 Millimeters of mercury Standard Deviation 6.63	3.3 Millimeters of mercury Standard Deviation 5.68	3.0 Millimeters of mercury Standard Deviation 12.65	0.7 Millimeters of mercury Standard Deviation 6.84	3.8 Millimeters of mercury Standard Deviation 8.07	0.5 Millimeters of mercury Standard Deviation 7.50
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) DBP, Week 40,n=2,0,0,0,0,6	0.5 Millimeters of mercury Standard Deviation 4.95	—	—	—	—	-3.5 Millimeters of mercury Standard Deviation 6.95

PRIMARY outcome

Timeframe: Baseline and at 2 and 8 hours at Day 1; Days 2, 3, 4 and 5; Weeks 1, 2, 4, 8, 12, 18, 24, 26, 32, 36 and 40

Population: Safety Population. Only those participants with planned assessments at that particular time point has been presented (represented by n= X in the category titles).

Temperature was assessed in a supine position after 5 minutes of rest. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Placebo n=12 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Change From Baseline in Temperature 2 hours Day1,n=12,6,6,9,9,6	0.05 Degree Celsius Standard Deviation 0.419	0.32 Degree Celsius Standard Deviation 0.293	0.13 Degree Celsius Standard Deviation 0.163	0.30 Degree Celsius Standard Deviation 0.474	0.03 Degree Celsius Standard Deviation 0.328	0.00 Degree Celsius Standard Deviation 0.420
Change From Baseline in Temperature Category title 2. 8 hours Day1,n=12,6,6,9,9,6	0.13 Degree Celsius Standard Deviation 0.405	0.40 Degree Celsius Standard Deviation 0.410	0.07 Degree Celsius Standard Deviation 0.234	0.24 Degree Celsius Standard Deviation 0.513	0.18 Degree Celsius Standard Deviation 0.291	0.35 Degree Celsius Standard Deviation 0.589
Change From Baseline in Temperature Week 24,n=12,6,6,9,9,6	-0.07 Degree Celsius Standard Deviation 0.396	0.08 Degree Celsius Standard Deviation 0.488	0.08 Degree Celsius Standard Deviation 0.319	-0.02 Degree Celsius Standard Deviation 0.367	-0.07 Degree Celsius Standard Deviation 0.316	-0.02 Degree Celsius Standard Deviation 0.133
Change From Baseline in Temperature Week 1,n=12,6,6,9,9,6	-0.13 Degree Celsius Standard Deviation 0.293	0.32 Degree Celsius Standard Deviation 0.492	0.18 Degree Celsius Standard Deviation 0.147	0.12 Degree Celsius Standard Deviation 0.399	0.01 Degree Celsius Standard Deviation 0.359	0.18 Degree Celsius Standard Deviation 0.232
Change From Baseline in Temperature Category title 3. Day 2,n=12,6,6,9,9,6	-0.01 Degree Celsius Standard Deviation 0.312	0.23 Degree Celsius Standard Deviation 0.437	0.10 Degree Celsius Standard Deviation 0.429	-0.03 Degree Celsius Standard Deviation 0.559	-0.01 Degree Celsius Standard Deviation 0.333	-0.05 Degree Celsius Standard Deviation 0.259
Change From Baseline in Temperature Day 3,n=12,6,6,9,9,6	-0.10 Degree Celsius Standard Deviation 0.402	0.02 Degree Celsius Standard Deviation 0.538	0.02 Degree Celsius Standard Deviation 0.256	0.13 Degree Celsius Standard Deviation 0.439	0.02 Degree Celsius Standard Deviation 0.315	0.12 Degree Celsius Standard Deviation 0.343
Change From Baseline in Temperature Day 4,n=12,6,6,9,9,6	-0.03 Degree Celsius Standard Deviation 0.260	0.15 Degree Celsius Standard Deviation 0.554	0.08 Degree Celsius Standard Deviation 0.293	0.11 Degree Celsius Standard Deviation 0.382	0.22 Degree Celsius Standard Deviation 0.239	0.02 Degree Celsius Standard Deviation 0.397
Change From Baseline in Temperature Day 5,n=12,6,6,9,9,6	-0.08 Degree Celsius Standard Deviation 0.171	0.13 Degree Celsius Standard Deviation 0.516	0.25 Degree Celsius Standard Deviation 0.464	-0.07 Degree Celsius Standard Deviation 0.300	-0.04 Degree Celsius Standard Deviation 0.255	0.12 Degree Celsius Standard Deviation 0.293
Change From Baseline in Temperature Week 2,n=12,6,6,9,9,6	-0.29 Degree Celsius Standard Deviation 0.448	0.30 Degree Celsius Standard Deviation 0.460	0.03 Degree Celsius Standard Deviation 0.333	0.04 Degree Celsius Standard Deviation 0.340	0.08 Degree Celsius Standard Deviation 0.441	-0.08 Degree Celsius Standard Deviation 0.319
Change From Baseline in Temperature Week 4,n=12,6,6,9,9,6	-0.23 Degree Celsius Standard Deviation 0.172	0.20 Degree Celsius Standard Deviation 0.400	-0.02 Degree Celsius Standard Deviation 0.387	-0.09 Degree Celsius Standard Deviation 0.302	0.00 Degree Celsius Standard Deviation 0.671	-0.03 Degree Celsius Standard Deviation 0.258
Change From Baseline in Temperature Week 8,n=12,6,6,9,9,6	0.00 Degree Celsius Standard Deviation 0.280	0.32 Degree Celsius Standard Deviation 0.397	-0.18 Degree Celsius Standard Deviation 0.504	0.09 Degree Celsius Standard Deviation 0.446	0.02 Degree Celsius Standard Deviation 0.282	0.13 Degree Celsius Standard Deviation 0.197
Change From Baseline in Temperature Week 12,n=12,6,6,9,9,6	-0.10 Degree Celsius Standard Deviation 0.386	0.17 Degree Celsius Standard Deviation 0.356	-0.15 Degree Celsius Standard Deviation 0.187	0.09 Degree Celsius Standard Deviation 0.337	-0.09 Degree Celsius Standard Deviation 0.355	0.00 Degree Celsius Standard Deviation 0.369
Change From Baseline in Temperature Week 18,n=12,6,6,9,9,6	-0.07 Degree Celsius Standard Deviation 0.267	0.18 Degree Celsius Standard Deviation 0.662	0.02 Degree Celsius Standard Deviation 0.407	0.13 Degree Celsius Standard Deviation 0.512	0.07 Degree Celsius Standard Deviation 0.283	-0.05 Degree Celsius Standard Deviation 0.399
Change From Baseline in Temperature Week 26,n=12,6,6,9,9,6	-0.08 Degree Celsius Standard Deviation 0.311	0.03 Degree Celsius Standard Deviation 0.441	-0.02 Degree Celsius Standard Deviation 0.504	0.08 Degree Celsius Standard Deviation 0.424	0.00 Degree Celsius Standard Deviation 0.442	-0.22 Degree Celsius Standard Deviation 0.117
Change From Baseline in Temperature Week 32,n=6,6,6,0,0,6	-0.30 Degree Celsius Standard Deviation 0.569	0.48 Degree Celsius Standard Deviation 1.363	0.02 Degree Celsius Standard Deviation 0.306	—	—	0.08 Degree Celsius Standard Deviation 0.331
Change From Baseline in Temperature Week 36,n=6,0,0,9,9,0	0.22 Degree Celsius Standard Deviation 0.366	—	—	0.14 Degree Celsius Standard Deviation 0.433	-0.03 Degree Celsius Standard Deviation 0.212	—
Change From Baseline in Temperature Week 40,n=2,0,0,0,0,6	-0.10 Degree Celsius Standard Deviation 0.566	—	—	—	—	-0.05 Degree Celsius Standard Deviation 0.084

PRIMARY outcome

Timeframe: Baseline and at 2 and 8 hours at Day 1; Days 2, 3, 4 and 5; Weeks 1, 2, 4, 8, 12, 18, 24, 26, 32, 36 and 40

Population: Safety Population. Only those participants with planned assessments at that particular time point has been presented (represented by n= X in the category titles).

Heart rate was assessed in a supine position after 5 minutes of rest. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Placebo n=12 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Change From Baseline in Heart Rate Week 4,n=12,6,6,9,9,6	-3.2 Beats per minute Standard Deviation 8.46	-2.3 Beats per minute Standard Deviation 2.88	-1.5 Beats per minute Standard Deviation 5.96	-1.1 Beats per minute Standard Deviation 10.54	0.8 Beats per minute Standard Deviation 13.58	0.5 Beats per minute Standard Deviation 9.35
Change From Baseline in Heart Rate Week 18,n=12,6,6,9,9,6	-3.2 Beats per minute Standard Deviation 8.56	-2.0 Beats per minute Standard Deviation 7.07	-1.7 Beats per minute Standard Deviation 5.50	0.8 Beats per minute Standard Deviation 10.84	1.7 Beats per minute Standard Deviation 9.10	2.5 Beats per minute Standard Deviation 7.23
Change From Baseline in Heart Rate Week 24,n=12,6,6,9,9,6	-1.4 Beats per minute Standard Deviation 10.03	-0.8 Beats per minute Standard Deviation 6.85	1.8 Beats per minute Standard Deviation 7.68	-2.8 Beats per minute Standard Deviation 12.04	3.2 Beats per minute Standard Deviation 9.28	0.0 Beats per minute Standard Deviation 4.82
Change From Baseline in Heart Rate Week 26,n=12,6,6,9,9,6	-2.7 Beats per minute Standard Deviation 10.04	-0.2 Beats per minute Standard Deviation 2.56	-0.7 Beats per minute Standard Deviation 6.59	2.0 Beats per minute Standard Deviation 12.03	1.6 Beats per minute Standard Deviation 7.09	1.8 Beats per minute Standard Deviation 4.58
Change From Baseline in Heart Rate Week 40,n=2,0,0,0,0,6	-2.0 Beats per minute Standard Deviation 2.83	—	—	—	—	2.8 Beats per minute Standard Deviation 10.26
Change From Baseline in Heart Rate 2 hours Day1,n=12,6,6,9,9,6	2.2 Beats per minute Standard Deviation 13.62	-4.2 Beats per minute Standard Deviation 5.27	-3.3 Beats per minute Standard Deviation 8.64	0.8 Beats per minute Standard Deviation 14.45	0.9 Beats per minute Standard Deviation 10.74	5.2 Beats per minute Standard Deviation 5.46
Change From Baseline in Heart Rate 8 hours Day1,n=12,6,6,9,9,6	-1.0 Beats per minute Standard Deviation 7.05	-2.0 Beats per minute Standard Deviation 7.27	-3.2 Beats per minute Standard Deviation 3.37	0.3 Beats per minute Standard Deviation 14.21	1.0 Beats per minute Standard Deviation 11.62	4.8 Beats per minute Standard Deviation 8.06
Change From Baseline in Heart Rate Day 2,n=12,6,6,9,9,6	-1.2 Beats per minute Standard Deviation 6.59	-1.5 Beats per minute Standard Deviation 2.81	-1.7 Beats per minute Standard Deviation 3.83	-4.0 Beats per minute Standard Deviation 11.03	2.7 Beats per minute Standard Deviation 8.14	-0.7 Beats per minute Standard Deviation 3.50
Change From Baseline in Heart Rate Day 3,n=12,6,6,9,9,6	-0.2 Beats per minute Standard Deviation 4.82	0.2 Beats per minute Standard Deviation 5.88	1.3 Beats per minute Standard Deviation 8.41	0.7 Beats per minute Standard Deviation 4.92	4.7 Beats per minute Standard Deviation 3.94	-1.0 Beats per minute Standard Deviation 7.40
Change From Baseline in Heart Rate Day 4,n=12,6,6,9,9,6	3.8 Beats per minute Standard Deviation 7.53	1.7 Beats per minute Standard Deviation 4.84	4.7 Beats per minute Standard Deviation 8.98	-1.2 Beats per minute Standard Deviation 11.62	3.6 Beats per minute Standard Deviation 5.27	1.5 Beats per minute Standard Deviation 3.33
Change From Baseline in Heart Rate Day 5,n=12,6,6,9,9,6	1.1 Beats per minute Standard Deviation 4.91	2.8 Beats per minute Standard Deviation 8.61	1.2 Beats per minute Standard Deviation 7.83	-0.1 Beats per minute Standard Deviation 10.30	0.6 Beats per minute Standard Deviation 4.28	3.0 Beats per minute Standard Deviation 4.47
Change From Baseline in Heart Rate Week 1,n=12,6,6,9,9,6	-1.8 Beats per minute Standard Deviation 6.03	0.0 Beats per minute Standard Deviation 10.58	-1.8 Beats per minute Standard Deviation 7.05	-1.1 Beats per minute Standard Deviation 10.80	1.4 Beats per minute Standard Deviation 5.98	5.0 Beats per minute Standard Deviation 9.21
Change From Baseline in Heart Rate Week 2,n=12,6,6,9,9,6	-4.8 Beats per minute Standard Deviation 5.57	-1.3 Beats per minute Standard Deviation 5.89	-5.2 Beats per minute Standard Deviation 5.23	2.1 Beats per minute Standard Deviation 12.38	1.0 Beats per minute Standard Deviation 10.51	2.0 Beats per minute Standard Deviation 6.00
Change From Baseline in Heart Rate Week 8,n=12,6,6,9,9,6	-0.2 Beats per minute Standard Deviation 7.12	-1.8 Beats per minute Standard Deviation 7.14	-3.7 Beats per minute Standard Deviation 5.79	-4.9 Beats per minute Standard Deviation 15.39	-0.6 Beats per minute Standard Deviation 6.52	-0.3 Beats per minute Standard Deviation 4.72
Change From Baseline in Heart Rate Week 12,n=12,6,6,9,9,6	-1.2 Beats per minute Standard Deviation 10.47	3.3 Beats per minute Standard Deviation 8.38	-2.3 Beats per minute Standard Deviation 6.53	0.6 Beats per minute Standard Deviation 16.41	1.0 Beats per minute Standard Deviation 9.31	3.0 Beats per minute Standard Deviation 7.38
Change From Baseline in Heart Rate Week 32,n=6,6,6,0,0,6	-1.0 Beats per minute Standard Deviation 10.55	-2.2 Beats per minute Standard Deviation 5.19	0.7 Beats per minute Standard Deviation 6.06	—	—	0.8 Beats per minute Standard Deviation 7.28
Change From Baseline in Heart Rate Week 36,n=6,0,0,9,9,0	0.5 Beats per minute Standard Deviation 11.59	—	—	0.0 Beats per minute Standard Deviation 12.50	2.6 Beats per minute Standard Deviation 6.29	—

PRIMARY outcome

Timeframe: Baseline and at 2 and 8 hours at Day 1; Days 2, 3, 4 and 5; Weeks 1, 2, 4, 8, 12, 18, 24, 26, 32, 36 and 40

Population: Safety Population. Only those participants with planned assessments at that particular time point has been presented (represented by n= X in the category titles).

Respiration rate was assessed in a supine position after 5 minutes of rest. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Placebo n=12 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Change From Baseline in Respiration Rate 2 hours Day1,n=12,6,6,9,9,6	0.8 Breaths per minute Standard Deviation 2.42	1.2 Breaths per minute Standard Deviation 1.83	0.0 Breaths per minute Standard Deviation 2.53	0.3 Breaths per minute Standard Deviation 2.65	0.8 Breaths per minute Standard Deviation 1.72	2.2 Breaths per minute Standard Deviation 3.31
Change From Baseline in Respiration Rate Day 3,n=12,6,6,9,9,6	-1.0 Breaths per minute Standard Deviation 2.83	1.5 Breaths per minute Standard Deviation 3.27	-0.2 Breaths per minute Standard Deviation 2.40	1.1 Breaths per minute Standard Deviation 2.80	1.2 Breaths per minute Standard Deviation 2.11	0.7 Breaths per minute Standard Deviation 3.50
Change From Baseline in Respiration Rate Day 4,n=12,6,6,9,9,6	-0.1 Breaths per minute Standard Deviation 3.06	-1.0 Breaths per minute Standard Deviation 3.03	0.7 Breaths per minute Standard Deviation 1.21	0.3 Breaths per minute Standard Deviation 2.24	2.3 Breaths per minute Standard Deviation 1.87	0.2 Breaths per minute Standard Deviation 2.71
Change From Baseline in Respiration Rate Week 1,n=12,6,6,9,9,6	-0.5 Breaths per minute Standard Deviation 3.45	0.7 Breaths per minute Standard Deviation 3.67	-0.2 Breaths per minute Standard Deviation 1.33	-0.6 Breaths per minute Standard Deviation 1.67	0.4 Breaths per minute Standard Deviation 1.81	-1.8 Breaths per minute Standard Deviation 2.71
Change From Baseline in Respiration Rate Week 2,n=12,6,6,9,9,6	-0.3 Breaths per minute Standard Deviation 2.15	0.7 Breaths per minute Standard Deviation 4.08	0.2 Breaths per minute Standard Deviation 2.23	1.1 Breaths per minute Standard Deviation 2.76	0.9 Breaths per minute Standard Deviation 2.98	-0.2 Breaths per minute Standard Deviation 3.06
Change From Baseline in Respiration Rate Week 4,n=12,6,6,9,9,6	0.5 Breaths per minute Standard Deviation 3.18	1.5 Breaths per minute Standard Deviation 2.59	1.5 Breaths per minute Standard Deviation 1.22	0.4 Breaths per minute Standard Deviation 1.88	1.2 Breaths per minute Standard Deviation 2.17	-0.5 Breaths per minute Standard Deviation 3.89
Change From Baseline in Respiration Rate Week 8,n=12,6,6,9,9,6	-0.5 Breaths per minute Standard Deviation 2.71	0.5 Breaths per minute Standard Deviation 2.81	0.3 Breaths per minute Standard Deviation 2.42	0.1 Breaths per minute Standard Deviation 3.41	2.3 Breaths per minute Standard Deviation 2.18	0.7 Breaths per minute Standard Deviation 2.80
Change From Baseline in Respiration Rate Week 12,n=12,6,6,9,9,6	0.0 Breaths per minute Standard Deviation 3.49	0.7 Breaths per minute Standard Deviation 4.63	0.7 Breaths per minute Standard Deviation 2.16	1.2 Breaths per minute Standard Deviation 2.86	0.9 Breaths per minute Standard Deviation 1.69	-0.3 Breaths per minute Standard Deviation 2.88
Change From Baseline in Respiration Rate Week 36,n=6,0,0,9,9,0	0.2 Breaths per minute Standard Deviation 1.83	—	—	0.2 Breaths per minute Standard Deviation 2.64	1.3 Breaths per minute Standard Deviation 1.50	—
Change From Baseline in Respiration Rate Day 5,n=12,6,6,9,9,6	-1.1 Breaths per minute Standard Deviation 2.39	0.7 Breaths per minute Standard Deviation 3.20	-1.5 Breaths per minute Standard Deviation 1.05	0.0 Breaths per minute Standard Deviation 2.55	1.3 Breaths per minute Standard Deviation 2.18	0.0 Breaths per minute Standard Deviation 1.41
Change From Baseline in Respiration Rate 8 hours Day1,n=12,6,6,9,9,6	-0.1 Breaths per minute Standard Deviation 2.19	0.5 Breaths per minute Standard Deviation 3.27	-1.0 Breaths per minute Standard Deviation 1.79	1.0 Breaths per minute Standard Deviation 3.28	2.1 Breaths per minute Standard Deviation 1.83	0.3 Breaths per minute Standard Deviation 1.63
Change From Baseline in Respiration Rate Day 2,n=12,6,6,9,9,6	-0.7 Breaths per minute Standard Deviation 2.64	1.7 Breaths per minute Standard Deviation 2.58	-1.2 Breaths per minute Standard Deviation 1.47	1.9 Breaths per minute Standard Deviation 1.96	1.8 Breaths per minute Standard Deviation 1.30	1.5 Breaths per minute Standard Deviation 2.07
Change From Baseline in Respiration Rate Week 18,n=12,6,6,9,9,6	0.5 Breaths per minute Standard Deviation 3.66	-0.2 Breaths per minute Standard Deviation 3.06	-0.7 Breaths per minute Standard Deviation 1.97	1.4 Breaths per minute Standard Deviation 2.07	1.4 Breaths per minute Standard Deviation 1.42	1.2 Breaths per minute Standard Deviation 3.25
Change From Baseline in Respiration Rate Week 24,n=12,6,6,9,9,6	-0.8 Breaths per minute Standard Deviation 2.59	-0.7 Breaths per minute Standard Deviation 4.41	-0.7 Breaths per minute Standard Deviation 1.51	1.4 Breaths per minute Standard Deviation 2.13	0.7 Breaths per minute Standard Deviation 2.40	0.8 Breaths per minute Standard Deviation 1.94
Change From Baseline in Respiration Rate Week 26,n=12,6,6,9,9,6	-1.1 Breaths per minute Standard Deviation 2.43	0.5 Breaths per minute Standard Deviation 3.02	-0.7 Breaths per minute Standard Deviation 1.51	0.6 Breaths per minute Standard Deviation 2.01	1.6 Breaths per minute Standard Deviation 2.19	0.3 Breaths per minute Standard Deviation 3.01
Change From Baseline in Respiration Rate Week 32,n=6,6,6,0,0,6	-1.5 Breaths per minute Standard Deviation 1.76	1.3 Breaths per minute Standard Deviation 3.01	0.7 Breaths per minute Standard Deviation 2.34	—	—	1.0 Breaths per minute Standard Deviation 3.10
Change From Baseline in Respiration Rate Week 40,n=2,0,0,0,0,6	-2.0 Breaths per minute Standard Deviation 1.41	—	—	—	—	-0.3 Breaths per minute Standard Deviation 1.86

PRIMARY outcome

Timeframe: Baseline and at 2 and 8 hours on Day 1; Days 2, 3, 4 and 5; Weeks 1, 2, 4, 8, 12, 18, 24, 26, 32, 36 and 40

Population: Safety Population. Only those participants with planned assessments at that particular time point has been presented (represented by n= X in the category titles).

12-lead ECG were performed in a supine position using an automated ECG machine that calculated the heart rate and measured PR, QRS, QT and corrected QT (QTc) intervals. ECG measurements were performed in triplicate. When multiple ECGs were performed at the same planned timepoint, the average value of each parameter was used. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Placebo n=12 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Change From Baseline in Heart Rate: Electrocardiogram (ECG) Day 2,n=12,6,6,9,9,6	0.4 Beats per minute Standard Deviation 4.68	-0.4 Beats per minute Standard Deviation 5.67	0.8 Beats per minute Standard Deviation 5.29	-1.4 Beats per minute Standard Deviation 6.32	-0.3 Beats per minute Standard Deviation 7.34	0.3 Beats per minute Standard Deviation 1.06
Change From Baseline in Heart Rate: Electrocardiogram (ECG) Day 4,n=12,6,6,9,9,6	3.5 Beats per minute Standard Deviation 5.11	1.5 Beats per minute Standard Deviation 8.64	5.5 Beats per minute Standard Deviation 9.13	3.1 Beats per minute Standard Deviation 11.04	2.6 Beats per minute Standard Deviation 4.60	3.2 Beats per minute Standard Deviation 3.97
Change From Baseline in Heart Rate: Electrocardiogram (ECG) Day 5,n=12,6,6,9,9,6	1.8 Beats per minute Standard Deviation 4.78	1.5 Beats per minute Standard Deviation 9.63	0.8 Beats per minute Standard Deviation 5.24	2.5 Beats per minute Standard Deviation 5.29	-0.4 Beats per minute Standard Deviation 5.97	2.6 Beats per minute Standard Deviation 4.75
Change From Baseline in Heart Rate: Electrocardiogram (ECG) Week 2,n=12,6,6,9,9,6	-4.2 Beats per minute Standard Deviation 5.32	-2.3 Beats per minute Standard Deviation 5.02	-5.9 Beats per minute Standard Deviation 5.91	1.8 Beats per minute Standard Deviation 10.26	1.7 Beats per minute Standard Deviation 13.56	1.7 Beats per minute Standard Deviation 7.11
Change From Baseline in Heart Rate: Electrocardiogram (ECG) Week 4,n=12,6,6,9,9,6	-3.8 Beats per minute Standard Deviation 7.01	-1.6 Beats per minute Standard Deviation 3.75	-1.2 Beats per minute Standard Deviation 3.45	-1.6 Beats per minute Standard Deviation 7.53	-0.3 Beats per minute Standard Deviation 14.55	-0.9 Beats per minute Standard Deviation 6.25
Change From Baseline in Heart Rate: Electrocardiogram (ECG) Week 18,n=12,6,6,9,9,6	-3.4 Beats per minute Standard Deviation 9.05	-0.4 Beats per minute Standard Deviation 6.59	-3.3 Beats per minute Standard Deviation 5.20	1.6 Beats per minute Standard Deviation 6.92	0.6 Beats per minute Standard Deviation 8.78	2.2 Beats per minute Standard Deviation 4.65
Change From Baseline in Heart Rate: Electrocardiogram (ECG) Week 24,n=12,6,6,9,9,6	-2.7 Beats per minute Standard Deviation 7.95	-0.2 Beats per minute Standard Deviation 8.28	2.5 Beats per minute Standard Deviation 8.00	-0.3 Beats per minute Standard Deviation 9.13	1.7 Beats per minute Standard Deviation 11.03	1.2 Beats per minute Standard Deviation 6.47
Change From Baseline in Heart Rate: Electrocardiogram (ECG) Week 26,n=12,6,6,9,9,6	-2.0 Beats per minute Standard Deviation 9.35	-0.3 Beats per minute Standard Deviation 5.16	-1.5 Beats per minute Standard Deviation 7.18	2.5 Beats per minute Standard Deviation 11.97	2.0 Beats per minute Standard Deviation 8.22	0.3 Beats per minute Standard Deviation 7.66
Change From Baseline in Heart Rate: Electrocardiogram (ECG) Week 32,n=6,6,6,0,0,6	-2.7 Beats per minute Standard Deviation 9.21	-4.6 Beats per minute Standard Deviation 7.34	0.7 Beats per minute Standard Deviation 5.84	—	—	2.3 Beats per minute Standard Deviation 6.46
Change From Baseline in Heart Rate: Electrocardiogram (ECG) Week 36,n=6,0,0,9,9,0	1.5 Beats per minute Standard Deviation 7.13	—	—	-0.2 Beats per minute Standard Deviation 10.26	1.3 Beats per minute Standard Deviation 5.74	—
Change From Baseline in Heart Rate: Electrocardiogram (ECG) Week 40,n=2,0,0,0,0,6	-4.3 Beats per minute Standard Deviation 0.47	—	—	—	—	3.6 Beats per minute Standard Deviation 9.08
Change From Baseline in Heart Rate: Electrocardiogram (ECG) 2 hours Day1,n=12,6,5,9,8,6	1.4 Beats per minute Standard Deviation 11.13	-4.3 Beats per minute Standard Deviation 7.81	-4.6 Beats per minute Standard Deviation 4.56	0.2 Beats per minute Standard Deviation 11.06	0.3 Beats per minute Standard Deviation 11.85	6.8 Beats per minute Standard Deviation 7.01
Change From Baseline in Heart Rate: Electrocardiogram (ECG) 8 hours Day1,n=12,6,6,9,9,6	0.1 Beats per minute Standard Deviation 6.34	-0.8 Beats per minute Standard Deviation 8.93	-6.3 Beats per minute Standard Deviation 6.10	-1.3 Beats per minute Standard Deviation 6.23	0.0 Beats per minute Standard Deviation 14.05	4.1 Beats per minute Standard Deviation 6.20
Change From Baseline in Heart Rate: Electrocardiogram (ECG) Day 3,n=12,6,6,9,9,6	1.5 Beats per minute Standard Deviation 5.93	0.3 Beats per minute Standard Deviation 4.15	0.4 Beats per minute Standard Deviation 7.36	1.5 Beats per minute Standard Deviation 7.03	3.1 Beats per minute Standard Deviation 3.48	1.9 Beats per minute Standard Deviation 3.69
Change From Baseline in Heart Rate: Electrocardiogram (ECG) Week 1,n=12,6,6,9,9,6	-2.8 Beats per minute Standard Deviation 5.74	1.6 Beats per minute Standard Deviation 5.76	-2.4 Beats per minute Standard Deviation 5.53	2.4 Beats per minute Standard Deviation 9.66	2.0 Beats per minute Standard Deviation 4.76	4.9 Beats per minute Standard Deviation 7.60
Change From Baseline in Heart Rate: Electrocardiogram (ECG) Week 8,n=12,6,6,9,9,6	-0.8 Beats per minute Standard Deviation 5.91	-0.6 Beats per minute Standard Deviation 6.22	-2.0 Beats per minute Standard Deviation 6.02	-2.9 Beats per minute Standard Deviation 7.50	-0.7 Beats per minute Standard Deviation 9.14	0.6 Beats per minute Standard Deviation 4.97
Change From Baseline in Heart Rate: Electrocardiogram (ECG) Week 12,n=12,6,6,9,9,6	0.3 Beats per minute Standard Deviation 11.83	-1.3 Beats per minute Standard Deviation 6.24	-3.3 Beats per minute Standard Deviation 6.35	1.8 Beats per minute Standard Deviation 15.28	0.4 Beats per minute Standard Deviation 11.55	1.3 Beats per minute Standard Deviation 6.44

PRIMARY outcome

Timeframe: Baseline and at 2 and 8 hours on Day 1; Days 2, 3, 4 and 5; Weeks 1, 2, 4, 8, 12, 18, 24, 26, 32, 36 and 40

Population: Safety Population. Only those participants with planned assessments at that particular time point has been presented (represented by n= X in the category titles).

12-lead ECG were performed in a supine position using an automated ECG machine that calculated PR interval, QRS interval, QT interval and QTcF interval. ECG measurements were performed in triplicate. When multiple ECGs were performed at the same planned timepoint, the average value of each parameter was used. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Placebo n=12 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QRS Interval,Day 4,n=12,6,6,9,9,6	0.4 Milliseconds Standard Deviation 3.78	1.9 Milliseconds Standard Deviation 3.72	-7.8 Milliseconds Standard Deviation 5.52	1.1 Milliseconds Standard Deviation 5.28	-0.7 Milliseconds Standard Deviation 5.24	-2.2 Milliseconds Standard Deviation 3.38
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval PR Interval,2 hours Day1,n=12,6,5,9,8,6	-4.5 Milliseconds Standard Deviation 9.46	3.9 Milliseconds Standard Deviation 2.85	3.5 Milliseconds Standard Deviation 8.47	-4.3 Milliseconds Standard Deviation 9.10	3.7 Milliseconds Standard Deviation 1.075	-7.5 Milliseconds Standard Deviation 12.23
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval PR Interval,8 hours Day1,n=12,6,6,9,9,6	-4.1 Milliseconds Standard Deviation 8.49	3.1 Milliseconds Standard Deviation 6.02	-1.8 Milliseconds Standard Deviation 3.72	-4.5 Milliseconds Standard Deviation 11.76	1.9 Milliseconds Standard Deviation 11.39	-3.3 Milliseconds Standard Deviation 10.88
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval PR Interval,Day 4,n=12,6,6,9,9,6	-0.6 Milliseconds Standard Deviation 6.80	8.1 Milliseconds Standard Deviation 5.21	-2.5 Milliseconds Standard Deviation 6.12	-2.3 Milliseconds Standard Deviation 8.88	8.6 Milliseconds Standard Deviation 10.17	-4.3 Milliseconds Standard Deviation 7.54
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval PR Interval,Week 1,n=12,6,6,9,9,6	-0.3 Milliseconds Standard Deviation 8.12	0.8 Milliseconds Standard Deviation 5.58	2.2 Milliseconds Standard Deviation 5.69	-3.2 Milliseconds Standard Deviation 12.26	7.0 Milliseconds Standard Deviation 6.62	4.5 Milliseconds Standard Deviation 6.73
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval PR Interval,Week 2,n=12,6,6,9,9,6	-1.0 Milliseconds Standard Deviation 8.62	5.3 Milliseconds Standard Deviation 6.60	5.5 Milliseconds Standard Deviation 10.34	1.8 Milliseconds Standard Deviation 12.19	2.0 Milliseconds Standard Deviation 12.64	1.0 Milliseconds Standard Deviation 2.97
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval PR Interval,Week 4,n=12,6,6,8,9,6	1.7 Milliseconds Standard Deviation 10.27	5.2 Milliseconds Standard Deviation 3.37	1.8 Milliseconds Standard Deviation 12.71	-1.8 Milliseconds Standard Deviation 15.25	3.9 Milliseconds Standard Deviation 11.28	-4.0 Milliseconds Standard Deviation 17.49
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval PR Interval,Week 8,n=12,6,6,9,9,6	-3.1 Milliseconds Standard Deviation 8.27	3.2 Milliseconds Standard Deviation 9.65	-2.6 Milliseconds Standard Deviation 10.27	-3.6 Milliseconds Standard Deviation 10.33	3.4 Milliseconds Standard Deviation 8.10	-1.9 Milliseconds Standard Deviation 9.55
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval PR Interval,Week 12,n=12,6,6,9,9,6	-2.4 Milliseconds Standard Deviation 7.87	3.9 Milliseconds Standard Deviation 10.53	-4.4 Milliseconds Standard Deviation 12.18	-3.8 Milliseconds Standard Deviation 13.26	9.4 Milliseconds Standard Deviation 8.33	-2.1 Milliseconds Standard Deviation 10.04
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval PR Interval,Week 24,n=12,6,6,9,9,6	2.3 Milliseconds Standard Deviation 7.98	1.4 Milliseconds Standard Deviation 3.91	3.7 Milliseconds Standard Deviation 7.25	-7.4 Milliseconds Standard Deviation 11.56	5.5 Milliseconds Standard Deviation 12.45	-5.6 Milliseconds Standard Deviation 7.87
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval PR Interval,Week 26,n=12,6,6,9,9,6	1.1 Milliseconds Standard Deviation 6.20	3.0 Milliseconds Standard Deviation 4.67	3.7 Milliseconds Standard Deviation 11.62	-3.2 Milliseconds Standard Deviation 13.01	6.9 Milliseconds Standard Deviation 11.36	-4.8 Milliseconds Standard Deviation 11.69
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval PR Interval,Week 32,n=6,6,6,0,0,6	-4.3 Milliseconds Standard Deviation 8.16	5.4 Milliseconds Standard Deviation 7.23	0.0 Milliseconds Standard Deviation 7.99	—	—	-3.3 Milliseconds Standard Deviation 11.91
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval PR Interval,Week 36,n=6,0,0,9,9,0	-0.5 Milliseconds Standard Deviation 8.26	—	—	-3.7 Milliseconds Standard Deviation 8.49	2.9 Milliseconds Standard Deviation 12.08	—
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QRS Interval,Day 2,n=12,6,6,9,9,6	1.8 Milliseconds Standard Deviation 4.64	0.5 Milliseconds Standard Deviation 4.63	-4.9 Milliseconds Standard Deviation 4.60	-2.7 Milliseconds Standard Deviation 5.28	-3.0 Milliseconds Standard Deviation 6.27	-3.7 Milliseconds Standard Deviation 4.62
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QRS Interval,Week 2,n=12,6,6,9,9,6	2.1 Milliseconds Standard Deviation 3.76	2.1 Milliseconds Standard Deviation 4.82	-3.9 Milliseconds Standard Deviation 4.76	0.9 Milliseconds Standard Deviation 2.86	-3.0 Milliseconds Standard Deviation 5.47	-1.4 Milliseconds Standard Deviation 3.11
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QRS Interval,Week 4,n=12,6,6,8,9,6	2.0 Milliseconds Standard Deviation 6.49	1.8 Milliseconds Standard Deviation 7.34	-6.5 Milliseconds Standard Deviation 7.76	1.9 Milliseconds Standard Deviation 4.79	-2.6 Milliseconds Standard Deviation 4.98	-3.3 Milliseconds Standard Deviation 3.39
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QRS Interval,Week 12,n=12,6,6,9,9,6	1.6 Milliseconds Standard Deviation 4.20	3.1 Milliseconds Standard Deviation 3.28	-4.4 Milliseconds Standard Deviation 6.04	-0.1 Milliseconds Standard Deviation 5.23	-2.5 Milliseconds Standard Deviation 3.11	-1.1 Milliseconds Standard Deviation 3.21
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QRS Interval,Week 18,n=12,6,6,9,9,6	0.6 Milliseconds Standard Deviation 3.90	1.8 Milliseconds Standard Deviation 2.79	-5.0 Milliseconds Standard Deviation 5.43	0.4 Milliseconds Standard Deviation 3.16	-2.9 Milliseconds Standard Deviation 4.53	-1.6 Milliseconds Standard Deviation 4.17
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QRS Interval,Week 24,n=12,6,6,9,9,6	0.6 Milliseconds Standard Deviation 5.94	1.8 Milliseconds Standard Deviation 6.53	-6.5 Milliseconds Standard Deviation 5.56	-1.1 Milliseconds Standard Deviation 3.76	-3.1 Milliseconds Standard Deviation 2.01	-1.8 Milliseconds Standard Deviation 5.12
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QT Interval,8 hours Day1,n=12,6,6,9,9,6	-7.5 Milliseconds Standard Deviation 16.46	6.7 Milliseconds Standard Deviation 16.22	12.6 Milliseconds Standard Deviation 18.53	1.5 Milliseconds Standard Deviation 14.29	-0.7 Milliseconds Standard Deviation 29.93	-7.6 Milliseconds Standard Deviation 22.43
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QT Interval,Week 24,n=12,6,6,9,9,6	7.1 Milliseconds Standard Deviation 23.22	4.2 Milliseconds Standard Deviation 18.11	-9.9 Milliseconds Standard Deviation 27.45	0.7 Milliseconds Standard Deviation 19.24	-8.6 Milliseconds Standard Deviation 19.00	7.9 Milliseconds Standard Deviation 23.80
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QTcF Interval,Week 1,n=12,6,6,9,9,6	-0.2 Milliseconds Standard Deviation 10.95	10.3 Milliseconds Standard Deviation 7.33	-6.7 Milliseconds Standard Deviation 12.72	-5.4 Milliseconds Standard Deviation 8.38	2.8 Milliseconds Standard Deviation 12.12	5.5 Milliseconds Standard Deviation 13.80
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QTcF Interval,Week 2,n=12,6,6,9,9,6	0.9 Milliseconds Standard Deviation 16.40	6.3 Milliseconds Standard Deviation 6.98	-8.3 Milliseconds Standard Deviation 8.21	3.7 Milliseconds Standard Deviation 19.35	-2.3 Milliseconds Standard Deviation 12.64	11.5 Milliseconds Standard Deviation 12.63
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QTcF Interval,Week 18,n=12,6,6,9,9,6	-0.5 Milliseconds Standard Deviation 11.73	4.8 Milliseconds Standard Deviation 6.79	-10.4 Milliseconds Standard Deviation 9.42	-0.6 Milliseconds Standard Deviation 12.29	-5.2 Milliseconds Standard Deviation 12.81	5.9 Milliseconds Standard Deviation 11.16
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QTcF Interval,Week 26,n=12,6,6,9,9,6	-1.9 Milliseconds Standard Deviation 16.58	9.6 Milliseconds Standard Deviation 9.37	-3.9 Milliseconds Standard Deviation 14.54	-1.7 Milliseconds Standard Deviation 10.65	-4.4 Milliseconds Standard Deviation 12.21	12.8 Milliseconds Standard Deviation 8.59
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QT Interval,Day 2,n=12,6,6,9,9,6	-4.9 Milliseconds Standard Deviation 19.32	4.3 Milliseconds Standard Deviation 14.01	-14.1 Milliseconds Standard Deviation 16.26	-3.0 Milliseconds Standard Deviation 18.80	-6.1 Milliseconds Standard Deviation 15.86	-0.6 Milliseconds Standard Deviation 11.09
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval PR Interval,Day 2,n=12,6,6,9,9,6	-2.7 Milliseconds Standard Deviation 11.51	2.0 Milliseconds Standard Deviation 4.11	1.4 Milliseconds Standard Deviation 3.95	-4.4 Milliseconds Standard Deviation 9.86	6.2 Milliseconds Standard Deviation 11.05	-4.1 Milliseconds Standard Deviation 11.25
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval PR Interval, Day 3,n=12,6,6,9,9,6	2.3 Milliseconds Standard Deviation 6.68	5.2 Milliseconds Standard Deviation 4.29	0.5 Milliseconds Standard Deviation 5.62	-3.6 Milliseconds Standard Deviation 11.96	6.0 Milliseconds Standard Deviation 7.60	-1.4 Milliseconds Standard Deviation 8.82
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval PR Interval,Day 5,n=12,6,6,9,9,6	1.3 Milliseconds Standard Deviation 6.22	8.3 Milliseconds Standard Deviation 8.22	3.5 Milliseconds Standard Deviation 10.05	-0.2 Milliseconds Standard Deviation 4.54	10.0 Milliseconds Standard Deviation 8.44	-1.2 Milliseconds Standard Deviation 4.91
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval PR Interval,Week 18,n=12,6,6,9,9,6	1.5 Milliseconds Standard Deviation 10.74	1.5 Milliseconds Standard Deviation 3.99	0.1 Milliseconds Standard Deviation 7.74	-5.6 Milliseconds Standard Deviation 11.87	7.3 Milliseconds Standard Deviation 13.34	-2.0 Milliseconds Standard Deviation 9.72
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval PR Interval,Week 40,n=2,0,0,0,0,6	-13.7 Milliseconds Standard Deviation 6.60	—	—	—	—	-3.6 Milliseconds Standard Deviation 8.56
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QRS Interval,2 hours Day1,n=12,6,5,9,8,6	1.1 Milliseconds Standard Deviation 4.87	0.2 Milliseconds Standard Deviation 4.63	-7.2 Milliseconds Standard Deviation 4.97	0.0 Milliseconds Standard Deviation 4.43	-1.5 Milliseconds Standard Deviation 6.14	-1.2 Milliseconds Standard Deviation 3.62
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QRS Interval,8 hours Day1,n=12,6,6,9,9,6	-0.3 Milliseconds Standard Deviation 6.83	-0.2 Milliseconds Standard Deviation 6.81	-4.0 Milliseconds Standard Deviation 6.18	-1.1 Milliseconds Standard Deviation 3.18	-2.8 Milliseconds Standard Deviation 5.03	-3.1 Milliseconds Standard Deviation 4.42
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QRS Interval, Day 3,n=12,6,6,9,9,6	1.4 Milliseconds Standard Deviation 3.44	1.4 Milliseconds Standard Deviation 4.18	-1.3 Milliseconds Standard Deviation 3.14	-0.6 Milliseconds Standard Deviation 4.03	-2.6 Milliseconds Standard Deviation 5.15	-2.6 Milliseconds Standard Deviation 1.54
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QRS Interval,Day 5,n=12,6,6,9,9,6	-0.5 Milliseconds Standard Deviation 4.05	0.2 Milliseconds Standard Deviation 5.85	-7.3 Milliseconds Standard Deviation 4.79	-0.2 Milliseconds Standard Deviation 5.40	0.7 Milliseconds Standard Deviation 5.09	-2.9 Milliseconds Standard Deviation 2.35
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QRS Interval,Week 1,n=12,6,6,9,9,6	2.3 Milliseconds Standard Deviation 5.05	0.6 Milliseconds Standard Deviation 5.85	-3.7 Milliseconds Standard Deviation 6.18	0.6 Milliseconds Standard Deviation 4.90	-2.4 Milliseconds Standard Deviation 5.61	-2.8 Milliseconds Standard Deviation 4.20
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QRS Interval,Week 8,n=12,6,6,9,9,6	1.9 Milliseconds Standard Deviation 7.27	-1.0 Milliseconds Standard Deviation 4.35	-3.6 Milliseconds Standard Deviation 5.23	0.9 Milliseconds Standard Deviation 4.12	0.5 Milliseconds Standard Deviation 5.71	-1.9 Milliseconds Standard Deviation 1.83
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QRS Interval,Week 26,n=12,6,6,9,9,6	0.0 Milliseconds Standard Deviation 4.61	2.1 Milliseconds Standard Deviation 4.64	-5.5 Milliseconds Standard Deviation 5.75	0.4 Milliseconds Standard Deviation 5.55	-2.7 Milliseconds Standard Deviation 6.57	0.4 Milliseconds Standard Deviation 3.40
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QRS Interval,Week 32,n=6,6,6,0,0,6	2.9 Milliseconds Standard Deviation 5.78	2.0 Milliseconds Standard Deviation 5.17	-6.1 Milliseconds Standard Deviation 4.50	—	—	-1.3 Milliseconds Standard Deviation 2.56
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QRS Interval,Week 36,n=6,0,0,9,9,0	-3.7 Milliseconds Standard Deviation 6.19	—	—	0.7 Milliseconds Standard Deviation 5.14	-3.9 Milliseconds Standard Deviation 4.84	—
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QRS Interval,Week 40,n=2,0,0,0,0,6	0.0 Milliseconds Standard Deviation 0.47	—	—	—	—	-3.0 Milliseconds Standard Deviation 3.47
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QT Interval,2 hours Day1,n=12,6,5,9,8,6	-2.6 Milliseconds Standard Deviation 22.55	14.8 Milliseconds Standard Deviation 16.65	6.0 Milliseconds Standard Deviation 11.28	-2.9 Milliseconds Standard Deviation 20.19	-3.7 Milliseconds Standard Deviation 23.95	-9.2 Milliseconds Standard Deviation 18.68
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QT Interval, Day 3,n=12,6,6,9,9,6	-10.1 Milliseconds Standard Deviation 19.82	-0.9 Milliseconds Standard Deviation 10.33	-6.9 Milliseconds Standard Deviation 14.95	-7.6 Milliseconds Standard Deviation 18.49	-13.2 Milliseconds Standard Deviation 15.20	-2.4 Milliseconds Standard Deviation 9.29
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QT Interval,Day 4,n=12,6,6,9,9,6	-12.3 Milliseconds Standard Deviation 17.15	-2.2 Milliseconds Standard Deviation 14.32	-15.9 Milliseconds Standard Deviation 21.55	-11.6 Milliseconds Standard Deviation 25.81	-10.9 Milliseconds Standard Deviation 11.99	-3.2 Milliseconds Standard Deviation 17.05
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QT Interval,Day 5,n=12,6,6,9,9,6	-5.9 Milliseconds Standard Deviation 14.18	-2.2 Milliseconds Standard Deviation 21.88	-14.3 Milliseconds Standard Deviation 13.83	-9.5 Milliseconds Standard Deviation 14.97	-4.1 Milliseconds Standard Deviation 18.72	-1.3 Milliseconds Standard Deviation 11.57
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QT Interval,Week 1,n=12,6,6,9,9,6	5.3 Milliseconds Standard Deviation 17.30	8.7 Milliseconds Standard Deviation 14.19	0.0 Milliseconds Standard Deviation 21.14	-9.4 Milliseconds Standard Deviation 19.82	-1.0 Milliseconds Standard Deviation 22.22	-5.6 Milliseconds Standard Deviation 23.13
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QT Interval,Week 2,n=12,6,6,9,9,6	9.4 Milliseconds Standard Deviation 16.23	12.9 Milliseconds Standard Deviation 8.14	7.8 Milliseconds Standard Deviation 17.65	1.0 Milliseconds Standard Deviation 22.66	-6.1 Milliseconds Standard Deviation 17.10	8.3 Milliseconds Standard Deviation 20.06
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QT Interval,Week 4,n=12,6,6,8,9,6	9.4 Milliseconds Standard Deviation 20.43	11.0 Milliseconds Standard Deviation 4.78	-3.6 Milliseconds Standard Deviation 24.50	3.3 Milliseconds Standard Deviation 17.80	1.7 Milliseconds Standard Deviation 34.52	14.0 Milliseconds Standard Deviation 18.29
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QT Interval,Week 8,n=12,6,6,9,9,6	-0.6 Milliseconds Standard Deviation 20.74	6.9 Milliseconds Standard Deviation 9.28	1.0 Milliseconds Standard Deviation 23.62	4.6 Milliseconds Standard Deviation 19.06	-2.0 Milliseconds Standard Deviation 20.79	6.0 Milliseconds Standard Deviation 15.76
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QT Interval,Week 12,n=12,6,6,9,9,6	-6.8 Milliseconds Standard Deviation 20.64	8.1 Milliseconds Standard Deviation 16.21	4.2 Milliseconds Standard Deviation 22.53	-6.5 Milliseconds Standard Deviation 28.72	-2.1 Milliseconds Standard Deviation 26.69	1.1 Milliseconds Standard Deviation 14.24
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QT Interval,Week 18,n=12,6,6,9,9,6	7.3 Milliseconds Standard Deviation 22.44	6.3 Milliseconds Standard Deviation 15.00	-2.8 Milliseconds Standard Deviation 15.12	-4.5 Milliseconds Standard Deviation 19.10	-6.7 Milliseconds Standard Deviation 23.77	0.5 Milliseconds Standard Deviation 12.14
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QT Interval,Week 26,n=12,6,6,9,9,6	2.3 Milliseconds Standard Deviation 27.36	10.2 Milliseconds Standard Deviation 12.92	0.9 Milliseconds Standard Deviation 29.72	-6.1 Milliseconds Standard Deviation 22.91	-9.8 Milliseconds Standard Deviation 18.29	13.2 Milliseconds Standard Deviation 20.96
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QT Interval,Week 32,n=6,6,6,0,0,6	5.7 Milliseconds Standard Deviation 20.32	12.9 Milliseconds Standard Deviation 12.12	-14.4 Milliseconds Standard Deviation 17.64	—	—	5.3 Milliseconds Standard Deviation 14.64
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QT Interval,Week 36,n=6,0,0,9,9,0	-6.4 Milliseconds Standard Deviation 41.25	—	—	-3.4 Milliseconds Standard Deviation 29.83	-9.3 Milliseconds Standard Deviation 16.00	—
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QT Interval,Week 40,n=2,0,0,0,0,6	23.5 Milliseconds Standard Deviation 17.68	—	—	—	—	-0.9 Milliseconds Standard Deviation 24.13
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QTcF Interval,2 hours Day1,n=12,6,5,9,8,6	-0.6 Milliseconds Standard Deviation 9.11	4.1 Milliseconds Standard Deviation 8.67	-5.5 Milliseconds Standard Deviation 8.11	-3.4 Milliseconds Standard Deviation 6.40	-2.3 Milliseconds Standard Deviation 5.38	6.4 Milliseconds Standard Deviation 5.17
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QTcF Interval,8 hours Day1,n=12,6,6,9,9,6	-6.8 Milliseconds Standard Deviation 12.97	4.3 Milliseconds Standard Deviation 7.93	-3.6 Milliseconds Standard Deviation 12.32	-1.4 Milliseconds Standard Deviation 9.87	-0.4 Milliseconds Standard Deviation 8.32	2.1 Milliseconds Standard Deviation 13.97
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QTcF Interval,Day 2,n=12,6,6,9,9,6	-4.0 Milliseconds Standard Deviation 11.78	2.6 Milliseconds Standard Deviation 8.43	-12.8 Milliseconds Standard Deviation 10.87	-6.9 Milliseconds Standard Deviation 9.34	-5.9 Milliseconds Standard Deviation 5.70	-0.2 Milliseconds Standard Deviation 10.66
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QTcF Interval, Day 3,n=12,6,6,9,9,6	-6.8 Milliseconds Standard Deviation 14.99	0.4 Milliseconds Standard Deviation 5.82	-6.5 Milliseconds Standard Deviation 9.14	-5.3 Milliseconds Standard Deviation 9.95	-6.3 Milliseconds Standard Deviation 10.71	1.9 Milliseconds Standard Deviation 14.28
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QTcF Interval,Day 4,n=12,6,6,9,9,6	-4.9 Milliseconds Standard Deviation 14.08	0.7 Milliseconds Standard Deviation 7.62	-6.1 Milliseconds Standard Deviation 7.10	-7.7 Milliseconds Standard Deviation 12.56	-4.8 Milliseconds Standard Deviation 10.75	3.5 Milliseconds Standard Deviation 17.05
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QTcF Interval,Day 5,n=12,6,6,9,9,6	-1.7 Milliseconds Standard Deviation 11.97	1.5 Milliseconds Standard Deviation 14.24	-13.6 Milliseconds Standard Deviation 11.17	-4.7 Milliseconds Standard Deviation 9.86	-4.4 Milliseconds Standard Deviation 14.31	3.9 Milliseconds Standard Deviation 16.06
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QTcF Interval,Week 4,n=12,6,6,8,9,6	-0.6 Milliseconds Standard Deviation 11.22	7.3 Milliseconds Standard Deviation 7.10	-6.6 Milliseconds Standard Deviation 20.63	0.5 Milliseconds Standard Deviation 10.86	-0.7 Milliseconds Standard Deviation 10.97	11.4 Milliseconds Standard Deviation 6.33
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QTcF Interval,Week 8,n=12,6,6,9,9,6	-2.8 Milliseconds Standard Deviation 13.76	5.2 Milliseconds Standard Deviation 9.28	-4.8 Milliseconds Standard Deviation 14.70	-1.7 Milliseconds Standard Deviation 11.96	-2.9 Milliseconds Standard Deviation 14.10	8.1 Milliseconds Standard Deviation 20.96
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QTcF Interval,Week 12,n=12,6,6,9,9,6	-6.4 Milliseconds Standard Deviation 14.39	5.9 Milliseconds Standard Deviation 13.50	-5.3 Milliseconds Standard Deviation 10.66	-5.9 Milliseconds Standard Deviation 10.93	-1.1 Milliseconds Standard Deviation 11.91	4.7 Milliseconds Standard Deviation 10.23
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QTcF Interval,Week 24,n=12,6,6,9,9,6	1.4 Milliseconds Standard Deviation 15.42	3.0 Milliseconds Standard Deviation 10.83	-7.2 Milliseconds Standard Deviation 12.14	0.4 Milliseconds Standard Deviation 7.96	-3.9 Milliseconds Standard Deviation 12.69	10.1 Milliseconds Standard Deviation 15.15
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QTcF Interval,Week 32,n=6,6,6,0,0,6	0.4 Milliseconds Standard Deviation 10.98	1.3 Milliseconds Standard Deviation 7.93	-13.8 Milliseconds Standard Deviation 8.76	—	—	11.7 Milliseconds Standard Deviation 13.74
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QTcF Interval,Week 36,n=6,0,0,9,9,0	-3.7 Milliseconds Standard Deviation 24.89	—	—	-4.3 Milliseconds Standard Deviation 13.45	-5.5 Milliseconds Standard Deviation 14.23	—
Change From Baseline in PR Interval, QRS Interval, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) Interval QTcF Interval,Week 40,n=2,0,0,0,0,6	12.0 Milliseconds Standard Deviation 17.44	—	—	—	—	7.5 Milliseconds Standard Deviation 14.62

PRIMARY outcome

Timeframe: Baseline and at Days 2, 3, 4 and 5, Weeks 1, 2, 4, 8, 12, 18, 24, 26, 32, 36 and 40

Population: Safety Population. Only those participants with planned assessments at that particular time point has been presented (represented by n= X in the category titles).

Blood samples were collected at indicated time-points for analysis of clinical parameters like ALP, AST and ALT. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Placebo n=12 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) AST, Day 2,n=12,6,5,9,9,6	-3.5 International units per Liter Standard Deviation 3.55	-1.2 International units per Liter Standard Deviation 2.48	-0.8 International units per Liter Standard Deviation 7.19	-2.6 International units per Liter Standard Deviation 4.28	-3.9 International units per Liter Standard Deviation 5.42	-3.7 International units per Liter Standard Deviation 3.88
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) AST, Day 3,n=12,6,6,9,9,6	-3.8 International units per Liter Standard Deviation 4.86	-0.8 International units per Liter Standard Deviation 4.62	-1.2 International units per Liter Standard Deviation 7.22	-1.8 International units per Liter Standard Deviation 3.80	-5.6 International units per Liter Standard Deviation 6.58	-3.2 International units per Liter Standard Deviation 4.79
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) ALT, Day 3,n=12,6,6,9,9,6	0.3 International units per Liter Standard Deviation 5.96	2.5 International units per Liter Standard Deviation 8.17	5.3 International units per Liter Standard Deviation 17.94	-0.6 International units per Liter Standard Deviation 2.51	-1.0 International units per Liter Standard Deviation 3.20	1.2 International units per Liter Standard Deviation 4.96
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) AST, Week 24,n=12,6,6,9,9,6	1.2 International units per Liter Standard Deviation 18.52	1.3 International units per Liter Standard Deviation 2.73	0.8 International units per Liter Standard Deviation 5.42	-1.1 International units per Liter Standard Deviation 5.64	-2.8 International units per Liter Standard Deviation 8.76	-1.8 International units per Liter Standard Deviation 3.06
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) AST, Week 26,n=12,6,6,9,9,6	-2.7 International units per Liter Standard Deviation 4.08	1.8 International units per Liter Standard Deviation 1.60	0.2 International units per Liter Standard Deviation 3.37	0.0 International units per Liter Standard Deviation 7.00	0.1 International units per Liter Standard Deviation 9.21	0.2 International units per Liter Standard Deviation 3.97
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) ALP, Week 18,n=12,6,6,9,9,6	3.1 International units per Liter Standard Deviation 6.82	-2.0 International units per Liter Standard Deviation 6.48	-1.7 International units per Liter Standard Deviation 4.84	1.9 International units per Liter Standard Deviation 6.79	3.8 International units per Liter Standard Deviation 8.27	-3.5 International units per Liter Standard Deviation 6.80
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) ALP, Week 24,n=12,6,6,9,9,6	3.8 International units per Liter Standard Deviation 12.21	-1.2 International units per Liter Standard Deviation 7.94	-1.0 International units per Liter Standard Deviation 4.73	1.2 International units per Liter Standard Deviation 10.51	5.8 International units per Liter Standard Deviation 8.39	-0.7 International units per Liter Standard Deviation 6.74
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) ALP, Week 26,n=12,6,6,9,9,6	3.2 International units per Liter Standard Deviation 8.64	-6.2 International units per Liter Standard Deviation 8.30	-2.2 International units per Liter Standard Deviation 4.02	0.4 International units per Liter Standard Deviation 10.75	4.8 International units per Liter Standard Deviation 8.24	-1.7 International units per Liter Standard Deviation 6.02
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) ALT, Day 2,n=12,6,5,9,9,6	-0.3 International units per Liter Standard Deviation 5.12	0.3 International units per Liter Standard Deviation 3.56	4.0 International units per Liter Standard Deviation 14.20	-1.6 International units per Liter Standard Deviation 2.07	-0.1 International units per Liter Standard Deviation 3.26	-0.7 International units per Liter Standard Deviation 2.73
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) ALT, Day 4,n=12,6,6,9,9,6	1.0 International units per Liter Standard Deviation 5.85	3.3 International units per Liter Standard Deviation 11.08	4.2 International units per Liter Standard Deviation 13.83	-1.2 International units per Liter Standard Deviation 1.86	-0.1 International units per Liter Standard Deviation 2.71	1.2 International units per Liter Standard Deviation 3.43
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) ALT, Day 5,n=12,6,6,9,9,6	1.7 International units per Liter Standard Deviation 7.96	2.0 International units per Liter Standard Deviation 9.74	2.3 International units per Liter Standard Deviation 8.91	-0.6 International units per Liter Standard Deviation 3.64	0.2 International units per Liter Standard Deviation 3.42	4.5 International units per Liter Standard Deviation 5.32
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) ALT, Week 1,n=12,6,6,9,9,5	1.2 International units per Liter Standard Deviation 7.76	1.3 International units per Liter Standard Deviation 5.92	2.8 International units per Liter Standard Deviation 7.36	0.7 International units per Liter Standard Deviation 3.61	0.6 International units per Liter Standard Deviation 4.98	1.2 International units per Liter Standard Deviation 5.54
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) ALT, Week 2,n=12,6,6,9,9,6	-0.2 International units per Liter Standard Deviation 5.57	-5.3 International units per Liter Standard Deviation 7.97	-1.3 International units per Liter Standard Deviation 4.32	0.3 International units per Liter Standard Deviation 4.85	-2.3 International units per Liter Standard Deviation 4.97	3.0 International units per Liter Standard Deviation 2.53
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) ALT, Week 4,n=12,6,6,9,9,6	-0.3 International units per Liter Standard Deviation 6.43	-4.3 International units per Liter Standard Deviation 7.63	0.7 International units per Liter Standard Deviation 4.23	1.4 International units per Liter Standard Deviation 9.41	-2.6 International units per Liter Standard Deviation 2.55	-2.8 International units per Liter Standard Deviation 4.36
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) ALT, Week 8,n=12,6,6,9,9,6	0.3 International units per Liter Standard Deviation 7.25	-3.3 International units per Liter Standard Deviation 10.39	2.5 International units per Liter Standard Deviation 6.53	-1.6 International units per Liter Standard Deviation 3.40	1.8 International units per Liter Standard Deviation 9.56	-3.0 International units per Liter Standard Deviation 4.77
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) ALT, Week 12,n=12,6,6,9,9,6	-0.9 International units per Liter Standard Deviation 6.07	-1.7 International units per Liter Standard Deviation 4.18	0.5 International units per Liter Standard Deviation 3.94	-0.4 International units per Liter Standard Deviation 1.94	3.0 International units per Liter Standard Deviation 5.12	-0.7 International units per Liter Standard Deviation 2.66
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) ALT, Week 18,n=12,6,6,9,9,6	-0.1 International units per Liter Standard Deviation 6.13	-3.5 International units per Liter Standard Deviation 7.56	1.0 International units per Liter Standard Deviation 10.30	1.9 International units per Liter Standard Deviation 8.81	4.4 International units per Liter Standard Deviation 6.93	-0.7 International units per Liter Standard Deviation 5.20
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) ALT, Week 24,n=12,6,6,9,9,6	0.3 International units per Liter Standard Deviation 12.11	-3.5 International units per Liter Standard Deviation 7.64	5.2 International units per Liter Standard Deviation 14.18	2.2 International units per Liter Standard Deviation 10.76	7.3 International units per Liter Standard Deviation 12.97	0.8 International units per Liter Standard Deviation 5.34
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) ALT, Week 26,n=12,6,6,9,9,6	-2.1 International units per Liter Standard Deviation 6.13	-0.8 International units per Liter Standard Deviation 6.79	-0.5 International units per Liter Standard Deviation 6.47	5.1 International units per Liter Standard Deviation 19.63	6.2 International units per Liter Standard Deviation 13.08	2.5 International units per Liter Standard Deviation 7.87
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) ALT, Week 32,n=6,6,6,0,0,6	1.5 International units per Liter Standard Deviation 8.04	-1.7 International units per Liter Standard Deviation 9.89	-1.0 International units per Liter Standard Deviation 3.29	—	—	-3.0 International units per Liter Standard Deviation 4.60
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) ALT, Week 36,n=6,0,0,9,9,0	0.3 International units per Liter Standard Deviation 8.29	—	—	1.3 International units per Liter Standard Deviation 6.86	5.0 International units per Liter Standard Deviation 7.84	—
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) ALT, Week 40,n=2,0,0,0,0,6	-3.5 International units per Liter Standard Deviation 7.78	—	—	—	—	1.2 International units per Liter Standard Deviation 8.08
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) AST, Day 4,n=12,6,6,9,9,6	-4.3 International units per Liter Standard Deviation 4.27	-0.8 International units per Liter Standard Deviation 5.08	-2.0 International units per Liter Standard Deviation 4.34	-2.9 International units per Liter Standard Deviation 2.93	-4.9 International units per Liter Standard Deviation 6.33	-3.3 International units per Liter Standard Deviation 4.93
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) AST, Day 5,n=12,6,6,9,9,6	-2.6 International units per Liter Standard Deviation 4.10	-0.5 International units per Liter Standard Deviation 5.28	-1.7 International units per Liter Standard Deviation 3.67	-3.2 International units per Liter Standard Deviation 3.31	-3.7 International units per Liter Standard Deviation 7.57	-2.0 International units per Liter Standard Deviation 5.83
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) AST, Week 1,n=12,6,6,9,9,5	-2.8 International units per Liter Standard Deviation 4.12	0.0 International units per Liter Standard Deviation 3.74	-0.2 International units per Liter Standard Deviation 2.32	-1.9 International units per Liter Standard Deviation 2.85	-3.3 International units per Liter Standard Deviation 4.53	-4.6 International units per Liter Standard Deviation 4.39
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) AST, Week 2,n=12,6,6,9,9,6	-1.5 International units per Liter Standard Deviation 4.66	-0.3 International units per Liter Standard Deviation 4.55	-2.5 International units per Liter Standard Deviation 2.88	1.0 International units per Liter Standard Deviation 9.19	-3.8 International units per Liter Standard Deviation 6.44	-0.7 International units per Liter Standard Deviation 4.80
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) AST, Week 4,n=12,6,6,9,9,6	-1.5 International units per Liter Standard Deviation 3.97	-2.3 International units per Liter Standard Deviation 3.83	0.0 International units per Liter Standard Deviation 6.03	0.0 International units per Liter Standard Deviation 4.90	-4.3 International units per Liter Standard Deviation 6.87	-4.2 International units per Liter Standard Deviation 5.91
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) AST, Week 8,n=12,6,6,9,9,6	-0.9 International units per Liter Standard Deviation 7.45	-1.8 International units per Liter Standard Deviation 3.66	0.5 International units per Liter Standard Deviation 3.02	-0.2 International units per Liter Standard Deviation 3.77	-1.0 International units per Liter Standard Deviation 10.58	-4.7 International units per Liter Standard Deviation 4.50
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) AST, Week 12,n=12,6,6,9,9,6	-2.8 International units per Liter Standard Deviation 2.79	-1.2 International units per Liter Standard Deviation 1.94	1.2 International units per Liter Standard Deviation 3.71	-1.2 International units per Liter Standard Deviation 2.17	-1.4 International units per Liter Standard Deviation 6.98	-2.0 International units per Liter Standard Deviation 5.83
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) AST, Week 18,n=12,6,6,9,9,6	-1.8 International units per Liter Standard Deviation 4.14	-1.2 International units per Liter Standard Deviation 2.86	1.3 International units per Liter Standard Deviation 10.09	-0.7 International units per Liter Standard Deviation 3.64	-1.8 International units per Liter Standard Deviation 5.56	-3.3 International units per Liter Standard Deviation 5.61
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) AST, Week 32,n=6,6,6,0,0,6	-2.7 International units per Liter Standard Deviation 3.39	0.5 International units per Liter Standard Deviation 3.33	-2.5 International units per Liter Standard Deviation 1.52	—	—	-3.5 International units per Liter Standard Deviation 5.47
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) AST, Week 36,n=6,0,0,9,9,0	-1.0 International units per Liter Standard Deviation 4.69	—	—	-2.0 International units per Liter Standard Deviation 4.36	-3.2 International units per Liter Standard Deviation 6.70	—
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) AST, Week 40,n=2,0,0,0,0,6	-7.5 International units per Liter Standard Deviation 6.36	—	—	—	—	3.0 International units per Liter Standard Deviation 13.24
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) ALP, Day 2,n=12,6,5,9,9,6	-1.8 International units per Liter Standard Deviation 4.84	-3.3 International units per Liter Standard Deviation 1.37	1.0 International units per Liter Standard Deviation 4.18	-4.9 International units per Liter Standard Deviation 2.80	1.3 International units per Liter Standard Deviation 7.28	-1.5 International units per Liter Standard Deviation 7.77
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) ALP, Day 3,n=12,6,6,9,9,6	-1.8 International units per Liter Standard Deviation 5.66	-2.7 International units per Liter Standard Deviation 2.94	0.3 International units per Liter Standard Deviation 8.52	-1.8 International units per Liter Standard Deviation 3.99	-0.6 International units per Liter Standard Deviation 5.32	0.2 International units per Liter Standard Deviation 5.88
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) ALP, Day 4,n=12,6,6,9,9,6	-1.7 International units per Liter Standard Deviation 5.30	-1.3 International units per Liter Standard Deviation 3.20	0.0 International units per Liter Standard Deviation 9.17	-1.9 International units per Liter Standard Deviation 3.62	-0.2 International units per Liter Standard Deviation 6.34	-1.3 International units per Liter Standard Deviation 6.09
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) ALP, Day 5,n=12,6,6,9,9,6	0.1 International units per Liter Standard Deviation 5.74	-2.0 International units per Liter Standard Deviation 3.52	0.3 International units per Liter Standard Deviation 4.76	-1.4 International units per Liter Standard Deviation 5.25	1.9 International units per Liter Standard Deviation 9.44	-1.2 International units per Liter Standard Deviation 5.12
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) ALP, Week 1,n=12,6,6,9,9,5	0.2 International units per Liter Standard Deviation 5.86	-2.2 International units per Liter Standard Deviation 5.56	-2.5 International units per Liter Standard Deviation 6.06	-0.7 International units per Liter Standard Deviation 6.18	-1.1 International units per Liter Standard Deviation 4.62	-1.2 International units per Liter Standard Deviation 7.53
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) ALP, Week 2,n=12,6,6,9,9,6	1.0 International units per Liter Standard Deviation 3.44	-8.2 International units per Liter Standard Deviation 6.52	-4.2 International units per Liter Standard Deviation 3.54	-0.6 International units per Liter Standard Deviation 3.91	3.1 International units per Liter Standard Deviation 5.25	-1.0 International units per Liter Standard Deviation 8.32
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) ALP, Week 4,n=12,6,6,9,9,6	1.4 International units per Liter Standard Deviation 4.81	-8.2 International units per Liter Standard Deviation 8.30	-1.2 International units per Liter Standard Deviation 3.97	-3.2 International units per Liter Standard Deviation 4.32	2.6 International units per Liter Standard Deviation 5.50	-2.2 International units per Liter Standard Deviation 7.81
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) ALP, Week 8,n=12,6,6,9,9,6	1.9 International units per Liter Standard Deviation 6.88	-2.0 International units per Liter Standard Deviation 4.82	1.0 International units per Liter Standard Deviation 10.06	-4.4 International units per Liter Standard Deviation 4.03	3.7 International units per Liter Standard Deviation 3.61	-0.8 International units per Liter Standard Deviation 8.30
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) ALP, Week 12,n=12,6,6,9,9,6	-0.6 International units per Liter Standard Deviation 6.43	-4.3 International units per Liter Standard Deviation 7.09	7.2 International units per Liter Standard Deviation 10.46	-2.8 International units per Liter Standard Deviation 2.82	3.1 International units per Liter Standard Deviation 11.58	-0.3 International units per Liter Standard Deviation 5.09
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) ALP, Week 32,n=6,6,6,0,0,6	-2.0 International units per Liter Standard Deviation 8.51	-3.3 International units per Liter Standard Deviation 8.50	0.2 International units per Liter Standard Deviation 5.31	—	—	-1.0 International units per Liter Standard Deviation 7.72
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) ALP, Week 36,n=6,0,0,9,9,0	9.0 International units per Liter Standard Deviation 15.57	—	—	-0.6 International units per Liter Standard Deviation 11.19	7.2 International units per Liter Standard Deviation 8.39	—
Change From Baseline in Clinical Chemistry Parameters Like Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) ALP, Week 40,n=2,0,0,0,0,6	-5.5 International units per Liter Standard Deviation 0.71	—	—	—	—	-3.7 International units per Liter Standard Deviation 9.48

PRIMARY outcome

Timeframe: Baseline and at Days 2, 3, 4 and 5, Weeks 1, 2, 4, 8, 12, 18, 24, 26, 32, 36 and 40

Population: Safety Population. Only those participants with planned assessments at that particular time point has been presented (represented by n= X in the category titles).

Blood samples were collected at indicated time-points for analysis of clinical parameters like glucose, calcium, potassium, sodium, BUN, and magnesium. Baseline was defined as latest pre-dose assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Outcome measures

Outcome measures
Measure	Placebo n=12 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Glucose, Week 12,n=12,6,6,9,9,6	0.32 Millimoles per liter Standard Deviation 0.606	-0.15 Millimoles per liter Standard Deviation 0.428	0.13 Millimoles per liter Standard Deviation 1.093	0.08 Millimoles per liter Standard Deviation 0.905	-0.66 Millimoles per liter Standard Deviation 0.760	0.23 Millimoles per liter Standard Deviation 0.432
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Glucose, Week 1,n=11,6,6,9,9,5	0.00 Millimoles per liter Standard Deviation 0.656	-0.35 Millimoles per liter Standard Deviation 0.394	-0.18 Millimoles per liter Standard Deviation 1.280	-0.20 Millimoles per liter Standard Deviation 0.624	-0.23 Millimoles per liter Standard Deviation 1.015	0.50 Millimoles per liter Standard Deviation 1.345
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Glucose, Week 4,n=12,6,6,9,9,6	0.19 Millimoles per liter Standard Deviation 0.783	-0.33 Millimoles per liter Standard Deviation 0.543	0.03 Millimoles per liter Standard Deviation 0.582	-0.28 Millimoles per liter Standard Deviation 0.678	-0.08 Millimoles per liter Standard Deviation 0.919	0.33 Millimoles per liter Standard Deviation 0.476
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Glucose, Week 18,n=12,6,6,9,9,6	0.03 Millimoles per liter Standard Deviation 0.548	-0.02 Millimoles per liter Standard Deviation 0.331	0.42 Millimoles per liter Standard Deviation 1.017	-0.17 Millimoles per liter Standard Deviation 0.541	-0.23 Millimoles per liter Standard Deviation 0.825	0.15 Millimoles per liter Standard Deviation 0.288
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Glucose, Week 24,n=12,6,6,9,9,6	0.38 Millimoles per liter Standard Deviation 1.131	-0.13 Millimoles per liter Standard Deviation 0.333	0.02 Millimoles per liter Standard Deviation 0.773	-0.27 Millimoles per liter Standard Deviation 0.654	-0.26 Millimoles per liter Standard Deviation 0.928	0.50 Millimoles per liter Standard Deviation 0.590
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Glucose, Week 26,n=12,6,6,9,9,6	0.18 Millimoles per liter Standard Deviation 0.506	-0.10 Millimoles per liter Standard Deviation 0.346	0.62 Millimoles per liter Standard Deviation 1.144	-0.09 Millimoles per liter Standard Deviation 0.362	-0.22 Millimoles per liter Standard Deviation 0.758	0.38 Millimoles per liter Standard Deviation 0.445
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Glucose, Week 36,n=6,0,0,9,9,0	0.17 Millimoles per liter Standard Deviation 0.493	—	—	-0.26 Millimoles per liter Standard Deviation 0.436	-0.07 Millimoles per liter Standard Deviation 0.996	—
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Calcium, Week 4,n=12,6,6,9,9,6	-0.040 Millimoles per liter Standard Deviation 0.0615	-0.027 Millimoles per liter Standard Deviation 0.0766	-0.013 Millimoles per liter Standard Deviation 0.1198	-0.031 Millimoles per liter Standard Deviation 0.0729	0.022 Millimoles per liter Standard Deviation 0.0977	0.033 Millimoles per liter Standard Deviation 0.0301
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Calcium, Week 8,n=12,6,6,9,9,6	0.000 Millimoles per liter Standard Deviation 0.0621	-0.007 Millimoles per liter Standard Deviation 0.1171	-0.003 Millimoles per liter Standard Deviation 0.0898	-0.024 Millimoles per liter Standard Deviation 0.0767	0.031 Millimoles per liter Standard Deviation 0.0906	-0.003 Millimoles per liter Standard Deviation 0.0612
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Calcium, Week 18,n=12,6,6,9,9,6	0.003 Millimoles per liter Standard Deviation 0.0918	-0.013 Millimoles per liter Standard Deviation 0.0826	-0.033 Millimoles per liter Standard Deviation 0.0845	0.007 Millimoles per liter Standard Deviation 0.0860	0.031 Millimoles per liter Standard Deviation 0.0801	0.010 Millimoles per liter Standard Deviation 0.0690
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Potassium, Week 2,n=12,6,6,9,9,6	0.00 Millimoles per liter Standard Deviation 0.316	0.05 Millimoles per liter Standard Deviation 0.315	0.20 Millimoles per liter Standard Deviation 0.341	-0.04 Millimoles per liter Standard Deviation 0.201	0.09 Millimoles per liter Standard Deviation 0.352	0.02 Millimoles per liter Standard Deviation 0.299
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Potassium, Week 26,n=12,6,6,9,9,6	-0.13 Millimoles per liter Standard Deviation 0.360	-0.03 Millimoles per liter Standard Deviation 0.480	0.00 Millimoles per liter Standard Deviation 0.179	-0.01 Millimoles per liter Standard Deviation 0.280	0.07 Millimoles per liter Standard Deviation 0.235	0.07 Millimoles per liter Standard Deviation 0.327
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Potassium, Week 32,n=6,6,6,0,0,6	-0.15 Millimoles per liter Standard Deviation 0.476	0.03 Millimoles per liter Standard Deviation 0.242	0.12 Millimoles per liter Standard Deviation 0.223	—	—	0.12 Millimoles per liter Standard Deviation 0.147
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Potassium, Week 36,n=6,0,0,9,9,0	0.07 Millimoles per liter Standard Deviation 0.121	—	—	0.08 Millimoles per liter Standard Deviation 0.311	0.09 Millimoles per liter Standard Deviation 0.215	—
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Sodium, Day 3,n=12,6,6,9,9,6	1.2 Millimoles per liter Standard Deviation 1.75	0.0 Millimoles per liter Standard Deviation 0.89	0.3 Millimoles per liter Standard Deviation 1.21	0.4 Millimoles per liter Standard Deviation 1.33	0.9 Millimoles per liter Standard Deviation 1.96	2.0 Millimoles per liter Standard Deviation 1.55
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Sodium, Day 4,n=12,6,6,9,9,6	1.1 Millimoles per liter Standard Deviation 1.93	0.2 Millimoles per liter Standard Deviation 1.60	0.0 Millimoles per liter Standard Deviation 2.19	-0.8 Millimoles per liter Standard Deviation 2.11	0.3 Millimoles per liter Standard Deviation 1.32	1.3 Millimoles per liter Standard Deviation 1.86
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Sodium, Day 5,n=12,6,6,9,9,6	1.3 Millimoles per liter Standard Deviation 1.66	1.7 Millimoles per liter Standard Deviation 1.51	-1.3 Millimoles per liter Standard Deviation 1.86	-0.2 Millimoles per liter Standard Deviation 2.22	0.8 Millimoles per liter Standard Deviation 2.05	1.7 Millimoles per liter Standard Deviation 1.75
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Sodium, Week 2,n=12,6,6,9,9,6	0.1 Millimoles per liter Standard Deviation 1.51	1.0 Millimoles per liter Standard Deviation 1.26	-0.7 Millimoles per liter Standard Deviation 1.51	0.0 Millimoles per liter Standard Deviation 1.32	-0.3 Millimoles per liter Standard Deviation 1.66	1.0 Millimoles per liter Standard Deviation 2.28
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Sodium, Week 4,n=12,6,6,9,9,6	0.0 Millimoles per liter Standard Deviation 2.04	1.0 Millimoles per liter Standard Deviation 1.41	-1.2 Millimoles per liter Standard Deviation 0.98	-1.2 Millimoles per liter Standard Deviation 1.30	-0.6 Millimoles per liter Standard Deviation 1.67	1.0 Millimoles per liter Standard Deviation 1.41
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Sodium, Week 8,n=12,6,6,9,9,6	0.1 Millimoles per liter Standard Deviation 1.93	0.0 Millimoles per liter Standard Deviation 2.53	-0.5 Millimoles per liter Standard Deviation 1.52	-0.7 Millimoles per liter Standard Deviation 1.94	-1.1 Millimoles per liter Standard Deviation 1.05	1.5 Millimoles per liter Standard Deviation 3.45
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Sodium, Week 18,n=12,6,6,9,9,6	0.1 Millimoles per liter Standard Deviation 1.51	-0.7 Millimoles per liter Standard Deviation 2.25	-1.0 Millimoles per liter Standard Deviation 1.10	-0.7 Millimoles per liter Standard Deviation 1.22	0.0 Millimoles per liter Standard Deviation 1.66	0.8 Millimoles per liter Standard Deviation 1.60
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Sodium, Week 24,n=12,6,6,9,9,6	0.3 Millimoles per liter Standard Deviation 2.02	-0.2 Millimoles per liter Standard Deviation 1.60	-1.5 Millimoles per liter Standard Deviation 1.22	-0.9 Millimoles per liter Standard Deviation 2.37	0.2 Millimoles per liter Standard Deviation 1.64	1.2 Millimoles per liter Standard Deviation 1.72
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Sodium, Week 26,n=12,6,6,9,9,6	0.2 Millimoles per liter Standard Deviation 1.40	0.0 Millimoles per liter Standard Deviation 1.90	-0.7 Millimoles per liter Standard Deviation 2.88	-1.1 Millimoles per liter Standard Deviation 2.15	-1.1 Millimoles per liter Standard Deviation 1.54	1.7 Millimoles per liter Standard Deviation 1.97
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Sodium, Week 32,n=6,6,6,0,0,6	0.3 Millimoles per liter Standard Deviation 2.25	0.5 Millimoles per liter Standard Deviation 3.56	-1.8 Millimoles per liter Standard Deviation 1.17	—	—	0.7 Millimoles per liter Standard Deviation 2.07
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Sodium, Week 36,n=6,0,0,9,9,0	-0.3 Millimoles per liter Standard Deviation 2.66	—	—	-0.9 Millimoles per liter Standard Deviation 1.90	-1.3 Millimoles per liter Standard Deviation 1.00	—
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Magnesium, Day 2,n=12,6,5,9,9,6	-0.020 Millimoles per liter Standard Deviation 0.0467	-0.037 Millimoles per liter Standard Deviation 0.0585	0.008 Millimoles per liter Standard Deviation 0.0642	0.000 Millimoles per liter Standard Deviation 0.0361	-0.036 Millimoles per liter Standard Deviation 0.0623	-0.020 Millimoles per liter Standard Deviation 0.0310
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Magnesium, Day 3,n=12,6,6,9,9,6	-0.012 Millimoles per liter Standard Deviation 0.0542	-0.043 Millimoles per liter Standard Deviation 0.0388	-0.003 Millimoles per liter Standard Deviation 0.0709	0.007 Millimoles per liter Standard Deviation 0.0283	-0.064 Millimoles per liter Standard Deviation 0.0564	-0.037 Millimoles per liter Standard Deviation 0.0427
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Magnesium, Day 4,n=12,6,6,9,9,6	-0.013 Millimoles per liter Standard Deviation 0.0750	-0.020 Millimoles per liter Standard Deviation 0.0310	-0.007 Millimoles per liter Standard Deviation 0.0575	-0.007 Millimoles per liter Standard Deviation 0.0283	-0.060 Millimoles per liter Standard Deviation 0.0490	-0.047 Millimoles per liter Standard Deviation 0.0628
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium BUN, Week 4,n=12,6,6,9,9,6	-0.25 Millimoles per liter Standard Deviation 1.098	-0.75 Millimoles per liter Standard Deviation 0.524	0.75 Millimoles per liter Standard Deviation 0.822	0.22 Millimoles per liter Standard Deviation 0.972	0.17 Millimoles per liter Standard Deviation 1.225	-0.08 Millimoles per liter Standard Deviation 1.114
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium BUN, Week 8,n=12,6,6,9,9,6	-0.75 Millimoles per liter Standard Deviation 0.989	-0.17 Millimoles per liter Standard Deviation 1.033	1.17 Millimoles per liter Standard Deviation 1.252	0.06 Millimoles per liter Standard Deviation 1.074	0.28 Millimoles per liter Standard Deviation 1.093	-0.58 Millimoles per liter Standard Deviation 1.158
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium BUN, Week 12,n=12,6,6,9,9,6	-0.75 Millimoles per liter Standard Deviation 1.323	0.17 Millimoles per liter Standard Deviation 0.983	0.17 Millimoles per liter Standard Deviation 0.816	-0.06 Millimoles per liter Standard Deviation 0.527	0.06 Millimoles per liter Standard Deviation 0.682	0.25 Millimoles per liter Standard Deviation 1.037
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium BUN, Week 18,n=12,6,6,9,9,6	-1.08 Millimoles per liter Standard Deviation 1.505	0.50 Millimoles per liter Standard Deviation 1.414	0.58 Millimoles per liter Standard Deviation 1.068	0.39 Millimoles per liter Standard Deviation 1.516	0.00 Millimoles per liter Standard Deviation 0.866	-0.33 Millimoles per liter Standard Deviation 0.983
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Glucose, Day 2,n=12,6,5,9,9,6	0.06 Millimoles per liter Standard Deviation 0.912	-0.13 Millimoles per liter Standard Deviation 0.418	0.14 Millimoles per liter Standard Deviation 0.439	-0.11 Millimoles per liter Standard Deviation 0.533	-0.72 Millimoles per liter Standard Deviation 0.948	0.20 Millimoles per liter Standard Deviation 0.352
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Sodium, Week 12,n=12,6,6,9,9,6	0.0 Millimoles per liter Standard Deviation 2.00	1.0 Millimoles per liter Standard Deviation 1.26	-0.8 Millimoles per liter Standard Deviation 1.47	-0.2 Millimoles per liter Standard Deviation 1.56	-0.3 Millimoles per liter Standard Deviation 1.22	1.3 Millimoles per liter Standard Deviation 2.25
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Sodium, Week 40,n=2,0,0,0,0,6	0.5 Millimoles per liter Standard Deviation 2.12	—	—	—	—	0.0 Millimoles per liter Standard Deviation 1.90
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Glucose, Day 4,n=12,6,6,9,9,6	-0.11 Millimoles per liter Standard Deviation 0.712	0.12 Millimoles per liter Standard Deviation 0.987	-0.33 Millimoles per liter Standard Deviation 0.857	0.26 Millimoles per liter Standard Deviation 0.940	-0.34 Millimoles per liter Standard Deviation 1.364	0.50 Millimoles per liter Standard Deviation 1.103
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Glucose, Day 5,n=12,6,6,9,9,6	-0.06 Millimoles per liter Standard Deviation 0.647	-0.07 Millimoles per liter Standard Deviation 0.612	0.28 Millimoles per liter Standard Deviation 0.958	0.01 Millimoles per liter Standard Deviation 0.775	-0.17 Millimoles per liter Standard Deviation 0.728	0.05 Millimoles per liter Standard Deviation 0.539
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Glucose, Week 2,n=12,6,6,9,9,6	0.03 Millimoles per liter Standard Deviation 0.396	-0.05 Millimoles per liter Standard Deviation 0.295	0.00 Millimoles per liter Standard Deviation 0.525	-0.02 Millimoles per liter Standard Deviation 1.027	-0.18 Millimoles per liter Standard Deviation 0.902	-0.10 Millimoles per liter Standard Deviation 0.155
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Glucose, Week 8,n=12,6,6,9,9,6	0.06 Millimoles per liter Standard Deviation 0.444	-0.42 Millimoles per liter Standard Deviation 0.585	0.27 Millimoles per liter Standard Deviation 0.824	0.04 Millimoles per liter Standard Deviation 0.430	-0.36 Millimoles per liter Standard Deviation 1.193	0.42 Millimoles per liter Standard Deviation 0.722
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Calcium, Week 26,n=12,6,6,9,9,6	-0.018 Millimoles per liter Standard Deviation 0.0731	-0.067 Millimoles per liter Standard Deviation 0.0532	-0.017 Millimoles per liter Standard Deviation 0.1255	-0.056 Millimoles per liter Standard Deviation 0.0260	0.013 Millimoles per liter Standard Deviation 0.0529	-0.010 Millimoles per liter Standard Deviation 0.0767
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Glucose, Week 32,n=6,6,6,0,0,6	0.40 Millimoles per liter Standard Deviation 1.233	0.02 Millimoles per liter Standard Deviation 0.194	-0.28 Millimoles per liter Standard Deviation 0.703	—	—	0.32 Millimoles per liter Standard Deviation 0.354
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Glucose, Week 40,n=2,0,0,0,0,6	0.40 Millimoles per liter Standard Deviation 0.566	—	—	—	—	0.23 Millimoles per liter Standard Deviation 0.769
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Calcium, Day 2,n=12,6,5,9,9,6	-0.025 Millimoles per liter Standard Deviation 0.0645	-0.027 Millimoles per liter Standard Deviation 0.0615	-0.004 Millimoles per liter Standard Deviation 0.0865	-0.049 Millimoles per liter Standard Deviation 0.0736	0.016 Millimoles per liter Standard Deviation 0.1207	0.043 Millimoles per liter Standard Deviation 0.0480
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Calcium, Day 3,n=12,6,6,9,9,6	0.008 Millimoles per liter Standard Deviation 0.0833	-0.033 Millimoles per liter Standard Deviation 0.1009	0.027 Millimoles per liter Standard Deviation 0.1041	-0.011 Millimoles per liter Standard Deviation 0.0756	-0.022 Millimoles per liter Standard Deviation 0.1012	0.070 Millimoles per liter Standard Deviation 0.0415
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Calcium, Day 4,n=12,6,6,9,9,6	0.012 Millimoles per liter Standard Deviation 0.0658	-0.017 Millimoles per liter Standard Deviation 0.0612	0.017 Millimoles per liter Standard Deviation 0.0794	-0.033 Millimoles per liter Standard Deviation 0.0762	-0.007 Millimoles per liter Standard Deviation 0.0714	0.073 Millimoles per liter Standard Deviation 0.0301
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Calcium, Day 5,n=12,6,6,9,9,6	-0.023 Millimoles per liter Standard Deviation 0.0738	-0.050 Millimoles per liter Standard Deviation 0.0846	0.003 Millimoles per liter Standard Deviation 0.0942	-0.040 Millimoles per liter Standard Deviation 0.0640	-0.031 Millimoles per liter Standard Deviation 0.0933	0.043 Millimoles per liter Standard Deviation 0.0843
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Calcium, Week 1,n=11,6,6,9,9,5	-0.009 Millimoles per liter Standard Deviation 0.0745	-0.047 Millimoles per liter Standard Deviation 0.0723	0.017 Millimoles per liter Standard Deviation 0.0916	-0.044 Millimoles per liter Standard Deviation 0.0847	-0.029 Millimoles per liter Standard Deviation 0.0657	-0.040 Millimoles per liter Standard Deviation 0.0663
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Calcium, Week 2,n=12,6,6,9,9,6	-0.007 Millimoles per liter Standard Deviation 0.0634	-0.013 Millimoles per liter Standard Deviation 0.0547	-0.033 Millimoles per liter Standard Deviation 0.0855	-0.002 Millimoles per liter Standard Deviation 0.0863	0.062 Millimoles per liter Standard Deviation 0.0771	0.013 Millimoles per liter Standard Deviation 0.0163
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Calcium, Week 12,n=12,6,6,9,9,6	-0.017 Millimoles per liter Standard Deviation 0.0489	-0.060 Millimoles per liter Standard Deviation 0.0657	-0.003 Millimoles per liter Standard Deviation 0.1274	-0.020 Millimoles per liter Standard Deviation 0.0755	0.036 Millimoles per liter Standard Deviation 0.0581	-0.003 Millimoles per liter Standard Deviation 0.0794
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Potassium, Week 1,n=11,6,6,9,9,5	-0.02 Millimoles per liter Standard Deviation 0.340	0.05 Millimoles per liter Standard Deviation 0.451	0.18 Millimoles per liter Standard Deviation 0.194	0.22 Millimoles per liter Standard Deviation 0.342	0.07 Millimoles per liter Standard Deviation 0.300	0.00 Millimoles per liter Standard Deviation 0.200
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Calcium, Week 24,n=12,6,6,9,9,6	-0.035 Millimoles per liter Standard Deviation 0.0452	-0.053 Millimoles per liter Standard Deviation 0.0677	0.007 Millimoles per liter Standard Deviation 0.0864	-0.016 Millimoles per liter Standard Deviation 0.0942	0.022 Millimoles per liter Standard Deviation 0.1218	0.027 Millimoles per liter Standard Deviation 0.0797
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Potassium, Week 4,n=12,6,6,9,9,6	0.00 Millimoles per liter Standard Deviation 0.276	-0.07 Millimoles per liter Standard Deviation 0.372	0.27 Millimoles per liter Standard Deviation 0.344	-0.04 Millimoles per liter Standard Deviation 0.283	0.11 Millimoles per liter Standard Deviation 0.196	0.00 Millimoles per liter Standard Deviation 0.276
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Potassium, Week 8,n=12,6,6,9,9,6	0.18 Millimoles per liter Standard Deviation 0.234	0.00 Millimoles per liter Standard Deviation 0.352	0.12 Millimoles per liter Standard Deviation 0.117	0.00 Millimoles per liter Standard Deviation 0.269	0.14 Millimoles per liter Standard Deviation 0.207	-0.05 Millimoles per liter Standard Deviation 0.207
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Potassium, Week 12,n=12,6,6,9,9,6	-0.02 Millimoles per liter Standard Deviation 0.383	-0.02 Millimoles per liter Standard Deviation 0.387	0.12 Millimoles per liter Standard Deviation 0.331	0.00 Millimoles per liter Standard Deviation 0.278	0.04 Millimoles per liter Standard Deviation 0.213	0.03 Millimoles per liter Standard Deviation 0.273
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Potassium, Week 18,n=12,6,6,9,9,6	-0.02 Millimoles per liter Standard Deviation 0.343	0.00 Millimoles per liter Standard Deviation 0.329	0.07 Millimoles per liter Standard Deviation 0.234	0.03 Millimoles per liter Standard Deviation 0.287	0.13 Millimoles per liter Standard Deviation 0.308	0.02 Millimoles per liter Standard Deviation 0.293
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Potassium, Week 24,n=12,6,6,9,9,6	-0.03 Millimoles per liter Standard Deviation 0.458	-0.02 Millimoles per liter Standard Deviation 0.397	0.03 Millimoles per liter Standard Deviation 0.234	0.12 Millimoles per liter Standard Deviation 0.291	-0.04 Millimoles per liter Standard Deviation 0.260	0.07 Millimoles per liter Standard Deviation 0.288
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Calcium, Week 32,n=6,6,6,0,0,6	-0.020 Millimoles per liter Standard Deviation 0.1020	0.027 Millimoles per liter Standard Deviation 0.0776	0.020 Millimoles per liter Standard Deviation 0.0867	—	—	0.010 Millimoles per liter Standard Deviation 0.0724
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Calcium, Week 36,n=6,0,0,9,9,0	0.000 Millimoles per liter Standard Deviation 0.0607	—	—	-0.013 Millimoles per liter Standard Deviation 0.0624	0.029 Millimoles per liter Standard Deviation 0.0813	—
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Calcium, Week 40,n=2,0,0,0,0,6	0.000 Millimoles per liter Standard Deviation 0.1131	—	—	—	—	0.043 Millimoles per liter Standard Deviation 0.0774
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Potassium, Day 2,n=12,6,5,9,9,6	-0.03 Millimoles per liter Standard Deviation 0.230	0.02 Millimoles per liter Standard Deviation 0.179	0.44 Millimoles per liter Standard Deviation 0.365	0.06 Millimoles per liter Standard Deviation 0.397	0.18 Millimoles per liter Standard Deviation 0.307	0.17 Millimoles per liter Standard Deviation 0.234
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Potassium, Day 3,n=12,6,6,9,9,6	-0.07 Millimoles per liter Standard Deviation 0.290	0.03 Millimoles per liter Standard Deviation 0.258	0.02 Millimoles per liter Standard Deviation 0.204	0.14 Millimoles per liter Standard Deviation 0.332	0.01 Millimoles per liter Standard Deviation 0.136	0.12 Millimoles per liter Standard Deviation 0.194
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Potassium, Day 4,n=12,6,6,9,9,6	0.13 Millimoles per liter Standard Deviation 0.196	0.05 Millimoles per liter Standard Deviation 0.472	0.08 Millimoles per liter Standard Deviation 0.232	0.03 Millimoles per liter Standard Deviation 0.218	0.06 Millimoles per liter Standard Deviation 0.246	0.27 Millimoles per liter Standard Deviation 0.163
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Potassium Week 40,n=2,0,0,0,0,6	-0.35 Millimoles per liter Standard Deviation 0.495	—	—	—	—	0.13 Millimoles per liter Standard Deviation 0.356
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Sodium, Day 2,n=12,6,5,9,9,6	0.8 Millimoles per liter Standard Deviation 2.14	0.0 Millimoles per liter Standard Deviation 1.90	0.0 Millimoles per liter Standard Deviation 1.58	-0.3 Millimoles per liter Standard Deviation 1.94	0.9 Millimoles per liter Standard Deviation 1.76	1.8 Millimoles per liter Standard Deviation 1.72
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Potassium, Day 5,n=12,6,6,9,9,6	0.11 Millimoles per liter Standard Deviation 0.303	0.10 Millimoles per liter Standard Deviation 0.276	0.00 Millimoles per liter Standard Deviation 0.126	0.11 Millimoles per liter Standard Deviation 0.267	0.04 Millimoles per liter Standard Deviation 0.207	0.15 Millimoles per liter Standard Deviation 0.217
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Sodium, Week 1,n=11,6,6,9,9,5	0.8 Millimoles per liter Standard Deviation 2.14	0.8 Millimoles per liter Standard Deviation 2.32	-1.7 Millimoles per liter Standard Deviation 1.03	0.1 Millimoles per liter Standard Deviation 1.45	-0.1 Millimoles per liter Standard Deviation 1.69	0.4 Millimoles per liter Standard Deviation 2.19
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Magnesium, Week 26,n=12,6,6,9,9,6	0.002 Millimoles per liter Standard Deviation 0.0542	-0.057 Millimoles per liter Standard Deviation 0.0320	-0.017 Millimoles per liter Standard Deviation 0.0463	0.000 Millimoles per liter Standard Deviation 0.0469	-0.036 Millimoles per liter Standard Deviation 0.0477	-0.027 Millimoles per liter Standard Deviation 0.0432
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Magnesium, Day 5,n=12,6,6,9,9,6	-0.017 Millimoles per liter Standard Deviation 0.0545	-0.047 Millimoles per liter Standard Deviation 0.0745	-0.033 Millimoles per liter Standard Deviation 0.0413	0.007 Millimoles per liter Standard Deviation 0.0283	-0.036 Millimoles per liter Standard Deviation 0.0536	-0.020 Millimoles per liter Standard Deviation 0.0632
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Magnesium, Week 1,n=11,6,6,9,9,5	-0.004 Millimoles per liter Standard Deviation 0.0427	-0.003 Millimoles per liter Standard Deviation 0.0638	0.017 Millimoles per liter Standard Deviation 0.0480	-0.007 Millimoles per liter Standard Deviation 0.0520	-0.040 Millimoles per liter Standard Deviation 0.0346	-0.032 Millimoles per liter Standard Deviation 0.0460
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium BUN, Week 24,n=12,6,6,9,9,6	-0.79 Millimoles per liter Standard Deviation 1.389	-0.17 Millimoles per liter Standard Deviation 0.876	1.42 Millimoles per liter Standard Deviation 1.594	0.11 Millimoles per liter Standard Deviation 1.453	0.33 Millimoles per liter Standard Deviation 1.146	0.17 Millimoles per liter Standard Deviation 0.683
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Magnesium, Week 32,n=6,6,6,0,0,6	-0.010 Millimoles per liter Standard Deviation 0.0245	-0.023 Millimoles per liter Standard Deviation 0.0497	0.017 Millimoles per liter Standard Deviation 0.0480	—	—	-0.027 Millimoles per liter Standard Deviation 0.0301
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Magnesium, Week 2,n=12,6,6,9,9,6	0.005 Millimoles per liter Standard Deviation 0.0410	-0.003 Millimoles per liter Standard Deviation 0.0513	0.033 Millimoles per liter Standard Deviation 0.0484	0.018 Millimoles per liter Standard Deviation 0.0570	-0.036 Millimoles per liter Standard Deviation 0.0445	-0.027 Millimoles per liter Standard Deviation 0.0501
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Magnesium Week 36,n=6,0,0,9,9,0	-0.013 Millimoles per liter Standard Deviation 0.0532	—	—	0.004 Millimoles per liter Standard Deviation 0.0133	-0.013 Millimoles per liter Standard Deviation 0.0447	—
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Magnesium, Week 40,n=2,0,0,0,0,6	0.030 Millimoles per liter Standard Deviation 0.0424	—	—	—	—	-0.030 Millimoles per liter Standard Deviation 0.0329
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium BUN, Day 2,n=12,6,5,9,9,6	-0.83 Millimoles per liter Standard Deviation 1.135	-0.17 Millimoles per liter Standard Deviation 0.408	0.20 Millimoles per liter Standard Deviation 1.304	-0.67 Millimoles per liter Standard Deviation 0.791	-0.28 Millimoles per liter Standard Deviation 0.833	-1.25 Millimoles per liter Standard Deviation 1.084
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium BUN, Day 3,n=12,6,6,9,9,6	-0.79 Millimoles per liter Standard Deviation 1.373	0.00 Millimoles per liter Standard Deviation 0.316	-0.17 Millimoles per liter Standard Deviation 0.931	-0.72 Millimoles per liter Standard Deviation 0.833	-0.28 Millimoles per liter Standard Deviation 0.755	-1.17 Millimoles per liter Standard Deviation 1.402
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium BUN, Day 4,n=12,6,6,9,9,6	-0.75 Millimoles per liter Standard Deviation 1.357	-0.25 Millimoles per liter Standard Deviation 0.274	-0.33 Millimoles per liter Standard Deviation 1.169	-0.61 Millimoles per liter Standard Deviation 0.928	0.00 Millimoles per liter Standard Deviation 0.707	-0.50 Millimoles per liter Standard Deviation 1.673
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium BUN, Day 5,n=12,6,6,9,9,6	-0.71 Millimoles per liter Standard Deviation 1.339	-0.33 Millimoles per liter Standard Deviation 0.816	0.67 Millimoles per liter Standard Deviation 1.169	-0.61 Millimoles per liter Standard Deviation 0.961	-0.17 Millimoles per liter Standard Deviation 0.968	-0.67 Millimoles per liter Standard Deviation 1.602
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium BUN, Week 1,n=11,6,6,9,9,5	-0.45 Millimoles per liter Standard Deviation 1.150	-0.50 Millimoles per liter Standard Deviation 1.183	0.50 Millimoles per liter Standard Deviation 1.581	-0.44 Millimoles per liter Standard Deviation 1.014	0.11 Millimoles per liter Standard Deviation 0.782	-1.10 Millimoles per liter Standard Deviation 1.084
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium BUN, Week 2,n=12,6,6,9,9,6	-0.33 Millimoles per liter Standard Deviation 1.267	-0.75 Millimoles per liter Standard Deviation 1.037	0.33 Millimoles per liter Standard Deviation 1.780	0.06 Millimoles per liter Standard Deviation 0.726	-0.17 Millimoles per liter Standard Deviation 0.612	-0.33 Millimoles per liter Standard Deviation 1.080
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium BUN, Week 26,n=12,6,6,9,9,6	-0.38 Millimoles per liter Standard Deviation 1.069	-0.33 Millimoles per liter Standard Deviation 0.983	0.83 Millimoles per liter Standard Deviation 1.366	-0.17 Millimoles per liter Standard Deviation 1.000	0.22 Millimoles per liter Standard Deviation 0.755	0.08 Millimoles per liter Standard Deviation 1.068
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium BUN, Week 32,n=6,6,6,0,0,6	-1.00 Millimoles per liter Standard Deviation 0.949	-0.33 Millimoles per liter Standard Deviation 0.683	0.75 Millimoles per liter Standard Deviation 1.405	—	—	-0.08 Millimoles per liter Standard Deviation 0.801
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium BUN, Week 36,n=6,0,0,9,9,0	-0.58 Millimoles per liter Standard Deviation 1.855	—	—	-0.72 Millimoles per liter Standard Deviation 1.034	0.28 Millimoles per liter Standard Deviation 1.228	—
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium BUN, Week 40,n=2,0,0,0,0,6	-1.00 Millimoles per liter Standard Deviation 0.000	—	—	—	—	-0.42 Millimoles per liter Standard Deviation 1.201
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Magnesium, Week 4,n=12,6,6,9,9,6	0.007 Millimoles per liter Standard Deviation 0.0345	-0.033 Millimoles per liter Standard Deviation 0.0589	0.000 Millimoles per liter Standard Deviation 0.0456	0.007 Millimoles per liter Standard Deviation 0.0346	-0.027 Millimoles per liter Standard Deviation 0.0529	-0.017 Millimoles per liter Standard Deviation 0.0408
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Magnesium, Week 8,n=12,6,6,9,9,6	-0.003 Millimoles per liter Standard Deviation 0.0608	-0.027 Millimoles per liter Standard Deviation 0.0501	-0.007 Millimoles per liter Standard Deviation 0.0484	0.016 Millimoles per liter Standard Deviation 0.0240	-0.018 Millimoles per liter Standard Deviation 0.0338	-0.003 Millimoles per liter Standard Deviation 0.0585
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Magnesium, Week 12,n=12,6,6,9,9,6	-0.013 Millimoles per liter Standard Deviation 0.0492	-0.043 Millimoles per liter Standard Deviation 0.0686	0.000 Millimoles per liter Standard Deviation 0.0551	0.011 Millimoles per liter Standard Deviation 0.0448	-0.011 Millimoles per liter Standard Deviation 0.0501	0.000 Millimoles per liter Standard Deviation 0.0456
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Magnesium, Week 18,n=12,6,6,9,9,6	0.017 Millimoles per liter Standard Deviation 0.0525	-0.030 Millimoles per liter Standard Deviation 0.0576	0.000 Millimoles per liter Standard Deviation 0.0456	0.000 Millimoles per liter Standard Deviation 0.0566	-0.036 Millimoles per liter Standard Deviation 0.0773	0.000 Millimoles per liter Standard Deviation 0.0551
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Magnesium, Week 24,n=12,6,6,9,9,6	0.008 Millimoles per liter Standard Deviation 0.0422	-0.023 Millimoles per liter Standard Deviation 0.0585	-0.017 Millimoles per liter Standard Deviation 0.0686	0.000 Millimoles per liter Standard Deviation 0.0424	-0.047 Millimoles per liter Standard Deviation 0.0557	-0.003 Millimoles per liter Standard Deviation 0.0320
Change From Baseline in Clinical Chemistry Parameter Like Glucose, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), and Magnesium Glucose, Day 3,n=12,6,6,9,9,6	-0.28 Millimoles per liter Standard Deviation 0.673	-0.10 Millimoles per liter Standard Deviation 1.215	-0.93 Millimoles per liter Standard Deviation 1.117	-0.18 Millimoles per liter Standard Deviation 0.455	-0.21 Millimoles per liter Standard Deviation 0.647	0.15 Millimoles per liter Standard Deviation 0.521

PRIMARY outcome

Timeframe: Baseline and at Days 2, 3, 4 and 5, Weeks 1, 2, 4, 8, 12, 18, 24, 26, 32, 36 and 40

Population: Safety Population. Only those participants with planned assessments at that particular time point has been presented (represented by n= X in the category titles).

Urine samples were collected to analyze presence of ketones, occult blood, glucose, and protein in urine. In this dipstick test, the level of occult blood, glucose, ketones and urine protein in urine samples were recorded as negative, trace, 1+ and 2+ indicating proportional concentrations in urine. Only categories with abnormal significant values have been presented.

Outcome measures

Outcome measures
Measure	Placebo n=12 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Number of Participants With Presence of Ketones, Glucose, Occult Blood, and Protein Urine Ketone, Trace, Week 18,n=2,1,0,1,0,0	1 Participants	0 Participants	0 Participants	0 Participants	—	—
Number of Participants With Presence of Ketones, Glucose, Occult Blood, and Protein Urine Ketone, Trace, Week 24,n=1,1,0,4,0,0	1 Participants	0 Participants	0 Participants	0 Participants	—	—
Number of Participants With Presence of Ketones, Glucose, Occult Blood, and Protein Occult blood, Trace,Week 4,n=2,1,1,5,0,1	1 Participants	0 Participants	0 Participants	0 Participants	—	0 Participants
Number of Participants With Presence of Ketones, Glucose, Occult Blood, and Protein Urine Ketone, Trace,Day 2,n=1,2,0,2,0,0	1 Participants	0 Participants	—	0 Participants	—	—
Number of Participants With Presence of Ketones, Glucose, Occult Blood, and Protein Urine Ketone, Trace, Day 4,n=0,0,1,1,0,0	—	—	1 Participants	0 Participants	—	—
Number of Participants With Presence of Ketones, Glucose, Occult Blood, and Protein Urine Ketone, Trace, Day 5,n=2,0,0,2,1,0	1 Participants	—	—	0 Participants	0 Participants	—
Number of Participants With Presence of Ketones, Glucose, Occult Blood, and Protein Urine Ketone, Trace, Week 1,n=2,1,1,3,0,0	1 Participants	0 Participants	1 Participants	0 Participants	—	—
Number of Participants With Presence of Ketones, Glucose, Occult Blood, and Protein Urine Ketone, Trace, Week 2,n=1,0,0,3,1,0	1 Participants	—	—	1 Participants	0 Participants	—
Number of Participants With Presence of Ketones, Glucose, Occult Blood, and Protein Urine Ketone, Trace, Week 4,n=2,1,1,5,0,0	1 Participants	0 Participants	1 Participants	0 Participants	—	—
Number of Participants With Presence of Ketones, Glucose, Occult Blood, and Protein Urine Ketone, Trace, Week 26,n=0,0,0,2,0,0	—	—	—	1 Participants	—	—
Number of Participants With Presence of Ketones, Glucose, Occult Blood, and Protein Urine Ketone, Trace,Week 32,n=1,0,0,0,0,0	1 Participants	—	—	—	—	—
Number of Participants With Presence of Ketones, Glucose, Occult Blood, and Protein Urine Ketone, 1+, Week 40,n=0,0,0,0,0,1	—	—	—	—	—	1 Participants
Number of Participants With Presence of Ketones, Glucose, Occult Blood, and Protein Urine Protein, 2+, Week 4,n=2,1,1,5,0,1	1 Participants	0 Participants	0 Participants	0 Participants	—	0 Participants
Number of Participants With Presence of Ketones, Glucose, Occult Blood, and Protein Urine Protein, Trace, Week 8,n=1,0,0,2,0,0	1 Participants	—	—	0 Participants	—	—
Number of Participants With Presence of Ketones, Glucose, Occult Blood, and Protein Urine Protein, Trace, Week 18,n=2,1,0,1,0,0	1 Participants	0 Participants	—	0 Participants	—	—

PRIMARY outcome

Timeframe: Days 2, 3, 4 and 5, Weeks 1, 2, 4, 8, 12, 18, 24, 26, 32, 36 and 40

Population: Safety Population. Only those participants with planned assessments at that particular time point has been presented (represented by n= X in the category titles).

Urinary pH measurement is a routine part of urinalysis. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0).

Outcome measures

Outcome measures
Measure	Placebo n=3 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=1 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg n=1 Participants Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg n=5 Participants Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg n=1 Participants Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg n=1 Participants Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Urine Potential of Hydrogen (pH) Analysis by Dipstick Method Day 2,n=1,1,0,2,0,0	5.00 pH Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	7.00 pH Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	—	6.50 pH Standard Deviation 1.414	—	—
Urine Potential of Hydrogen (pH) Analysis by Dipstick Method Week 1,n=2,1,1,3,0,0	5.50 pH Standard Deviation 0.000	7.00 pH Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	6.00 pH Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	5.50 pH Standard Deviation 0.500	—	—
Urine Potential of Hydrogen (pH) Analysis by Dipstick Method Week 4,n=3,1,1,5,0,1	6.50 pH Standard Deviation 0.866	8.00 pH Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	5.50 pH Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	6.00 pH Standard Deviation 0.707	—	5.00 pH Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.
Urine Potential of Hydrogen (pH) Analysis by Dipstick Method Day 3,n=3,0,0,1,0,0	6.00 pH Standard Deviation 0.500	—	—	5.00 pH Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	—	—
Urine Potential of Hydrogen (pH) Analysis by Dipstick Method Day 4,n=0,0,1,1,0,0	—	—	6.50 pH Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	5.00 pH Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	—	—
Urine Potential of Hydrogen (pH) Analysis by Dipstick Method Day 5,n=2,0,0,2,1,0	5.50 pH Standard Deviation 0.707	—	—	5.75 pH Standard Deviation 1.061	5.50 pH Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	—
Urine Potential of Hydrogen (pH) Analysis by Dipstick Method Week 2,n=1,0,0,4,1,0	5.50 pH Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	—	—	5.63 pH Standard Deviation 0.479	8.50 pH Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	—
Urine Potential of Hydrogen (pH) Analysis by Dipstick Method Week 8,n=1,0,0,2,0,0	5.50 pH Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	—	—	5.50 pH Standard Deviation 0.000	—	—
Urine Potential of Hydrogen (pH) Analysis by Dipstick Method Week 12,n=0,1,0,1,0,0	—	6.50 pH Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	—	5.00 pH Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	—	—
Urine Potential of Hydrogen (pH) Analysis by Dipstick Method Week 18,n=3,1,0,1,0,0	5.67 pH Standard Deviation 0.577	7.00 pH Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	—	5.00 pH Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	—	—
Urine Potential of Hydrogen (pH) Analysis by Dipstick Method Week 24,n=1,1,0,4,0,0	6.00 pH Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	6.50 pH Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	—	5.38 pH Standard Deviation 0.479	—	—
Urine Potential of Hydrogen (pH) Analysis by Dipstick Method Week 26,n=0,0,0,2,0,0	—	—	—	5.50 pH Standard Deviation 0.000	—	—
Urine Potential of Hydrogen (pH) Analysis by Dipstick Method Week 32,n=1,0,0,0,0,0	7.50 pH Standard Deviation NA NA indicates that standard deviation could not be calculated for a single data point.	—	—	—	—	—

PRIMARY outcome

Timeframe: Baseline and at Days 2, 3, 4 and 5; Weeks 2, 4, 8, 12, 18, 24, 26, 32, 36 and 40

Population: Safety Population. Only those participants with planned assessments at that particular time point has been presented (represented by n= X in the category titles).

Blood samples were collected at indicated timepoints for analysis for complement (C3 and C4). Baseline was defined as latest pre-dose assessment with a non-missing value.

Outcome measures

Outcome measures
Measure	Placebo n=12 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Absolute Values of Complement (C)3 and C4 C3, Day 2,n=12,6,6,9,9,6	1.13 Grams per liter Interval 1.042 to 1.225	1.27 Grams per liter Interval 1.051 to 1.535	1.16 Grams per liter Interval 0.94 to 1.433	1.114 Grams per liter Interval 1.018 to 1.219	1.188 Grams per liter Interval 1.053 to 1.341	1.286 Grams per liter Interval 1.182 to 1.4
Absolute Values of Complement (C)3 and C4 C3, Day 3,n=12,6,6,9,9,6	1.187 Grams per liter Interval 1.063 to 1.325	1.244 Grams per liter Interval 1.029 to 1.503	1.236 Grams per liter Interval 1.011 to 1.511	1.142 Grams per liter Interval 1.037 to 1.258	1.157 Grams per liter Interval 1.038 to 1.29	1.322 Grams per liter Interval 1.197 to 1.46
Absolute Values of Complement (C)3 and C4 C3, Week 2,n=12,6,6,9,9,6	1.136 Grams per liter Interval 1.062 to 1.215	1.147 Grams per liter Interval 0.986 to 1.333	1.02 Grams per liter Interval 0.841 to 1.238	1.139 Grams per liter Interval 1.045 to 1.241	1.174 Grams per liter Interval 1.039 to 1.327	1.28 Grams per liter Interval 1.136 to 1.442
Absolute Values of Complement (C)3 and C4 C3, Week 4,n=12,6,6,9,9,6	1.114 Grams per liter Interval 1.043 to 1.191	1.05 Grams per liter Interval 0.873 to 1.262	1.111 Grams per liter Interval 0.9 to 1.37	1.07 Grams per liter Interval 0.957 to 1.197	1.148 Grams per liter Interval 1.019 to 1.293	1.22 Grams per liter Interval 1.085 to 1.372
Absolute Values of Complement (C)3 and C4 C3, Week 12,n=12,6,6,9,9,6	1.117 Grams per liter Interval 1.011 to 1.234	1.033 Grams per liter Interval 0.935 to 1.141	1.124 Grams per liter Interval 0.947 to 1.334	1.147 Grams per liter Interval 1.05 to 1.254	1.211 Grams per liter Interval 1.065 to 1.377	1.28 Grams per liter Interval 1.117 to 1.465
Absolute Values of Complement (C)3 and C4 C3, Week 26,n=12,6,6,9,9,6	1.204 Grams per liter Interval 1.106 to 1.311	0.927 Grams per liter Interval 0.45 to 1.91	1.142 Grams per liter Interval 0.963 to 1.355	1.156 Grams per liter Interval 1.07 to 1.249	1.222 Grams per liter Interval 1.081 to 1.381	1.298 Grams per liter Interval 1.123 to 1.501
Absolute Values of Complement (C)3 and C4 C3, Week 32,n=6,6,6,0,0,6	1.173 Grams per liter Interval 0.985 to 1.398	1.243 Grams per liter Interval 1.137 to 1.358	1.231 Grams per liter Interval 1.016 to 1.491	—	—	1.204 Grams per liter Interval 1.116 to 1.299
Absolute Values of Complement (C)3 and C4 C3, Week 36,n=6,0,0,9,9,0	1.243 Grams per liter Interval 1.107 to 1.397	—	—	1.188 Grams per liter Interval 1.085 to 1.301	1.236 Grams per liter Interval 1.106 to 1.382	—
Absolute Values of Complement (C)3 and C4 C4, Baseline,n=12,6,6,9,9,6	0.2576 Grams per liter Interval 0.2108 to 0.3147	0.2061 Grams per liter Interval 0.1653 to 0.257	0.1919 Grams per liter Interval 0.1337 to 0.2755	0.2144 Grams per liter Interval 0.1727 to 0.2663	0.1939 Grams per liter Interval 0.1496 to 0.2512	0.215 Grams per liter Interval 0.1859 to 0.2488
Absolute Values of Complement (C)3 and C4 C4, Week 4,n=12,6,6,9,9,6	0.2602 Grams per liter Interval 0.2078 to 0.3258	0.1928 Grams per liter Interval 0.1623 to 0.229	0.189 Grams per liter Interval 0.1292 to 0.2766	0.2063 Grams per liter Interval 0.1636 to 0.2602	0.1872 Grams per liter Interval 0.1419 to 0.2468	0.1929 Grams per liter Interval 0.1733 to 0.2146
Absolute Values of Complement (C)3 and C4 C4, Week 8,n=12,6,6,9,9,6	0.2738 Grams per liter Interval 0.2186 to 0.3431	0.2547 Grams per liter Interval 0.201 to 0.3226	0.2045 Grams per liter Interval 0.1315 to 0.318	0.2009 Grams per liter Interval 0.1654 to 0.2441	0.1901 Grams per liter Interval 0.1542 to 0.2343	0.2231 Grams per liter Interval 0.1778 to 0.28
Absolute Values of Complement (C)3 and C4 C4, Week 18,n=12,6,6,9,9,6	0.261 Grams per liter Interval 0.1992 to 0.342	0.2266 Grams per liter Interval 0.1873 to 0.2742	0.2025 Grams per liter Interval 0.1322 to 0.3102	0.226 Grams per liter Interval 0.192 to 0.266	0.1678 Grams per liter Interval 0.1255 to 0.2245	0.216 Grams per liter Interval 0.174 to 0.2681
Absolute Values of Complement (C)3 and C4 C4, Week 24,n=12,6,6,8,9,6	0.2474 Grams per liter Interval 0.1894 to 0.3232	0.2244 Grams per liter Interval 0.1742 to 0.289	0.197 Grams per liter Interval 0.1324 to 0.2932	0.206 Grams per liter Interval 0.1801 to 0.2357	0.1909 Grams per liter Interval 0.15 to 0.243	0.2114 Grams per liter Interval 0.1682 to 0.2658
Absolute Values of Complement (C)3 and C4 C4, Week 36,n=6,0,0,9,9,0	0.2844 Grams per liter Interval 0.211 to 0.3834	—	—	0.2025 Grams per liter Interval 0.1637 to 0.2504	0.206 Grams per liter Interval 0.1626 to 0.2611	—
Absolute Values of Complement (C)3 and C4 C4, Week 40,n=2,0,0,0,0,6	0.1699 Grams per liter NA indicates not available as 95% Confidence Interval (CI) was only available when at least 3 participants contribute to the statistics	—	—	—	—	0.2134 Grams per liter Interval 0.1766 to 0.258
Absolute Values of Complement (C)3 and C4 C3, Baseline,n=12,6,6,9,9,6	1.149 Grams per liter Interval 1.061 to 1.243	1.182 Grams per liter Interval 0.995 to 1.404	1.086 Grams per liter Interval 0.941 to 1.254	1.074 Grams per liter Interval 0.982 to 1.175	1.137 Grams per liter Interval 1.013 to 1.277	1.254 Grams per liter Interval 1.122 to 1.402
Absolute Values of Complement (C)3 and C4 C3, Day 4,n=12,6,6,9,9,6	1.17 Grams per liter Interval 1.051 to 1.302	1.284 Grams per liter Interval 1.023 to 1.611	1.181 Grams per liter Interval 1.016 to 1.374	1.144 Grams per liter Interval 1.051 to 1.245	1.165 Grams per liter Interval 1.038 to 1.307	1.316 Grams per liter Interval 1.189 to 1.458
Absolute Values of Complement (C)3 and C4 C3, Day 5,n=12,6,6,9,9,6	1.136 Grams per liter Interval 1.011 to 1.277	1.122 Grams per liter Interval 0.993 to 1.268	1.092 Grams per liter Interval 0.909 to 1.311	1.113 Grams per liter Interval 1.011 to 1.226	1.165 Grams per liter Interval 1.026 to 1.323	1.305 Grams per liter Interval 1.159 to 1.469
Absolute Values of Complement (C)3 and C4 C3, Week 8,n=12,6,6,9,9,6	1.224 Grams per liter Interval 1.15 to 1.303	1.226 Grams per liter Interval 1.115 to 1.347	1.097 Grams per liter Interval 0.875 to 1.376	1.117 Grams per liter Interval 0.993 to 1.257	1.167 Grams per liter Interval 1.085 to 1.254	1.34 Grams per liter Interval 1.191 to 1.506
Absolute Values of Complement (C)3 and C4 C3, Week 18,n=12,6,6,9,9,6	1.173 Grams per liter Interval 1.065 to 1.291	1.215 Grams per liter Interval 0.984 to 1.5	1.124 Grams per liter Interval 0.922 to 1.37	1.184 Grams per liter Interval 1.045 to 1.342	1.231 Grams per liter Interval 1.119 to 1.353	1.283 Grams per liter Interval 1.158 to 1.422
Absolute Values of Complement (C)3 and C4 C3, Week 24,n=12,6,6,8,9,6	1.15 Grams per liter Interval 1.067 to 1.238	1.136 Grams per liter Interval 1.031 to 1.252	1.171 Grams per liter Interval 1.029 to 1.332	1.157 Grams per liter Interval 1.019 to 1.312	1.243 Grams per liter Interval 1.107 to 1.395	1.222 Grams per liter Interval 1.1 to 1.356
Absolute Values of Complement (C)3 and C4 C3, Week 40,n=2,0,0,0,0,6	1.181 Grams per liter NA indicates not available as 95% Confidence Interval (CI) was only available when at least 3 participants contribute to the statistics	—	—	—	—	1.231 Grams per liter Interval 1.069 to 1.417
Absolute Values of Complement (C)3 and C4 C4, Day 2,n=12,6,6,9,9,6	0.2525 Grams per liter Interval 0.2037 to 0.313	0.2161 Grams per liter Interval 0.1832 to 0.2549	0.2061 Grams per liter Interval 0.1469 to 0.2891	0.2133 Grams per liter Interval 0.1784 to 0.2549	0.203 Grams per liter Interval 0.1597 to 0.2581	0.22 Grams per liter Interval 0.1832 to 0.2643
Absolute Values of Complement (C)3 and C4 C4, Day 3,n=12,6,6,9,9,6	0.2647 Grams per liter Interval 0.2068 to 0.3389	0.2038 Grams per liter Interval 0.1685 to 0.2464	0.2212 Grams per liter Interval 0.1464 to 0.3342	0.2142 Grams per liter Interval 0.1759 to 0.2609	0.1962 Grams per liter Interval 0.1514 to 0.2544	0.223 Grams per liter Interval 0.1921 to 0.2589
Absolute Values of Complement (C)3 and C4 C4, Day 4,n=12,6,6,9,9,6	0.253 Grams per liter Interval 0.2013 to 0.3179	0.2303 Grams per liter Interval 0.1918 to 0.2767	0.2006 Grams per liter Interval 0.1416 to 0.2842	0.2128 Grams per liter Interval 0.1766 to 0.2564	0.1935 Grams per liter Interval 0.1472 to 0.2543	0.2188 Grams per liter Interval 0.1867 to 0.2564
Absolute Values of Complement (C)3 and C4 C4, Day 5,n=12,6,6,9,9,6	0.2497 Grams per liter Interval 0.1929 to 0.3232	0.1892 Grams per liter Interval 0.1572 to 0.2277	0.1866 Grams per liter Interval 0.1327 to 0.268	0.2073 Grams per liter Interval 0.1685 to 0.2551	0.1943 Grams per liter Interval 0.1492 to 0.2531	0.2163 Grams per liter Interval 0.1869 to 0.2503
Absolute Values of Complement (C)3 and C4 C4, Week 2,n=12,6,6,9,9,6	0.2555 Grams per liter Interval 0.2028 to 0.322	0.2108 Grams per liter Interval 0.1768 to 0.2514	0.1781 Grams per liter Interval 0.1172 to 0.2706	0.221 Grams per liter Interval 0.1813 to 0.2695	0.2018 Grams per liter Interval 0.1497 to 0.272	0.2169 Grams per liter Interval 0.1765 to 0.2664
Absolute Values of Complement (C)3 and C4 C4, Week 12,n=12,6,6,9,9,6	0.2413 Grams per liter Interval 0.1901 to 0.3063	0.1862 Grams per liter Interval 0.1567 to 0.2213	0.2034 Grams per liter Interval 0.1307 to 0.3167	0.2114 Grams per liter Interval 0.1723 to 0.2594	0.196 Grams per liter Interval 0.1494 to 0.2572	0.2074 Grams per liter Interval 0.1792 to 0.24
Absolute Values of Complement (C)3 and C4 C4, Week 26,n=12,6,6,9,9,6	0.2517 Grams per liter Interval 0.1926 to 0.3291	0.202 Grams per liter Interval 0.1319 to 0.3095	0.1939 Grams per liter Interval 0.1291 to 0.2912	0.2115 Grams per liter Interval 0.1704 to 0.2627	0.163 Grams per liter Interval 0.125 to 0.2126	0.226 Grams per liter Interval 0.1887 to 0.2627
Absolute Values of Complement (C)3 and C4 C4, Week 32,n=6,6,6,0,0,6	0.2772 Grams per liter Interval 0.1617 to 0.4754	0.2401 Grams per liter Interval 0.2003 to 0.2877	0.2007 Grams per liter Interval 0.1297 to 0.3105	—	—	0.2051 Grams per liter Interval 0.1808 to 0.2326

SECONDARY outcome

Timeframe: Pre-dose, 2 and 8 hours on Day 1; Days 2,3,5, Weeks 1, 2, 4, 8, 12, 18, 24, and 26 post-dose

Population: Pharmacokinetic Population.

Blood samples were collected from participants at indicated time points and analyzed for AUC (0-inf). Pharmacokinetic parameters were calculated by standard non compartmental analysis. Pharmacokinetic Population included participants in the Safety population for whom a pharmcokinetic sample was obtained and analyzed.

Outcome measures

Outcome measures
Measure	Placebo n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Area Under the Curve From Time Zero to Infinity (AUC[0-inf]) of GSK3511294 2 mg and 10 mg	24.795 Day*microgram per milliliter Geometric Coefficient of Variation 51.6	68.904 Day*microgram per milliliter Geometric Coefficient of Variation 23.6	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 2 and 8 hours on Day 1; Days 2,3,5, Weeks 1, 2, 4, 8, 12, 18, 24, 26 and 36 post-dose

Population: Pharmacokinetic Population.

Blood samples were collected from participants at indicated time points and analyzed for AUC (0-inf). Pharmacokinetic parameters were calculated by standard non compartmental analysis.

Outcome measures

Outcome measures
Measure	Placebo n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
AUC(0-inf) of GSK3511294 30 mg and 100 mg	208.308 Day*microgram per milliliter Geometric Coefficient of Variation 39.6	846.686 Day*microgram per milliliter Geometric Coefficient of Variation 7.3	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 2 and 8 hours on Day 1; Days 2,3,5, Weeks 1, 2, 4, 8, 12, 18, 24, 26, 32 and 40 post-dose

Population: Pharmacokinetic Population.

Blood samples were collected from participants at indicated time points and analyzed for AUC (0-inf). Pharmacokinetic parameters were calculated by standard non compartmental analysis.

Outcome measures

Outcome measures
Measure	Placebo n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
AUC(0-inf) of GSK3511294 300 mg	1873.657 Day*microgram per milliliter Geometric Coefficient of Variation 25.5	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 2 and 8 hours on Day 1; Days 2,3,5, Weeks 1, 2, 4, 8, 12, 18, 24, and 26 post-dose

Population: Pharmacokinetic Population.

Blood samples were collected from participants at indicated time points and analyzed for AUC (0-t). Pharmacokinetic parameters were calculated by standard non compartmental analysis.

Outcome measures

Outcome measures
Measure	Placebo n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Area Under the Curve From Time Zero to the Last Measurable Concentration (AUC[0-t]) of GSK3511294 2 mg and 10 mg	18.369 Day*microgram per milliliter Geometric Coefficient of Variation 59.2	62.101 Day*microgram per milliliter Geometric Coefficient of Variation 28.4	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 2 and 8 hours on Day 1; Days 2,3,5, Weeks 1, 2, 4, 8, 12, 18, 24, 26 and 36 post-dose

Population: Pharmacokinetic Population

Blood samples were collected from participants at indicated time points and analyzed for AUC (0-t). Pharmacokinetic parameters were calculated by standard non compartmental analysis.

Outcome measures

Outcome measures
Measure	Placebo n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
AUC(0-t) of GSK3511294 30 mg and 100 mg	201.434 Day*microgram per milliliter Geometric Coefficient of Variation 41.1	830.245 Day*microgram per milliliter Geometric Coefficient of Variation 7.4	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 2 and 8 hours on Day 1; Days 2,3,5, Weeks 1, 2, 4, 8, 12, 18, 24, 26, 32 and 40 post-dose

Population: Pharmacokinetic Population

Blood samples were collected from participants at indicated time points and analyzed for AUC (0-t). Pharmacokinetic parameters was calculated by standard non compartmental analysis.

Outcome measures

Outcome measures
Measure	Placebo n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
AUC(0-t) of GSK3511294 300 mg	1855.619 Day*microgram per milliliter Geometric Coefficient of Variation 25.8	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 2 and 8 hours on Day 1; Days 2,3,5, Weeks 1, 2, and 4 post-dose

Population: Pharmacokinetic Population

Blood samples were collected from participants at indicated time points and analyzed for AUC (0-Week 4). Pharmacokinetic parameters was calculated by standard non compartmental analysis.

Outcome measures

Outcome measures
Measure	Placebo n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Area Under the Concentration-time Curve From Time Zero to Week 4 (AUC[0-Week 4]) of GSK3511294	6.856 Day*microgram per milliliter Geometric Coefficient of Variation 22.0	19.685 Day*microgram per milliliter Geometric Coefficient of Variation 14.0	62.994 Day*microgram per milliliter Geometric Coefficient of Variation 40.6	292.698 Day*microgram per milliliter Geometric Coefficient of Variation 11.0	676.055 Day*microgram per milliliter Geometric Coefficient of Variation 22.7	—

SECONDARY outcome

Timeframe: Pre-dose, 2 and 8 hours on Day 1; Days 2,3,5, Weeks 1, 2, 4, 8 and 12 post-dose

Population: Pharmacokinetic Population

Blood samples were collected from participants at indicated time points and analyzed for AUC (0-Week 12). Pharmacokinetic parameters were calculated by standard non compartmental analysis.

Outcome measures

Outcome measures
Measure	Placebo n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Area Under the Concentration-time Curve From Time Zero to Week 12 (AUC[0-Week 12]) of GSK3511294	16.102 Day*microgram per milliliter Geometric Coefficient of Variation 37.1	48.389 Day*microgram per milliliter Geometric Coefficient of Variation 22.7	148.798 Day*microgram per milliliter Geometric Coefficient of Variation 37.8	663.984 Day*microgram per milliliter Geometric Coefficient of Variation 8.1	1445.726 Day*microgram per milliliter Geometric Coefficient of Variation 23.8	—

SECONDARY outcome

Timeframe: Pre-dose, 2 and 8 hours on Day 1; Days 2,3,5, Weeks 1, 2, 4, 8, 12, 18, 24 and 26 post-dose

Population: Pharmacokinetic Population

Blood samples were collected from participants at indicated time points and analyzed for AUC (0-Week 26). Pharmacokinetic parameters was calculated by standard non compartmental analysis.

Outcome measures

Outcome measures
Measure	Placebo n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Area Under the Concentration-time Curve From Time Zero to Week 26 (AUC [0-Week 26]) of GSK3511294	21.829 Day*microgram per milliliter Geometric Coefficient of Variation 42.7	64.453 Day*microgram per milliliter Geometric Coefficient of Variation 24.3	199.893 Day*microgram per milliliter Geometric Coefficient of Variation 39.9	805.359 Day*microgram per milliliter Geometric Coefficient of Variation 7.7	1789.451 Day*microgram per milliliter Geometric Coefficient of Variation 26.3	—

SECONDARY outcome

Timeframe: Pre-dose, 2 and 8 hours on Day 1; Days 2,3,5, Weeks 1, 2, 4, 8, 12, 18, 24, and 26 post-dose

Population: Pharmacokinetic Population

Blood samples were collected from participants at indicated time points and analyzed for %AUCex. Pharmacokinetic parameters was calculated by standard non compartmental analysis.

Outcome measures

Outcome measures
Measure	Placebo n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Percentage of AUC (0-inf) Obtained by Extrapolation (%AUCex) of GSK3511294 2 mg and 10 mg	24.3560 Percentage of AUCex Geometric Coefficient of Variation 35.8	7.7705 Percentage of AUCex Geometric Coefficient of Variation 81.6	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 2 and 8 hours on Day 1; Days 2,3,5, Weeks 1, 2, 4, 8, 12, 18, 24, 26 and 36 post-dose

Population: Pharmacokinetic Population

Blood samples were collected from participants at indicated time points and analyzed for %AUCex. Pharmacokinetic parameters was calculated by standard non compartmental analysis.

Outcome measures

Outcome measures
Measure	Placebo n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
%AUCex of GSK3511294 30 mg and 100 mg	2.9636 Percentage of AUCex Geometric Coefficient of Variation 55.6	1.4162 Percentage of AUCex Geometric Coefficient of Variation 88.3	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 2 and 8 hours on Day 1; Days 2,3,5, Weeks 1, 2, 4, 8, 12, 18, 24, 26, 32 and 40 post-dose

Population: Pharmacokinetic Population

Blood samples were collected from participants at indicated time points and analyzed for %AUCex. Pharmacokinetic parameters was calculated by standard non compartmental analysis.

Outcome measures

Outcome measures
Measure	Placebo n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
%AUCex of GSK3511294 300 mg	0.9096 Percentage of AUCex Geometric Coefficient of Variation 35.1	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 2 and 8 hours on Day 1; Days 2,3,5, Weeks 1, 2, 4, 8, 12, 18, 24, and 26 post-dose

Population: Pharmacokinetic Population

Blood samples were collected from participants at indicated time points and analyzed for Cmax. Pharmacokinetic parameters was calculated by standard non compartmental analysis.

Outcome measures

Outcome measures
Measure	Placebo n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Maximum Observed Concentration (Cmax) of GSK3511294 2 mg and 10 mg	0.3400 Microgram per milliliter Geometric Coefficient of Variation 25.3	0.8759 Microgram per milliliter Geometric Coefficient of Variation 18.3	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 2 and 8 hours on Day 1; Days 2,3,5, Weeks 1, 2, 4, 8, 12, 18, 24, 26 and 36 post-dose

Population: Pharmacokinetic Population

Blood samples were collected from participants at indicated time points and analyzed for Cmax. Pharmacokinetic parameters was calculated by standard non compartmental analysis.

Outcome measures

Outcome measures
Measure	Placebo n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Cmax of GSK3511294 30 mg and 100 mg	2.8101 Microgram per milliliter Geometric Coefficient of Variation 41.1	12.2471 Microgram per milliliter Geometric Coefficient of Variation 15.9	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 2 and 8 hours on Day 1; Days 2,3,5, Weeks 1, 2, 4, 8, 12, 18, 24, 26, 32 and 40 post-dose

Population: Pharmacokinetic Population

Blood samples were collected from participants at indicated time points and analyzed for Cmax. Pharmacokinetic parameters was calculated by standard non compartmental analysis.

Outcome measures

Outcome measures
Measure	Placebo n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Cmax of GSK3511294 300 mg	28.5987 Microgram per milliliter Geometric Coefficient of Variation 23.3	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 2 and 8 hours on Day 1; Days 2,3,5, Weeks 1, 2, 4, 8, 12, 18, 24, and 26 post-dose

Population: Pharmacokinetic Population

Blood samples were collected from participants at indicated time points and analyzed for Tmax. Pharmacokinetic parameters was calculated by standard non compartmental analysis.

Outcome measures

Outcome measures
Measure	Placebo n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Time of Occurrence of Cmax (Tmax) of GSK3511294 2 mg and 10 mg	10.966 Days Interval 6.99 to 27.98	7.956 Days Interval 7.0 to 28.91	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 2 and 8 hours on Day 1; Days 2,3,5, Weeks 1, 2, 4, 8, 12, 18, 24, 26 and 36 post-dose

Population: Pharmacokinetic Population

Blood samples were collected from participants at indicated time points and analyzed for Tmax. Pharmacokinetic parameters was calculated by standard non compartmental analysis.

Outcome measures

Outcome measures
Measure	Placebo n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Tmax of GSK3511294 30 mg and 100 mg	13.943 Days Interval 4.0 to 28.02	13.970 Days Interval 3.97 to 16.0	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 2 and 8 hours on Day 1; Days 2,3,5, Weeks 1, 2, 4, 8, 12, 18, 24, 26, 32 and 40 post-dose

Population: Pharmacokinetic Population

Blood samples were collected from participants at indicated time points and analyzed for Tmax. Pharmacokinetic parameters was calculated by standard non compartmental analysis.

Outcome measures

Outcome measures
Measure	Placebo n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Tmax of GSK3511294 300 mg	13.909 Days Interval 2.0 to 15.0	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 2 and 8 hours on Day 1; Days 2,3,5, Weeks 1, 2, 4, 8, 12, 18, 24, and 26 post-dose

Population: Pharmacokinetic Population

Blood samples were collected from participants at indicated time points and analyzed for Tlast. Pharmacokinetic parameters was calculated by standard non compartmental analysis.

Outcome measures

Outcome measures
Measure	Placebo n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Time of Last Quantifiable Concentration (Tlast) of GSK3511294 2 mg and 10 mg	84.47 Days Interval 84.0 to 182.0	176.46 Days Interval 126.0 to 185.0	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 2 and 8 hours on Day 1; Days 2,3,5, Weeks 1, 2, 4, 8, 12, 18, 24, 26 and 36 post-dose

Population: Pharmacokinetic Population.

Blood samples were collected from participants at indicated time points and analyzed for Tlast. Pharmacokinetic parameters was calculated by standard non compartmental analysis.

Outcome measures

Outcome measures
Measure	Placebo n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Tlast of GSK3511294 30 mg and 100 mg	182.01 Days Interval 182.0 to 254.8	252.00 Days Interval 250.0 to 255.0	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 2 and 8 hours on Day 1; Days 2,3,5, Weeks 1, 2, 4, 8, 12, 18, 24, 26, 32 and 40 post-dose

Population: Pharmacokinetic Population

Blood samples were collected from participants at indicated time points and analyzed for Tlast. Pharmacokinetic parameters was calculated by standard non compartmental analysis.

Outcome measures

Outcome measures
Measure	Placebo n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Tlast of GSK3511294 300 mg	279.99 Days Interval 278.0 to 283.0	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 2 and 8 hours on Day 1; Days 2,3,5, Weeks 1, 2, 4, 8, 12, 18, 24, and 26 post-dose

Population: Pharmacokinetic Population

Blood samples were collected from participants at indicated time points and analyzed for CL/F. CL/F was calculated as dose divided by AUC(0-inf). Pharmacokinetic parameters was calculated by standard non compartmental analysis.

Outcome measures

Outcome measures
Measure	Placebo n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Apparent Clearance Following Subcutaneous Dosing (CL/F) of GSK3511294 2 mg and 10 mg	0.08066 Liters per day Geometric Coefficient of Variation 51.6	0.14513 Liters per day Geometric Coefficient of Variation 23.6	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 2 and 8 hours on Day 1; Days 2,3,5, Weeks 1, 2, 4, 8, 12, 18, 24, 26 and 36 post-dose

Population: Pharmacokinetic Population

Outcome measures

Outcome measures
Measure	Placebo n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
CL/F of GSK3511294 30 mg and 100 mg	0.14402 Liters per day Geometric Coefficient of Variation 39.6	0.11811 Liters per day Geometric Coefficient of Variation 7.3	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 2 and 8 hours on Day 1; Days 2,3,5, Weeks 1, 2, 4, 8, 12, 18, 24, 26, 32 and 40 post-dose

Population: Pharmacokinetic Population

Outcome measures

Outcome measures
Measure	Placebo n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
CL/F of GSK3511294 300 mg	0.16011 Liters per day Geometric Coefficient of Variation 25.5	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 2 and 8 hours on Day 1; Days 2,3,5, Weeks 1, 2, 4, 8, 12, 18, 24, and 26 post-dose

Population: Pharmacokinetic Population

Blood samples were collected from participants at indicated time points and analyzed for Vd/F. Vd/F was calculated as dose divided by terminal elimination rate constant (lambda\_z) \*AUC(0-inf). Pharmacokinetic parameters were calculated by standard non compartmental analysis.

Outcome measures

Outcome measures
Measure	Placebo n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Apparent Volume of Distribution After Subcutaneous Administration (Vd/F) of GSK3511294 2 mg and 10 mg	6.113 Liters Geometric Coefficient of Variation 37.6	9.193 Liters Geometric Coefficient of Variation 34.7	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 2 and 8 hours on Day 1; Days 2,3,5, Weeks 1, 2, 4, 8, 12, 18, 24, 26 and 36 post-dose

Population: Pharmacokinetic Population

Blood samples were collected from participants at indicated time points and analyzed for Vd/F. Vd/F was calculated as dose divided by \[lambda\_z \*AUC(0-inf)\]. Pharmacokinetic parameters was calculated by standard non compartmental analysis.

Outcome measures

Outcome measures
Measure	Placebo n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Vd/F of GSK3511294 30 mg and 100 mg	7.812 Liters Geometric Coefficient of Variation 40.4	6.630 Liters Geometric Coefficient of Variation 12.1	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 2 and 8 hours on Day 1; Days 2,3,5, Weeks 1, 2, 4, 8, 12, 18, 24, 26, 32 and 40 post-dose

Population: Pharmacokinetic Population

Outcome measures

Outcome measures
Measure	Placebo n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Vd/F of GSK3511294 300 mg	9.337 Liters Geometric Coefficient of Variation 30.6	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 2 and 8 hours on Day 1; Days 2,3,5, Weeks 1, 2, 4, 8, 12, 18, 24, and 26 post-dose

Population: Pharmacokinetic Population

Blood samples were collected from participants at indicated time points and analyzed for lambda\_z. Pharmacokinetic parameters was calculated by standard non compartmental analysis.

Outcome measures

Outcome measures
Measure	Placebo n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Terminal Phase Elimination Rate Constant (Lambda_z) of GSK3511294 2 mg and 10 mg	0.013195 Day^-1 Geometric Coefficient of Variation 37.3	0.015787 Day^-1 Geometric Coefficient of Variation 16.2	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 2 and 8 hours on Day 1; Days 2,3,5, Weeks 1, 2, 4, 8, 12, 18, 24, 26 and 36 post-dose

Population: Pharmacokinetic Population

Blood samples were collected from participants at indicated time points and analyzed for lambda\_z. Pharmacokinetic parameters was calculated by standard non compartmental analysis.

Outcome measures

Outcome measures
Measure	Placebo n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Lambda_z of GSK3511294 30 mg and 100 mg	0.018435 Day^-1 Geometric Coefficient of Variation 10.7	0.017813 Day^-1 Geometric Coefficient of Variation 11.7	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 2 and 8 hours on Day 1; Days 2,3,5, Weeks 1, 2, 4, 8, 12, 18, 24, 26, 32 and 40 post-dose

Population: Pharmacokinetic Population

Blood samples were collected from participants at indicated time points and analyzed for lambda\_z. Pharmacokinetic parameters was calculated by standard non compartmental analysis.

Outcome measures

Outcome measures
Measure	Placebo n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Lambda_z of GSK3511294 300 mg	0.017148 Day^-1 Geometric Coefficient of Variation 6.3	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 2 and 8 hours on Day 1; Days 2,3,5, Weeks 1, 2, 4, 8, 12, 18, 24, and 26 post-dose

Population: Pharmacokinetic Population

Blood samples were collected from participants at indicated time points and analyzed for t1/2. Pharmacokinetic parameters was calculated by standard non compartmental analysis.

Outcome measures

Outcome measures
Measure	Placebo n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Terminal Phase Half-life (t1/2) of GSK3511294 2 mg and 10 mg	52.531 Days Geometric Coefficient of Variation 37.3	43.907 Days Geometric Coefficient of Variation 16.2	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 2 and 8 hours on Day 1; Days 2,3,5, Weeks 1, 2, 4, 8, 12, 18, 24, 26 and 36 post-dose

Population: Pharmacokinetic Population

Blood samples were collected from participants at indicated time points and analyzed for t1/2. Pharmacokinetic parameters was calculated by standard non compartmental analysis.

Outcome measures

Outcome measures
Measure	Placebo n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
T1/2 of GSK3511294 30 mg and 100 mg	37.599 Days Geometric Coefficient of Variation 10.7	38.913 Days Geometric Coefficient of Variation 11.7	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 2 and 8 hours on Day 1; Days 2,3,5, Weeks 1, 2, 4, 8, 12, 18, 24, 26, 32 and 40 post-dose

Population: Pharmacokinetic Population

Blood samples were collected from participants at indicated time points and analyzed for t1/2. Pharmacokinetic parameters was calculated by standard non compartmental analysis.

Outcome measures

Outcome measures
Measure	Placebo n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
T1/2 of GSK3511294 300 mg	40.422 Days Geometric Coefficient of Variation 6.3	—	—	—	—	—

SECONDARY outcome

Timeframe: Baseline, Days 2, 3, 4, 5, Weeks 1, 2, 4, 8, 12, 18, 24, 26, 32, 36, and 40

Population: Pharmacodynamic Population. Only those participants with planned assessments at that particular time point has been presented (represented by n=X in category titles)

Blood samples were collected at indicated time-points. Analysis was performed using a mixed model repeated measures analysis (MMRM) model on log-transformed data with fixed categorical effects of treatment, planned timepoint and treatment-by-planned timepoint interaction and fixed continuous covariates of log Baseline blood eosinophil count and log Baseline blood eosinophil count-by-planned timepoint interaction. Baseline is defined as the latest predose non-missing blood eosinophil count. Ratio to Baseline is defined as post-dose visit value divided by Baseline value. Pharmacodynamic Population included participants in the 'Safety' population for whom a post-dose pharmacodynamic (ie blood eosinophil) sample was obtained and analyzed.

Outcome measures

Outcome measures
Measure	Placebo n=12 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Ratio to Baseline in Absolute Blood Eosinophil Count Day 2, n=12, 6, 6, 8, 9, 6	1.083 Ratio of eosinophils in blood Interval 0.828 to 1.418	0.562 Ratio of eosinophils in blood Interval 0.382 to 0.827	0.522 Ratio of eosinophils in blood Interval 0.356 to 0.765	0.434 Ratio of eosinophils in blood Interval 0.313 to 0.601	0.496 Ratio of eosinophils in blood Interval 0.364 to 0.677	0.466 Ratio of eosinophils in blood Interval 0.317 to 0.683
Ratio to Baseline in Absolute Blood Eosinophil Count Day 5, n=11, 6, 6, 9, 9, 6	0.927 Ratio of eosinophils in blood Interval 0.705 to 1.22	0.300 Ratio of eosinophils in blood Interval 0.204 to 0.442	0.267 Ratio of eosinophils in blood Interval 0.182 to 0.391	0.219 Ratio of eosinophils in blood Interval 0.159 to 0.3	0.280 Ratio of eosinophils in blood Interval 0.205 to 0.382	0.299 Ratio of eosinophils in blood Interval 0.204 to 0.438
Ratio to Baseline in Absolute Blood Eosinophil Count Week 12, n=12, 5, 6, 9, 9, 5	1.031 Ratio of eosinophils in blood Interval 0.788 to 1.35	0.373 Ratio of eosinophils in blood Interval 0.25 to 0.557	0.171 Ratio of eosinophils in blood Interval 0.116 to 0.25	0.123 Ratio of eosinophils in blood Interval 0.089 to 0.168	0.161 Ratio of eosinophils in blood Interval 0.118 to 0.22	0.164 Ratio of eosinophils in blood Interval 0.11 to 0.244
Ratio to Baseline in Absolute Blood Eosinophil Count Week 26, n=12, 6, 6, 9, 9, 6	1.119 Ratio of eosinophils in blood Interval 0.855 to 1.464	0.776 Ratio of eosinophils in blood Interval 0.527 to 1.141	0.663 Ratio of eosinophils in blood Interval 0.452 to 0.972	0.317 Ratio of eosinophils in blood Interval 0.231 to 0.435	0.199 Ratio of eosinophils in blood Interval 0.146 to 0.271	0.186 Ratio of eosinophils in blood Interval 0.127 to 0.273
Ratio to Baseline in Absolute Blood Eosinophil Count Week 18, n=12, 6, 6, 9, 9, 6	1.079 Ratio of eosinophils in blood Interval 0.824 to 1.412	0.466 Ratio of eosinophils in blood Interval 0.317 to 0.685	0.314 Ratio of eosinophils in blood Interval 0.214 to 0.46	0.152 Ratio of eosinophils in blood Interval 0.111 to 0.208	0.139 Ratio of eosinophils in blood Interval 0.102 to 0.19	0.179 Ratio of eosinophils in blood Interval 0.122 to 0.262
Ratio to Baseline in Absolute Blood Eosinophil Count Week 24, n=11, 6, 6, 9, 9, 6	1.005 Ratio of eosinophils in blood Interval 0.763 to 1.322	0.661 Ratio of eosinophils in blood Interval 0.449 to 0.972	0.563 Ratio of eosinophils in blood Interval 0.384 to 0.825	0.285 Ratio of eosinophils in blood Interval 0.208 to 0.391	0.149 Ratio of eosinophils in blood Interval 0.109 to 0.203	0.202 Ratio of eosinophils in blood Interval 0.137 to 0.296
Ratio to Baseline in Absolute Blood Eosinophil Count Day 3, n=12, 6, 6, 9, 9, 6	0.977 Ratio of eosinophils in blood Interval 0.747 to 1.279	0.431 Ratio of eosinophils in blood Interval 0.293 to 0.633	0.350 Ratio of eosinophils in blood Interval 0.238 to 0.512	0.281 Ratio of eosinophils in blood Interval 0.205 to 0.386	0.262 Ratio of eosinophils in blood Interval 0.192 to 0.357	0.403 Ratio of eosinophils in blood Interval 0.275 to 0.591
Ratio to Baseline in Absolute Blood Eosinophil Count Day 4, n=12, 6, 6, 8, 8, 6	1.008 Ratio of eosinophils in blood Interval 0.77 to 1.319	0.400 Ratio of eosinophils in blood Interval 0.272 to 0.589	0.340 Ratio of eosinophils in blood Interval 0.232 to 0.499	0.215 Ratio of eosinophils in blood Interval 0.155 to 0.298	0.250 Ratio of eosinophils in blood Interval 0.182 to 0.344	0.360 Ratio of eosinophils in blood Interval 0.246 to 0.528
Ratio to Baseline in Absolute Blood Eosinophil Count Week 1, n=12, 6, 6, 9, 9, 5	1.136 Ratio of eosinophils in blood Interval 0.868 to 1.487	0.304 Ratio of eosinophils in blood Interval 0.206 to 0.447	0.223 Ratio of eosinophils in blood Interval 0.152 to 0.326	0.226 Ratio of eosinophils in blood Interval 0.165 to 0.311	0.237 Ratio of eosinophils in blood Interval 0.173 to 0.323	0.250 Ratio of eosinophils in blood Interval 0.167 to 0.373
Ratio to Baseline in Absolute Blood Eosinophil Count Week 2, n=12, 6, 5, 9, 9, 6	1.174 Ratio of eosinophils in blood Interval 0.897 to 1.536	0.274 Ratio of eosinophils in blood Interval 0.186 to 0.403	0.225 Ratio of eosinophils in blood Interval 0.151 to 0.336	0.170 Ratio of eosinophils in blood Interval 0.124 to 0.233	0.214 Ratio of eosinophils in blood Interval 0.157 to 0.292	0.265 Ratio of eosinophils in blood Interval 0.18 to 0.388
Ratio to Baseline in Absolute Blood Eosinophil Count Week 4,n=12, 6, 5, 9, 9, 6	1.062 Ratio of eosinophils in blood Interval 0.812 to 1.39	0.198 Ratio of eosinophils in blood Interval 0.134 to 0.291	0.195 Ratio of eosinophils in blood Interval 0.131 to 0.29	0.131 Ratio of eosinophils in blood Interval 0.095 to 0.179	0.185 Ratio of eosinophils in blood Interval 0.135 to 0.252	0.180 Ratio of eosinophils in blood Interval 0.123 to 0.264
Ratio to Baseline in Absolute Blood Eosinophil Count Week 8, n=12, 6, 6, 9, 9, 6	1.095 Ratio of eosinophils in blood Interval 0.837 to 1.434	0.201 Ratio of eosinophils in blood Interval 0.137 to 0.296	0.129 Ratio of eosinophils in blood Interval 0.088 to 0.189	0.102 Ratio of eosinophils in blood Interval 0.075 to 0.14	0.126 Ratio of eosinophils in blood Interval 0.092 to 0.172	0.178 Ratio of eosinophils in blood Interval 0.121 to 0.261
Ratio to Baseline in Absolute Blood Eosinophil Count Week 32, n=6, 6, 6, 0, 0, 6	0.912 Ratio of eosinophils in blood Interval 0.656 to 1.268	0.968 Ratio of eosinophils in blood Interval 0.655 to 1.43	0.837 Ratio of eosinophils in blood Interval 0.569 to 1.229	—	—	0.210 Ratio of eosinophils in blood Interval 0.142 to 0.308
Ratio to Baseline in Absolute Blood Eosinophil Count Week 36, n=6, 0, 0, 9, 9, 0	0.975 Ratio of eosinophils in blood Interval 0.691 to 1.376	—	—	0.858 Ratio of eosinophils in blood Interval 0.624 to 1.18	0.374 Ratio of eosinophils in blood Interval 0.274 to 0.511	—
Ratio to Baseline in Absolute Blood Eosinophil Count Week 40, n=2, 0, 0, 0, 0, 6	1.210 Ratio of eosinophils in blood Interval 0.604 to 2.422	—	—	—	—	0.258 Ratio of eosinophils in blood Interval 0.172 to 0.387

SECONDARY outcome

Timeframe: Up to Week 40

Population: Safety Population.

Serum samples were collected to determine the presence of anti-GSK3511294 binding antibodies using a validated bioanalytical method. Data for any time post-Baseline is reported. The results were categorized as negative, transient positive (defined as a single confirmatory positive immunogenic response that does not occur at the final study assessment) and persistent positive (defined as a confirmatory positive immunogenic response for at least 2 consecutive assessments or a single result at the final study assessment).

Outcome measures

Outcome measures
Measure	Placebo n=12 Participants Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg n=9 Participants Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg n=6 Participants Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Number of Participants With Anti-drug Antibody (ADA) Binding to GSK3511294 Transient positive	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Anti-drug Antibody (ADA) Binding to GSK3511294 Negative	12 Participants	6 Participants	5 Participants	4 Participants	7 Participants	5 Participants
Number of Participants With Anti-drug Antibody (ADA) Binding to GSK3511294 Persistent positive	0 Participants	0 Participants	1 Participants	5 Participants	1 Participants	1 Participants

SECONDARY outcome

Timeframe: Up to Week 40

Population: Safety Population. Only participants with positive results for ADA were analyzed.

Outcome measures

Outcome measures
Measure	Placebo Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg n=1 Participants Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg n=5 Participants Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg n=2 Participants Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg n=1 Participants Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Titers of Binding ADA to GSK3511294	—	—	80.0 Titer Interval 80.0 to 80.0	160.0 Titer Interval 80.0 to 320.0	80.0 Titer Interval 80.0 to 80.0	80.0 Titer Interval 80.0 to 320.0

Adverse Events

Placebo

Serious events: 0 serious events

Other events: 11 other events

Deaths: 0 deaths

GSK3511294 2mg

Serious events: 0 serious events

Other events: 2 other events

Deaths: 0 deaths

GSK3511294 10mg

Serious events: 0 serious events

Other events: 6 other events

Deaths: 0 deaths

GSK3511294 30mg

Serious events: 0 serious events

Other events: 8 other events

Deaths: 0 deaths

GSK3511294 100mg

Serious events: 0 serious events

Other events: 9 other events

Deaths: 0 deaths

GSK3511294 300mg

Serious events: 0 serious events

Other events: 4 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure	Placebo n=12 participants at risk Participants were administered a single subcutaneous dose of GSK3511294 matching placebo on Day 1	GSK3511294 2mg n=6 participants at risk Participants were administered a single subcutaneous dose of GSK3511294 2 milligram (mg) on Day 1	GSK3511294 10mg n=6 participants at risk Participants were administered a single subcutaneous dose of GSK3511294 10 mg on Day 1	GSK3511294 30mg n=9 participants at risk Participants were administered a single subcutaneous dose of GSK3511294 30 mg on Day 1	GSK3511294 100mg n=9 participants at risk Participants were administered a single subcutaneous dose of GSK3511294 100 mg on Day 1	GSK3511294 300mg n=6 participants at risk Participants were administered a single subcutaneous dose of GSK3511294 300 mg on Day 1
Infections and infestations Nasopharyngitis	16.7% 2/12 • Number of events 3 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	33.3% 2/6 • Number of events 4 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	16.7% 1/6 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	33.3% 3/9 • Number of events 3 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	55.6% 5/9 • Number of events 5 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	33.3% 2/6 • Number of events 2 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Infections and infestations Rhinitis	25.0% 3/12 • Number of events 3 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	16.7% 1/6 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	11.1% 1/9 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	22.2% 2/9 • Number of events 2 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Infections and infestations Gastroenteritis	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	22.2% 2/9 • Number of events 2 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Infections and infestations Gastrointestinal infection	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	11.1% 1/9 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Infections and infestations Otitis media acute	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	11.1% 1/9 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Infections and infestations Respiratory tract infection	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	16.7% 1/6 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Infections and infestations Root canal infection	8.3% 1/12 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Infections and infestations Viral diarrhoea	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	16.7% 1/6 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Infections and infestations Viral upper respiratory tract infection	8.3% 1/12 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Nervous system disorders Headache	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	16.7% 1/6 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	16.7% 1/6 • Number of events 2 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	22.2% 2/9 • Number of events 4 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	33.3% 3/9 • Number of events 4 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	33.3% 2/6 • Number of events 2 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Nervous system disorders Hypoaesthesia	8.3% 1/12 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	11.1% 1/9 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Nervous system disorders Lethargy	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	11.1% 1/9 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Nervous system disorders Paraesthesia	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	11.1% 1/9 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Nervous system disorders Sciatica	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	16.7% 1/6 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Injury, poisoning and procedural complications Arthropod sting	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	22.2% 2/9 • Number of events 2 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Injury, poisoning and procedural complications Contusion	8.3% 1/12 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	11.1% 1/9 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Injury, poisoning and procedural complications Rib fracture	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	33.3% 2/6 • Number of events 2 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Injury, poisoning and procedural complications Back injury	8.3% 1/12 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Injury, poisoning and procedural complications Fall	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	11.1% 1/9 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Injury, poisoning and procedural complications Hand fracture	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	16.7% 1/6 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Injury, poisoning and procedural complications Ligament rupture	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	11.1% 1/9 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Injury, poisoning and procedural complications Limb injury	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	16.7% 1/6 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Injury, poisoning and procedural complications Muscle strain	8.3% 1/12 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Injury, poisoning and procedural complications Post-traumatic pain	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	16.7% 1/6 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Injury, poisoning and procedural complications Skin abrasion	8.3% 1/12 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Injury, poisoning and procedural complications Soft tissue injury	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	11.1% 1/9 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Injury, poisoning and procedural complications Splinter	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	11.1% 1/9 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Injury, poisoning and procedural complications Tendon injury	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	11.1% 1/9 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Gastrointestinal disorders Diarrhoea	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	16.7% 1/6 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	11.1% 1/9 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Gastrointestinal disorders Dyspepsia	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	33.3% 2/6 • Number of events 2 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Gastrointestinal disorders Abdominal discomfort	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	11.1% 1/9 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Gastrointestinal disorders Dental pulp disorder	8.3% 1/12 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Gastrointestinal disorders Food poisoning	8.3% 1/12 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Gastrointestinal disorders Mouth ulceration	8.3% 1/12 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Gastrointestinal disorders Tongue discomfort	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	11.1% 1/9 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Gastrointestinal disorders Toothache	8.3% 1/12 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Immune system disorders Seasonal allergy	16.7% 2/12 • Number of events 2 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	16.7% 1/6 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	33.3% 2/6 • Number of events 3 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	22.2% 2/9 • Number of events 2 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	11.1% 1/9 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	16.7% 1/6 • Number of events 4 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Immune system disorders Allergy to animal	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	16.7% 1/6 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	11.1% 1/9 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	8.3% 1/12 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	16.7% 1/6 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	22.2% 2/9 • Number of events 2 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	16.7% 1/6 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Respiratory, thoracic and mediastinal disorders Asthma	8.3% 1/12 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	11.1% 1/9 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	11.1% 1/9 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Respiratory, thoracic and mediastinal disorders Cough	25.0% 3/12 • Number of events 3 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	16.7% 1/6 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Respiratory, thoracic and mediastinal disorders Nasal congestion	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	11.1% 1/9 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Respiratory, thoracic and mediastinal disorders Nasal discomfort	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	16.7% 1/6 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Respiratory, thoracic and mediastinal disorders Rhinorrhoea	8.3% 1/12 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Skin and subcutaneous tissue disorders Dry skin	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	22.2% 2/9 • Number of events 2 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Skin and subcutaneous tissue disorders Acne	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	11.1% 1/9 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Skin and subcutaneous tissue disorders Papule	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	11.1% 1/9 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Skin and subcutaneous tissue disorders Rash	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	11.1% 1/9 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Musculoskeletal and connective tissue disorders Back pain	8.3% 1/12 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	22.2% 2/9 • Number of events 2 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	11.1% 1/9 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Musculoskeletal and connective tissue disorders Neck pain	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	16.7% 1/6 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	11.1% 1/9 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Investigations Peak expiratory flow rate decreased	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	11.1% 1/9 • Number of events 3 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	16.7% 1/6 • Number of events 4 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Eye disorders Dry eye	8.3% 1/12 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Metabolism and nutrition disorders Vitamin B12 deficiency	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	11.1% 1/9 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Pyogenic granuloma	8.3% 1/12 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Psychiatric disorders Anxiety	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	16.7% 1/6 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Surgical and medical procedures Dental care	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	11.1% 1/9 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
Vascular disorders Haematoma	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	11.1% 1/9 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
General disorders Medical device site reaction	16.7% 2/12 • Number of events 2 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	16.7% 1/6 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	11.1% 1/9 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
General disorders Injection site haematoma	8.3% 1/12 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	16.7% 1/6 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
General disorders Chest discomfort	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	11.1% 1/9 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
General disorders Cyst	8.3% 1/12 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
General disorders Fatigue	8.3% 1/12 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
General disorders Hernia pain	8.3% 1/12 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups
General disorders Injection site swelling	0.00% 0/12 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/6 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	0.00% 0/9 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups	16.7% 1/6 • Number of events 1 • Non-serious AEs and SAEs were collected from the start of the study treatment (Day 1) up to Week 32 for GSK3511294 2 mg and 10 mg, up to Week 36 for GSK3511294 30 mg and GSK3511294 100 mg and up to Week 40 for GSK3511294 300 mg; and up to 40 weeks for placebo. Non-SAEs and SAEs were reported for the Safety Population. Within each cohort participants were assigned to active or placebo in a 3:1 ratio. A pooled placebo group was to be used as comparison group. An identical proportion of participants in pooled placebo group had same total duration of study as participants in each of the active dose groups

Additional Information

GSK Response Center

GlaxoSmithKline

Phone: 8664357343

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
Publication restrictions are in place

Restriction type: OTHER